Scientific Program - American Academy of Dermatology

Transcription

20
11
Scientific Program
Powerful. Potent. Professional.
Introducing
A NEW comprehensive
antiaging system of
potent, multi-action
products developed to
address photoaging
at all skin layers.
The most powerful
ingredients working
synergistically to address
the multiple mechanisms
of skin aging. Reverse the
appearance of deep lines
and wrinkles, sagging
skin and discoloration.
Physician dispensed.
©2011 NeoStrata Company
new
Elite Science. Professional Results.
Contact your NeoStrata representative or call 1-800-628-9904
CONTINUING MEDICAL EDUCATION INFORMATION
MISSION
The American Academy of Dermatology (AAD) is the premier
provider of dermatology CME activities. The purpose of its CME
Program is to advance quality dermatologic care and improve
competence and performance.
DEFINITION OF CONTINUING MEDICAL EDUCATION
Continuing medical education consists of educational activities
which serve to maintain, develop, or increase the knowledge,
skills, and professional performance and relationships that a
physician uses to provide services for patients, the public, or the
profession. The content of CME is that body of knowledge and
skills generally recognized and accepted by the profession as
within the basic medical sciences, the discipline of clinical
medicine, and the provision of health care to the public.
Source: www.accme.org
COMMERCIAL BIAS
A personal judgment in favor of a specific proprietary business
interest of a commercial interest.
Source: www.accme.org
Scientific Assembly Committee
Henry W. Lim, M.D., FAAD; Chair
Janet A. Fairley, M.D., FAAD
Ilona J. Frieden, M.D., FAAD
Joan Guitart, M.D., FAAD
Ronald L. Moy, M.D., FAAD; President
Daniel M. Siegel M.D., FAAD; President-Elect
Robert D. Greenberg, M.D., FAAD; Secretary-Treasurer
Suzanne Olbricht, M.D., FAAD; Assistant Secretary-Treasurer
Robert S. Kirsner, M.D., Ph.D., FAAD; Chair, Council On Education
Edward W. Cowen, M.D., FAAD; Chair,
Annual Meeting Evaluation Task Force
M. Christine Lee, M.D., FAAD; Chair, Needs Assessment Task Force
LEARNER BILL OF RIGHTS
AAD recognizes that you are a life-long learner who has chosen to
engage in continuing medical education to identify or fill a gap in
knowledge or skill; and to attain or enhance a desired competency.
As part of AAD’s duty to you as a learner, you have the right to
expect that your continuing medical education experience with
AAD includes the following.
Content that:
• Promotes improvements or quality in healthcare
• Is current, valid, reliable, accurate and evidence-based
• Addresses the stated objectives or purpose
•Is driven and based on independent survey and analysis
of learner needs, not commercial interests
• Has been reviewed for bias and scientific rigor
• Offers balanced presentations that are free of commercial bias
•Is vetted through a process that resolves any conflicts of interest
of planners and faculty
•Is evaluated for its effectiveness in meeting the identified
educational need
A learning environment that:
•Is based on adult learning principles that support the use
of various modalities
• Supports learners’ abilities to meet their individual needs
• Respects and attends to any special needs of the learners
• Respects the diversity of groups of learners
• Is free of promotional, commercial and/or sales activities
Disclosure of:
•Relevant financial relationships that planners, teachers
and authors have with commercial interests related
to the content of the activity
• Commercial support (funding or in-kind resources) of this activity
American Academy of Dermatology
930 East Woodfield Road, Schaumburg, Illinois 60173
Phone: 847.330.0230, Fax: 847.330.1090, Website: www.aad.org
© 2011 American Academy of Dermatology, Schaumburg, Illinois
No part of this publication may be reproduced without the prior written permission of
the American Academy of Dermatology.
Register for the meeting and make hotel reservations online at
www.aad.org
President’s Message
Dermatology: the new colossus
It was more than a century ago when the iconic Statue of Liberty was engraved with Emma Lazarus’s sonnet “The New
Colossus.” Most are familiar with its immortal line, “Give me your tired, your poor, your huddled masses, but the
sonnet also includes these words: “From her beacon-hand glows world-wide welcome.” The grand statue has become
synonymous with New York, but it’s the words on the statue that express the true sentiment: all are welcome.
I think the American Academy of Dermatology’s Summer Academy Meeting 2011 aspires to similar ideals. In modern
terms, the “huddled masses” have endured, grown, diversified, and prospered; and may loosely describe everyone from the
dermatologists who diagnose and treat patients to the patients themselves.
And although the Statue of Liberty will invariably be a symbol of New York City, I think it’s good to remember
the “world-wide welcome” Lady Liberty was offering. New York City is a hub; a gathering place, as it will be for
the Summer Academy Meeting 2011. The actual components of the meeting, however, come from across the United
States and abroad; a world-wide group of specialists, lecturers, presenters, and attendees.
The Summer Academy Meeting 2011 serves as a “port of entry” to the newest advances in dermatology, including
many new courses, often unveiled for the first time, and some one-of-a-kind sessions and events that only happen at
the summer meeting.
As you look through the program book, you’ll find the summation of a century of dermatology advances made relevant
for today’s practitioner, and tools you’ll need to move forward into the next century. I want to welcome the world to
engage in Summer Academy Meeting 2011, to appreciate the diversity of our specialty, and marvel at the colossus of
modern medicine dermatology has become.
Sincerely,
Ronald Moy, M.D., FAAD
President, American Academy of Dermatology
2
|
American Academy of Dermatology • SUMMER ACADEMY MEETING 2011
Chair’s Message
There are several reasons that the American Academy of Dermatology offers two scientific meetings each year.
A major reason is the high demand for quality dermatology education. In addition to the core curriculum, the AAD’s Summer
Academy Meetings offer many new sessions, and some that are not available at the Annual Meeting.
Another reason the Academy presents two scientific meetings a year is that it addresses the rapid advances in dermatology
over a relatively short period of time. For today’s dermatologist to keep up with the changes in science, health care, practice
management, treatments, as well as to anticipate future changes in the specialty, the Summer Academy Meeting 2011 provides
the ideal venue to do so.
In addition to all the Summer Academy Meeting 2011 offers, I’m particularly excited about the plenary session this summer. We have
an array of well recognized experts who will provide the latest advances in dermatology science and research.
Timothy M. Johnson, M.D., is presenting the Everett C. Fox, M.D., Memorial Lectureship, and will address the controversy
of sentinel node biopsies in dermatology. This summer’s guest speaker at the Sunday Plenary Session is emblematic of the sort
of change and shift we are all undergoing as the world moves a little faster each year. Author and lecturer Don Tapscott is an
internationally renowned authority on the strategic impact of information technology on innovation, marketing and talent,
facets that are applicable to dermatologists facing a new era of technology.
Erik J. Stratman, M.D., has been passionately involved in dermatology education over the years. His talk on “Overhauling
CME and Dermatology Education: Laps, Gaps, Maps, and Traps,” will not only assess the current education system but offer a
glimpse at its future.
Attendees will be taken on an epidemiologic journey of contact dermatitis, through an informative presentation by David Eric
Cohen, M.D., who will also talk about the relevence of patch testing.
Sam T. Hwang, M.D., Ph.D., will provide “An Update in CTCL: A Tale of Two Kinds of T-Cells” to explain the clinical
manifestations of Sézary syndrome and mycosis fungoides. Another hot dermatology topic is comparative effectiveness
research, which makes use of existing therapeutic options to determine which therapy provides the greatest benefits for
patients. David J. Margolis, M.D., will talk about the basics of comparative effectiveness in dermatology and how it will
impact the provisions of health care.
The plenary also includes a presentation by Roy G. Geronemus, M.D., who will provide the latest development in nonablative and ablative fractional resurfacing.
As reflected by the Plenary session topics, we have planned the Summer Academy Meeting 2011 with the need of our
Academy members in mind. I do hope that you will find the program informative and educational. In addition, New York
City is a great city to visit in the summer. The meeting venue is within walking distance to theatres, museum, Central Park,
and many tourist sites. I encourage you to start reviewing the program book today, and plan to attend the sessions that will
inform and affect your practice in the future.
Sincerely,
Henry W. Lim, M.D., FAAD
Chair, Scientific Assembly Committee
4
|
When dry skin calls for a serious solution…
Recommend AmLactin
®
recommended by dermatologists
for rough, dry skin1
AmLactin® Rejuvenating Moisturizers
Nourishing formulas— combine emollients, humectants, and alpha-hydroxy acid to
exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP)
●
AmLactin Moisturizing Body Lotion & Cream
®
Everyday hydration— 12% lactic acid provides powerful therapy leaving skin
noticeably soft and smooth
●
AmLactin XL® Moisturizing Lotion
Visit us online at
www.amlactin.com
for samples, coupons
& more information!
Targets severely dry skin— features ULTRAPLEX,® an extra-strength blend of three
alpha-hydroxy compounds, clinically proven to improve smoothness and hydration
Serious care for softer skin
TM
For complete directions and cautions, please refer to individual product labels.
Reference: 1. Most recommended moisturizing product for rough, dry skin. Omnibus Study. Dermatology Times. May 2009.
1-800-654-2299 www.upsher-smith.com
©2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369
103985.02
Table of Contents
Table of Contents
General Information
Accreditation............................................................................ 18
Attendance Verification...................................................... 25, 28
Badge Information
Mailing of............................................................................ 25
Identification........................................................................ 26
Certificate of Attendance.......................................................... 26
Chair’s Message.......................................................................... 4
Charitable Contribution.......................................................... 26
Committee Meetings.............................................................. 103
Continuing Medical Education Information
Mission.................................................................................. 1
Definition of.......................................................................... 1
Commercial Bias.................................................................... 1
Learner Bill of rights.............................................................. 1
Statement of Need............................................................... 12
Target Audience................................................................... 12
Global Learning Objectives.................................................. 12
Disclosure Information................................................... 12-13
Disclaimer............................................................................ 13
CME Credit Information......................................................... 14
Evaluation and CME Verification............................................ 29
Exhibits
AAD Resource Center............................................... 28, 33-34
Electronic Posters...................................................... 29, 83-85
Technical................................................................. 28, 87-100
Alphabetical Directory............................................... 87-97
Product Category Directory..................................... 98-100
Independence in CME......................................................... 30
Disclosure............................................................................ 30
Content Validation............................................................... 31
Outcomes Measurement...................................................... 31
Age Limits............................................................................ 31
Camera/Video Recording..................................................... 31
Cell Phones.......................................................................... 31
Smoking............................................................................... 31
Alcoholic Beverages.............................................................. 31
Official Language................................................................. 32
Scientific Sessions................................................................. 32
Hotel and Travel Information
Hotel Accommodations and Reservations............................ 26
Payment Information........................................................... 26
Hotel Cancellation............................................................... 27
Air Travel............................................................................. 27
Car Rental............................................................................ 27
Indices
Subject........................................................................ 104-107
Faculty........................................................................ 108-110
Advertising......................................................................... 112
Letters of Invitation................................................................. 26
Meeting Handouts................................................................... 30
Meeting Location..................................................................... 21
On-Site Services and Exhibits
Academy Offices/Exhibits.................................................... 28
Registration.......................................................................... 28
Attendance Verification........................................................ 28
Speaker Ready Room........................................................... 28
Exhibits..............................................................28-29, 83-100
Business Center.................................................................... 29
Cyber Center....................................................................... 29
Press Information................................................................. 30
Tours.................................................................................... 30
Child Care Services.............................................................. 30
Personal Program Schedule...................................................... 19
President’s Message..................................................................... 2
Program Overview.............................................................. 17-18
Registration Information
Member Instruction........................................................ 21-22
Non-member Instructions............................................... 21-22
Spouse/Guest Instructions............................................... 21-22
Confirmations and Changes................................................. 22
Registration Categories, Access and Fees.............................. 23
Session Categories, Access and Fees...................................... 24
Cancellations........................................................................ 25
Payment Information........................................................... 26
Scientific Assembly Committee.................................................. 1
Scientific Sessions
Thursday, August 4......................................................... 37-51
Friday, August 5.............................................................. 52-62
Saturday, August 6.......................................................... 63-74
Sunday, August 7............................................................ 75-78
What’s New This Year.............................................................. 24
Separate Enclosure
Registration and Housing Brochure
Registration and Housing Form / Office Staff / Registered Nurses Registration Form / Hotel Reservation Information
6
|
SOLODYN is indicated to treat only inflammatory
lesions of non-nodular moderate to severe acne
vulgaris in patients 12 years of age and older.
SOLODYN did not demonstrate any effect on noninflammatory lesions. Safety of SOLODYN has not
been established beyond 12 weeks of use. This
formulation of minocycline has not been evaluated in
the treatment of infections. To reduce the development
of drug-resistant bacteria as well as to maintain the
effectiveness of other antibacterial drugs, SOLODYN
should be used only as indicated.
Important Safety Information
for SOLODYN Tablets
• The most commonly reported side effects were
headache, fatigue, dizziness, and pruritus.
• Minocycline, like other tetracyclines, can cause fetal
harm when administered to a pregnant woman.
• Tetracycline drugs should not be used during tooth
development (last half of pregnancy and up to
8 years of age) as they may cause permanent
discoloration of teeth.
• Pseudomembranous colitis has been reported with
nearly all antibacterial agents and may range from
mild to life-threatening; therefore, it is important
to consider this diagnosis in patients who present
with diarrhea subsequent to the administration of
antibacterial agents.
• In rare cases, photosensitivity has been reported.
• Should not be used during pregnancy nor by
individuals of either gender who are attempting to
conceive a child; concurrent use of tetracyclines with
oral contraceptives may render oral contraceptives
less effective.
• This drug is contraindicated in persons who have
shown hypersensitivity to any of the tetracyclines.
• Safety beyond 12 weeks of use has
not been established.
• Central nervous system side effects, including
light-headedness, dizziness, and vertigo, have been
reported with minocycline therapy.
Reference: 1. IMS Health. National Prescription Audit (NPA). Data through December 2010. Data on file, Medicis Pharmaceutical Corporation.
See following pages for Brief Summary of Full Prescribing Information.
SOLODYN is a registered trademark of Medicis Pharmaceutical Corporation. SOL 10 - 038R 01/31/12
BRIEF SUMMARY
(see package insert for full
prescribing information)
SOLODYN®
(minocycline HCl, USP) Extended Release
Tablets
Rx Only
KEEP OUT OF REACH OF CHILDREN
INDICATIONS AND USAGE
Indication
SOLODYN is indicated to treat only
inflammatory lesions of non-nodular
moderate to severe acne vulgaris in
patients 12 years of age and older.
Limitations of Use
SOLODYN did not demonstrate any effect
on non-inflammatory acne lesions. Safety
of SOLODYN has not been established
beyond 12 weeks of use. This formulation
of minocycline has not been evaluated in
the treatment of infections.
treated early in pregnancy (see Use in
Specific Populations).
Pseudomembranous Colitis
Pseudomembranous colitis has been
reported with nearly all antibacterial
agents and may range from mild
to life-threatening. Therefore, it is
important to consider this diagnosis
in patients who present with diarrhea
subsequent to the administration of
antibacterial agents.
Treatment with antibacterial agents
alters the normal flora of the colon and
may permit overgrowth of clostridia.
Studies indicate that a toxin produced by
Clostridium difficile is a primary cause of
“antibiotic-associated colitis”.
After the diagnosis of pseudomembranous
colitis has been established, therapeutic
measures should be initiated. Mild
cases of pseudomembranous colitis
usually respond to discontinuation of
To reduce the development of drugthe drug alone. In moderate to severe
resistant bacteria as well as to maintain the cases, consideration should be given to
effectiveness of other antibacterial drugs,
management with fluids and electrolytes,
SOLODYN should be used only as indicated protein supplementation, and treatment
(see Warnings and Precautions).
with an antibacterial drug clinically effective
against Clostridium difficile colitis.
CONTRAINDICATIONS
This drug is contraindicated in persons
who have shown hypersensitivity to any of
the tetracyclines.
WARNINGS AND PRECAUTIONS
Teratogenic Effects
A. MINOCYCLINE, LIKE OTHER
TETRACYCLINE-CLASS ANTIBIOTICS,
CAN CAUSE FETAL HARM WHEN
ADMINISTERED TO A PREGNANT
WOMAN. IF ANY TETRACYCLINE IS USED
DURING PREGNANCY OR IF THE PATIENT
BECOMES PREGNANT WHILE TAKING
THESE DRUGS, THE PATIENT SHOULD
BE APPRISED OF THE POTENTIAL
HAZARD TO THE FETUS.
Hepatotoxicity
Post-marketing cases of serious liver injury,
including irreversible drug-induced hepatitis
and fulminant hepatic failure (sometimes
fatal) have been reported with minocycline
use in the treatment of acne.
Metabolic Effects
The anti-anabolic action of the tetracyclines
may cause an increase in BUN. While
this is not a problem in those with normal
renal function, in patients with significantly
impaired function, higher serum levels of
tetracycline-class antibiotics may lead to
azotemia, hyperphosphatemia, and acidosis.
If renal impairment exists, even usual oral
or parenteral doses may lead to excessive
systemic accumulations of the drug
and possible liver toxicity. Under such
conditions, lower than usual total doses
are indicated, and if therapy is prolonged,
serum level determinations of the drug
may be advisable.
visual disturbances prior to initiation of
treatment with tetracyclines and should be
routinely checked for papilledema while on
treatment. Concomitant use of isotretinoin
and minocycline should be avoided because
isotretinoin, a systemic retinoid, is also
known to cause pseudotumor cerebri.
Autoimmune Syndromes
Tetracyclines have been associated with the
development of autoimmune syndromes.
The long-term use of minocycline in the
treatment of acne has been associated
with drug-induced lupus-like syndrome,
autoimmune hepatitis and vasculitis.
Sporadic cases of serum sickness have
presented shortly after minocycline
use. Symptoms may be manifested by
fever, rash, arthralgia, and malaise. In
symptomatic patients, liver function tests,
ANA, CBC, and other appropriate tests
should be performed to evaluate the
patients. Use of all tetracycline-class drugs
should be discontinued immediately.
ADVERSE REACTIONS
Clinical Trial Experience
Because clinical trials are conducted under
prescribed conditions, adverse reaction
rates observed in the clinical trial may not
reflect the rates observed in practice.
The following table summarizes selected
adverse reactions reported in clinical trials
at a rate of ≥1% for SOLODYN.
Selected Treatment-Emergent Adverse
Reactions in at least 1% of Clinical
Trial Subjects
Adverse Reactions SOLODYN PLACEBO
(1 mg/kg) N=364
N=674 (%) (%)
At least one treatment- 379 (56) 197 (54)
emergent event
Photosensitivity
Headache
152 (23) 83 (23)
Photosensitivity manifested by an
Fatigue
62 (9)
24 (7)
exaggerated sunburn reaction has been
Dizziness
59 (9)
17 (5)
observed in some individuals taking
Pruritus
31 (5)
16 (4)
tetracyclines. This has been reported
Malaise
26 (4)
9 (3)
rarely with minocycline. Patients should
minimize or avoid exposure to natural or
Mood alteration
17 (3)
9 (3)
artificial sunlight (tanning beds or UVA/B
Somnolence
13 (2)
3 (1)
treatment) while using minocycline. If
Urticaria
10 (2)
1 (0)
patients need to be outdoors while using
Tinnitus
10 (2)
5 (1)
minocycline, they should wear loose-fitting Arthralgia
9 (1)
2 (0)
clothes that protect skin from sun exposure Vertigo
8 (1)
3 (1)
and discuss other sun protection measures Dry mouth
7 (1)
5 (1)
with their physician.
Myalgia
7 (1)
4 (1)
Postmarketing Experience
Serious Skin/Hypersensitivity
Reaction
Adverse reactions that have been reported
Post-marketing cases of anaphylaxis
with minocycline hydrochloride use in a
and serious skin reactions such as
variety of indications include:
Stevens-Johnson syndrome and erythema Skin and hypersensitivity reactions:
multiforme have been reported with
fixed drug eruptions, balanitis, erythema
minocycline use in treatment of acne.
multiforme, Stevens-Johnson syndrome,
Tissue Hyperpigmentation
Tetracycline-class antibiotics are known
to cause hyperpigmentation. Tetracycline
therapy may induce hyperpigmentation in
many organs, including nails, bone, skin,
eyes, thyroid, visceral tissue, oral cavity
(teeth, mucosa, alveolar bone), sclerae and
B. THE USE OF DRUGS OF THE
heart valves. Skin and oral pigmentation
Central Nervous System Effects
TETRACYCLINE-CLASS DURING
has been reported to occur independently
TOOTH DEVELOPMENT (LAST HALF OF Central nervous system side effects
of time or amount of drug administration,
PREGNANCY, INFANCY, AND CHILDHOOD including light-headedness, dizziness or
vertigo have been reported with minocycline whereas other tissue pigmentation has
UP TO THE AGE OF 8 YEARS) MAY
been reported to occur upon prolonged
therapy. Patients who experience these
CAUSE PERMANENT DISCOLORATION
administration. Skin pigmentation includes
OF THE TEETH (YELLOW-GRAY-BROWN). symptoms should be cautioned about
diffuse pigmentation as well as over sites
driving vehicles or using hazardous
This adverse reaction is more common
of scars or injury.
machinery while on minocycline therapy.
during long-term use of the drug but
These symptoms may disappear during
Development of Drug Resistant
has been observed following repeated
therapy and usually rapidly disappear
Bacteria
short-term courses. Enamel hypoplasia
when the drug is discontinued.
Bacterial resistance to the tetracyclines
has also been reported. TETRACYCLINE
may develop in patients using SOLODYN,
Benign Intracranial Hypertension
DRUGS, THEREFORE, SHOULD NOT BE
therefore, the susceptibility of bacteria
Pseudotumor cerebri (benign intracranial
USED DURING TOOTH DEVELOPMENT.
associated with infection should be
hypertension) in adults and adolescents
C. All tetracyclines form a stable calcium
considered in selecting antimicrobial
has been associated with the use
complex in any bone-forming tissue. A
therapy. Because of the potential for
of tetracyclines. Minocycline has
decrease in fibula growth rate has been been reported to cause or precipitate
drug-resistant bacteria to develop during
observed in premature human infants
the use of SOLODYN, it should be used only
pseudotumor cerebri, the hallmark
given oral tetracycline in doses of 25
as indicated.
of which is papilledema. Clinical
mg/kg every 6 hours. This reaction was manifestations include headache and
Superinfection
shown to be reversible when the drug
blurred vision. Bulging fontanels have been As with other antibiotic preparations, use
was discontinued.
associated with the use of tetracyclines
of SOLODYN may result in overgrowth of
Results of animal studies indicate that
in infants. Although signs and symptoms
nonsusceptible organisms, including fungi.
tetracyclines cross the placenta, are
of pseudotumor cerebri resolve after
If superinfection occurs, the antibiotic
found in fetal tissues, and can cause
discontinuation of treatment, the possibility should be discontinued and appropriate
retardation of skeletal development
for permanent sequelae such as visual
therapy instituted.
on the developing fetus. Evidence of
loss that may be permanent or severe
embryotoxicity has been noted in animals exists. Patients should be questioned for
SOLODYN should not be used during
pregnancy or by individuals of either
gender who are attempting to conceive
a child (see Nonclinical Toxicology & Use
in Specific Populations).
Laboratory Monitoring
Periodic laboratory evaluations of organ
systems, including hematopoietic, renal
and hepatic studies should be performed.
Appropriate tests for autoimmune syndromes
should be performed as indicated.
anaphylactoid purpura, photosensitivity,
pigmentation of skin and mucous
membranes, hypersensitivity reactions,
angioneurotic edema, anaphylaxis.
Autoimmune conditions: polyarthralgia,
pericarditis, exacerbation of systemic lupus,
pulmonary infiltrates with eosinophilia,
transient lupus-like syndrome.
Central nervous system: pseudotumor
cerebri, bulging fontanels in infants,
decreased hearing.
Endocrine: thyroid discoloration, abnormal
thyroid function.
Oncology: papillary thyroid cancer.
Oral: glossitis, dysphagia, tooth
discoloration.
Gastrointestinal: enterocolitis, pancreatitis,
hepatitis, liver failure.
Renal: reversible acute renal failure.
Hematology: hemolytic anemia,
thrombocytopenia, eosinophilia.
Preliminary studies suggest that use of
minocycline may have deleterious effects
on human spermatogenesis (see Nonclinical
Toxicology).
DRUG INTERACTIONS
Anticoagulants
Because tetracyclines have been shown
to depress plasma prothrombin activity,
patients who are on anticoagulant therapy
may require downward adjustment of their
anticoagulant dosage.
Penicillin
Since bacteriostatic drugs may interfere
with the bactericidal action of penicillin, it is
advisable to avoid giving tetracycline-class
drugs in conjunction with penicillin.
Methoxyflurane
The concurrent use of tetracycline and
methoxyflurane has been reported to result
in fatal renal toxicity.
Antacids and Iron Preparations
Absorption of tetracyclines is impaired by
antacids containing aluminum, calcium
or magnesium and iron-containing
preparations.
Low Dose Oral Contraceptives
In a multi-center study to evaluate the
effect of SOLODYN on low dose oral
contraceptives, hormone levels over one
menstrual cycle with and without
SOLODYN 1 mg/kg once-daily were
measured. Based on the results of this
trial, minocycline-related changes in
estradiol, progestinic hormone, FSH and
LH plasma levels, of breakthrough
bleeding, or of contraceptive failure, can
not be ruled out. To avoid contraceptive
failure, female patients are advised to use
a second form of contraceptive during
treatment with minocycline.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamine
levels may occur due to interference with
the fluorescence test.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy category D
(see Warnings and Precautions)
SOLODYN should not be used during
pregnancy. If the patient becomes pregnant
while taking this drug, the patient should be
apprised of the potential hazard to the fetus
and stop treatment immediately.
There are no adequate and well-controlled
studies on the use of minocycline in
pregnant women. Minocycline, like other
tetracycline-class drugs, crosses the
placenta and may cause fetal harm when
administered to a pregnant woman.
Rare spontaneous reports of congenital
anomalies including limb reduction have
been reported with minocycline use in
pregnancy in post-marketing experience.
Only limited information is available
regarding these reports; therefore, no
conclusion on causal association can
be established.
Minocycline induced skeletal malformations
(bent limb bones) in fetuses when
administered to pregnant rats and rabbits in
doses of 30 mg/kg/day and 100 mg/kg/day,
respectively, (resulting in approximately
3 times and 2 times, respectively, the
systemic exposure to minocycline
observed in patients as a result of use of
SOLODYN). Reduced mean fetal body
weight was observed in studies in which
minocycline was administered to pregnant
rats at a dose of 10 mg/kg/day (which
resulted in approximately the same level of
systemic exposure to minocycline as that
observed in patients who use SOLODYN).
Minocycline was assessed for effects on
peri- and post-natal development of rats in
a study that involved oral administration to
pregnant rats from day 6 of gestation
through the period of lactation (postpartum
day 20), at dosages of 5, 10, or 50
mg/kg/day. In this study, body weight gain
was significantly reduced in pregnant
females that received 50 mg/kg/day
(resulting in approximately 2.5 times the
systemic exposure to minocycline observed
in patients as a result of use of SOLODYN).
No effects of treatment on the duration of
the gestation period or the number of live
pups born per litter were observed. Gross
external anomalies observed in F1 pups
(offspring of animals that received
minocycline) included reduced body size,
improperly rotated forelimbs, and reduced
size of extremities. No effects were
observed on the physical development,
behavior, learning ability, or reproduction
of F1 pups, and there was no effect on
gross appearance of F2 pups (offspring
of F1 animals).
evaluate the carcinogenic potential of
minocycline. A structurally related
compound, oxytetracycline, was found
to produce adrenal and pituitary tumors
in rats.
contains minocycline hydrochloride
equivalent to 65 mg minocycline, supplied
as follows:
Mutagenesis—Minocycline was not
mutagenic in vitro in a bacterial reverse
mutation assay (Ames test) or CHO/HGPRT
mammalian cell assay in the presence
or absence of metabolic activation.
Minocycline was not clastogenic in vitro
using human peripheral blood lymphocytes
or in vivo in a mouse micronucleus test.
The 80 mg extended release tablets are
gray, unscored, coated, and debossed
with “DYN-080” on one side. Each tablet
as follows:
NDC 99207-463-30
NDC 99207-466-30
Bottle of 30
Bottle of 30
Impairment of Fertility—Male and
yellow, unscored, coated, and debossed
female reproductive performance in
rats was unaffected by oral doses of
minocycline of up to 300 mg/kg/day (which
resulted in up to approximately 40 times the
as follows:
level of systemic exposure to minocycline
observed in patients as a result of use of
NDC 99207-461-30
Bottle of 30
SOLODYN). However, oral administration of NDC 99207-461-10
Bottle of 100
100 or 300 mg/kg/day of minocycline to
The
105
mg
extended
release
tablets are
male rats (resulting in approximately 15 to
40 times the level of systemic exposure to purple, unscored, coated, and debossed
minocycline observed in patients as a result with “DYN-105” on one side. Each tablet
Nursing Mothers
of use of SOLODYN) adversely affected
Tetracycline-class antibiotics are excreted
spermatogenesis. Effects observed at 300 equivalent to 105 mg minocycline, supplied
as follows:
in human milk. Because of the potential for mg/kg/day included a reduced number
serious adverse effects on bone and tooth of sperm cells per gram of epididymis,
NDC 99207-467-30
Bottle of 30
development in nursing infants from the
an apparent reduction in the percentage
tetracycline-class antibiotics, a decision
of sperm that were motile, and (at 100
should be made whether to discontinue
green, unscored, coated, and debossed
and 300 mg/kg/day) increased numbers
nursing or discontinue the drug, taking into of morphologically abnormal sperm cells.
account the importance of the drug to the Morphological abnormalities observed in
mother (see Warnings and Precautions).
equivalent to 115 mg minocycline,
sperm samples included absent heads,
supplied as follows:
misshapen heads, and abnormal flagella.
Pediatric Use
SOLODYN is indicated to treat only
NDC 99207-464-30
Bottle of 30
Limited human studies suggest that
inflammatory lesions of non-nodular
minocycline may have a deleterious effect
moderate to severe acne vulgaris
on spermatogenesis.
pink (orange-brown), unscored, coated,
in patients 12 years and older.
SOLODYN should not be used by individuals and debossed with “DYN-135” on one
Safety and effectiveness in pediatric
of either gender who are attempting to
side. Each tablet contains minocycline
patients below the age of 12 has not
conceive a child.
hydrochloride equivalent to 135 mg
been established.
minocycline, supplied as follows:
Use of tetracycline-class antibiotics below HOW SUPPLIED/STORAGE AND
HANDLING
NDC 99207-462-30
Bottle of 30
the age of 8 is not recommended due to
How Supplied
NDC 99207-462-10
Bottle of 100
the potential for tooth discoloration (see
SOLODYN (minocycline HCl, USP) Extended
Warnings and Precautions).
Storage
Release Tablets are supplied as aqueous
Geriatric Use
film coated tablets containing minocycline Store at 25ºC (77ºF); excursions are
Clinical studies of SOLODYN did not
hydrochloride equivalent to 45 mg, 55 mg, permitted to 15º-30ºC (59º-86ºF)
[See USP Controlled Room Temperature].
include sufficient numbers of subjects aged 65 mg, 80 mg, 90 mg, 105 mg, 115 mg
65 and over to determine whether they
or 135 mg minocycline, are supplied
Handling
respond differently from younger subjects. as follows.
Keep out of reach of children
Other reported clinical experience has not
Protect from light, moisture, and
identified differences in responses between The 45 mg extended release tablets are
excessive heat.
the elderly and younger patients. In general, gray, unscored, coated, and debossed
dose selection for an elderly patient should with “DYN-045” on one side. Each tablet
Dispense in tight, light-resistant container
be cautious, usually starting at the low end contains minocycline hydrochloride
with child-resistant closure.
equivalent
to
45
mg
minocycline,
supplied
of the dosing range, reflecting the greater
as follows:
U.S. Patent 5,908,838* and Patents Pending
frequency of decreased hepatic, renal, or
*90 mg is also covered by U.S. Patents
cardiac function, and concomitant disease NDC 99207-460-30
Bottle of 30
7,541,347 and 7,544,373
or other drug therapy.
NDC 99207-460-10
Bottle of 100
Manufactured for:
OVERDOSAGE
Medicis, The Dermatology Company
In case of overdosage, discontinue
pink, unscored, coated, and debossed
Scottsdale, AZ 85256
medication, treat symptomatically and
institute supportive measures. Minocycline contains minocycline hydrochloride
August 2010
is not removed in significant quantities by
17110163
hemodialysis or peritoneal dialysis.
as follows:
NONCLINICAL TOXICOLOGY
NDC 99207-465-30
Bottle of 30
Carcinogenesis, Mutagenesis,
The
65
mg
extended
release
tablets are
Impairment of Fertility
blue, unscored, coated, and debossed
Carcinogenesis—Long-term animal
studies have not been performed to
CME Information
SUMMER ACADEMY MEETING 2011
DIRECTLY SPONSORED BY
The American Academy Of Dermatology
STATEMENT OF NEED
The American Academy of Dermatology’s Summer Academy Meeting
2011 is planned to comprehensively address the nine content areas
within the Dermatologic Core Curriculum and provide
dermatologists and other dermatology health care professionals with
high quality educational opportunities for the optimization of
dermatologic knowledge, competence and performance.
TARGET AUDIENCE
The primary target audience of the American Academy of
Dermatology’s Summer Academy Meeting is its members. Secondary
audiences for the Summer Academy Meeting 2011 include
dermatology residents and other dermatology health care professionals.
GLOBAL LEARNING OBJECTIVES
This comprehensive meeting provides learners with opportunities to:
•Review and apply basic knowledge and skills in medical
dermatology, dermatologic surgery, pediatric dermatology, and
dermatopathology.
•Update their knowledge about recent advances in the diagnosis,
management and treatment of diseases of the skin, hair, nails,
and mucous membranes.
•Assess the relationship of evidence-based diagnostic approaches
and therapies with new dermatologic treatment developments.
•Self assess current practice management skills and develop
strategies for improving these skills.
•Develop new skills to improve their everyday practice of
dermatology.
NOTE: Each session has its own specific learning objectives which
are included with the session description in the scientific sessions
portion of the Program Book.
DISCLOSURES
CME Information
PLANNER DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
The following planning committee members reported they have no relationship(s) with commercial interest(s) to disclose relevant to the
content of this CME activity:
• Michael E. Ming, M.D.
• Erik J. Stratman, M.D.
• Janet A. Fairley, M.D.
• Robert David Greenberg, M.D.
• Suzanne Olbricht, M.D.
The following planning committee members reported they do have relationship(s) with commercial interest(s) to be disclosed to learners:
Planner
Role
Commercial Interest
Robert T. Brodell, M.D.
Honoraria – Speaker
M/Graceway Pharmaceuticals, Allergan, Dermik/BenzaClin, GlaxoSmithKline,
3
Novartis Pharmaceuticals, Galderma Laboratories, L.P., Medicis, SanofiAventis, PharmaDerm/Veregen
Honoraria – Investigator
Abbott Laboratories, Centocor Ortho Biotech, Genentech
Honoraria – Consultant
Dow Pharmaceuticals Sciences, Promius
Lawrence F. Eichenfield, M.D.
Coria
Galderma, Johnson & Johnson, Ortho Dermatologics
Royalty
Elsevier, Wiley-Blackwell
Investigator – No
Compensation Received
Allerderm, Amgen, Astellas, Galderma, Johnson & Johnson,
Novartis, Stiefel
Ilona J. Frieden, M.D.
Pierre Fabre Dermatology
Joan Guitart, M.D.
Bristol-Myers Squibb, Genzyme
Honoraria – Advisory Board
Astellas
Grants – Investigator
Eisai, Yaupon
William D. James, M.D.
Honoraria – Other
American College of Physicians, Elsevier, Webmd
Royalty
Elsevier
Robert S. Kirsner, M.D.
Advanced Biohealing, Healthpoint, Tissue Repair Company
Honoraria – Advisory Board
Molynecke, National Healing Board, Organogenesis
Honoraria – Other
GlaxoSmithKline
Advisory Board – No Compensation Received
Mosaic
Henry W. Lim, M.D.
Clinuvel, La Roche-Posay, Orfagen
Ronald L. Moy, M.D.
Lumenis, Medicis
Investigator – No Compensation Received
Inamed
Suneva
Stockholder – Investigator
CLRS Technology
The Academy staff involved with this CME activity and all content validation/peer reviewers of this CME activity have reported no
relevant financial relationships with commercial interest(s).
12
|
CME Information
FACULTY DISCLOSURE OF RELEVANT
FINANCIAL RELATIONSHIP(S)
UNAPPROVED USE DISCLOSURE
Session director and faculty disclosure information is
located within the Program-at-a-Glance book after the
scientific schedule. Faculty have been asked to also make
a verbal disclosure at the start of their presentations
supplemented by a disclosure slide in order to verify
the accuracy of the disclosure information printed in
the Program-at-a-Glance and ensure their disclosure
information is shared with the learners PRIOR to the
presentation taking place.
COMMERCIAL SUPPORT DISCLOSURE
It is the policy of AAD that all faculty participating in a
CME-certified activity are required to disclose to AAD and
to learners relevant financial relationships with any
commercial interest(s) that they or their first-degree relative
(spouse, parent, sibling, or child). “Relevant financial
relationships” include financial relationships in any amount
occurring within the past 12 months that create a conflict of
interest. Typically, such relationships would be with
companies that sell health care products or services that are
consumed by or used in the treatment of patients. The intent
of this disclosure is not to prevent participation in CMEcertified educational activities by individuals with a relevant
financial relationship with commercial interest(s), but rather
to provide learners with information on which they can make
their own determination whether or not said relationship(s)
influenced the content of the educational activity.
In accordance with the ACCME Standards for Commercial
Support of CME, the American Academy of Dermatology
has implemented mechanisms, prior to the planning and
implementation of this CME activity, to identify and
mitigate conflicts of interest for all individuals in a position
to control the content of this CME activity.
The following commercial interests provided in-kind
support for the Summer Academy Meeting 2011:
Merz Aesthetics
Injectables for Live Patient Demonstration
DISCLAIMER
The American Academy of Dermatology is not responsible
for statements made by faculty. Statements or opinions
expressed in this program reflect the views of the faculty
and do not reflect the official policy of the American
Academy of Dermatology. The information provided at this
CME activity is for continuing education purposes only
and is not meant to substitute for the independent medical
judgment of a healthcare provider relative to the diagnostic,
management and treatment options of a specific patient’s
medical condition.
ACCREDITATION
The American Academy of Dermatology is accredited by the
Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
For the Latest Program Book Information PLEASE REFER TO
www.aad.org
|
13
CME Information
RESOLUTION OF CONFLICTS OF INTEREST
The American Academy of Dermatology requires CME
faculty (speakers) to disclose to attendees when products or
procedures being discussed are off-label (not approved for the
indications being discussed), unlabeled (not approved for any
indications), experimental, and/or investigational (not FDA
approved); and any limitations on the information that is
presented, such as data that are preliminary or that represent
ongoing research, interim analyses, and/or unsupported
opinion. This information is intended solely for continuing
medical education and is not intended to promote off-label
use of these products/procedures. If you have questions,
contact the medical affairs department of the manufacturer
for the most recent approval information. Faculty at this
meeting will be discussing information about pharmaceutical
agents that is outside of U.S. Food and Drug Administration
approved labeling.
CME Information
AMA PRA CATEGORY 1 CREDIT TM
DESIGNATION
The American Academy of Dermatology designates this
live activity for a maximum of 30 AMA PRA Category 1
CreditsTM. Physicians should claim the credit commensurate
only with the extent of their participation in the activity.
AAD RECOGNIZED CREDIT
The American Academy of Dermatology’s Summer Academy
Meeting 2011 is recognized by the American Academy of
Dermatology for 30 AAD Recognized Category 1 CME
Credits and may be used toward the American Academy of
Dermatology’s Continuing Medical Education Award.
NON-MEMBER PHYSICIAN CME CREDIT
CERTIFICATE
Non-member physicians who attend the meeting can
receive a CME Credit Certificate which includes
documentation of the total CME credits claimed. If you
are a physician and would like to receive a CME Credit
Certificate, please submit a copy of the CME Claim Form
and check “yes” where asked if you would like to receive the
CME Credit Certificate.
All Summer Academy Meeting 2011 activities, unless
otherwise specified, are approved for direct-sponsored
AAD Category 1 CME Credit.
CME Information
WHAT YOU NEED TO DO TO RECEIVE
CME CREDIT
CME Credit is awarded based on actual participation in the
learning activities. An overall evaluation form and CME
credit claim form will be provided in the registration bag
distributed on-site at registration. Learners should complete
the session evaluation forms and drop them into the boxes
labeled “CME Evaluations” throughout the duration of
the meeting.
Prior to departure, learners should complete the CME
credit claim form and drop it into the “CME Evaluations”
boxes for processing. CME credits can also be claimed
online at www.aad.org/cme/claim. The online claim system
is available for 2 weeks post meeting. Credit is calculated on
a 1/4-hour basis and will be reflected on member transcripts
within four to six weeks after the meeting.
14
|
When comedonal acne is your primary concern…
PRESCRIBE DIFFERIN® GEL, 0.3%
Primarily comedonal acne:
EXAMPLE A
EXAMPLE B
POWERFUL EFFICACY
HIGH PATIENT SATISFACTION
From baseline to week 12, lesion reduction
(total, noninflammatory, and inflammatory)
was similar to tazarotene gel, 0.1%1*
86% of patients on adapalene gel, 0.3%
were satisfied or very satisfied vs 69%
on tazarotene gel, 0.1%1*
Local tolerability scores comparable
to tretinoin gel microsphere, 0.04%2†
*A phase 3b, 12-week, noninferiority, multicenter, investigator-blinded, controlled clinical study of patients 12 to 35 years of age with acne vulgaris (N=172). At the end of 12 weeks,
neither product was found to be inferior. 160 patients participated in the satisfaction survey.
A single-center, randomized, investigator/evaluator-blinded, bilateral (split-face) comparison of healthy subjects ≥18 years of age (N=30). Subjects received Differin® Gel, 0.3%
on one half of the face and tretinoin gel microsphere, 0.04% on the other half for 22 days.
†
Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or
stinging/burning) during the clinical trial, the majority of cases were mild to moderate in
severity, occurred early in treatment, and decreased thereafter. Adverse events that occurred
in greater than 1% of the subjects included dry skin (14.0%), skin discomfort (5.8%), pruritus
(1.9%), desquamation (1.6%), and sunburn (1.2%). Pregnancy Category C.
Concomitant use of potentially irritating products or overexposure to sunlight or sunlamps,
extreme wind or cold, may increase the potential for irritation. Use of sunscreen and
protective clothing over treated areas are recommended when exposure cannot be avoided.
Please see brief summary of Prescribing Information on adjacent page.
www.differin.com
®
D ug Interactions:
As D FFER NGel,
Ge 0.3%
0.3% h
DIFFERIN
(adapalene)
tan u eSUMMARY
o other pot
BRIEF
eRxpatien
only
g
For
usebeonly
Not for
or cular
intravaginal
li topical
e) should
ap roa
hedophthalmic,
wi h cautionoralPart
ca t onuse
sh
®
su CATIONS
ur resorcinol,
salic ic
acid in comb
FFERfor
N the
Ge topic
, 0.3%l tr a ment
ese prepa
havs inbeen
used
IND
AND or
USAGE
DIFFERIN
G l, nation
0 3% i th
ndiD ated
of ac et ons
vulgar
patients
adv of
s bage
e not
star
12it is
years
andtoolder.
Carcinogenesis, Mutagenesis
of Fertility:
rc no enicity
adap rl hyp
e have
been
CONTRAINDICATIONS:
DIFFERIN®Impa
Gel, rment
0.3% should
not beC dmin
tered tos udie
nd v dwia hs who
rsens
t vecon
to
op al
doses of in
0 he
, gel
.3, nd
4.0
a ucted
apal n om ce
ny at
of the
omponents
ehicle
mg/kg/day. Th
PRECAUTIONS:
®
Gel 0 3%.
In th a da
at theal:m Cx mum
humaa ddose
(MRHD
to esuch
2.5 gra sryD FFER
Gene
rta n ommen
taneou digns
symp
oms ofa sumed
treatment
ema, scaling,
d yness,
s udy, increasedmay
inc dence
of benign with
and mal
pheoch® Gel,
omocytom
s in heare
adrena
of male
rats the
wa
0 3%. These
most medul
likely toasoccur
during
stinging/burning
be experienced
use gnant
of DIFFERIN
erved.
fiob
st four
weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the
ogen cityupon
stud he
es wer
d. sid
An al
ud pat
es have
wn
sk use
n n aoplasm
mNod photoc
cation rc
D pending
ev rco
ty ofduct
th se
ffe ts,
ents
ld an
be creased
structed rtoskeother
mo s
w her,the
e othe
pharm
ic ppli
y s it ar
e.g., re® G
inol,ds)
when
exposed
to UV
tur
redu ce
freq no oy of
ondrugs
of DIFFERIN
0.3%
o di
cont nue
use
un ght
hough thesens
s g ti vity
ica ce
thes als ur tation
es to occ
um ns,use
n thc ar,
patcate on
ts should
hould bebeadvi
If oa rea
tion sA ggesting
or of
chemi
usei of
med
d s ed
ontonua od
or minimtozesunlight,
exposu including
to either sunlamps,
sunlight o should
artif cialbeUVminimized
irradiationduring
sources.
Exposure
use of adapalene. Patients who normally
Ad rip nce
len hdid
no e of
h bit
n , or
ects in sv tro
s sun
est, should
Chinesebeh mst
y cel as
exp
gh levels
sun utag
xpo ur
andgeth otoxic
se withe nherent
nsi ivAm
ty to
arn rd ov
to xercise
mouse
mphoma
TK assay)
andand
in vivo
(mou
m cngonucl
test).areas is recommended when exposure cannot
tion
Us of
suns reen
products
protec
ve loth
over us
treated
product
function
fe til ysuch
stud es wind
were co duct
d no may
ats adm
ered
doses
adap ene
in amounts
beR avo
ded eWeath
r e nd
tremes,
old, al
be rri tat
ng otoa pati
ntso under
re tment
with
up to 20
adapalene
on thecon
reproductive
or fe t lit
of nose,
he F males
or females
There were
no etec
ab not
e e fects
on the
Avoid
act with theperformanc
eyes, lips, angles
of the
and mucous
membranes.
Thealso
product
should
be applied
of t r tFnoids
offspru eg.of “waxing” as a depilatory method
dev ions,
lopm czemato
nt and subs or
e su nbur
t reproduct
tog owth,
uts, abra
ed skinveAsfunc
wi hionother
Pregnancy:
eratogenic
fects wPre
nancy C
should
be avo ded
on sk n et eated
th dapalene
®
pregnant
pa eP eti nts
as been
o be Gel,
eratogenic
ats and
bbits
mi nform
stere tion
oral nd
(see
An mc
0 3%, hould
rec ve
thewhen
follo ng
instr
Info
matiowomen.
for PatAd
e ts
usingshown
DIFFERIN
Dat
tions
du min dicat
pregn
n yo on
if the
benefit
justiphysician.
ies the
1.s dThis
on is
be yused
onpotential
y as directed
by the
N® xternal
el 0.3%
pre
. isR for
useinonly
Da ct with the eyes, lips, angles of the nose, and mucous membranes.
3.. Human
Avo d con
®
n4. Cle
lin se
l t aff
ia cted
involar angw t FFER
Gel,
0.3%cleanser
in the treat
of acne
is, wo
a mi or
soapless
befo en
applying
thi ulga
med cati
n
n5 ated
reat nt
on be
y used
ter h vf nec
g h dsary;
a n gh wivever,
pr pg ancy
andning
usedalpe ae ydro
ve b yt orc ng ycoli
rol m asu
dur n
Mo s urize
may
ducts cs nta
ac d sshould
apyavoided.
How
be
s el
ed h oh babi
by n nm ead t ns
e y stwo
nts de iv con
ed prem
a deye
th
he
pregn ecy,oftwo
ien to
6 Expos
thep ye
th medi
may sresult
ch st swelling,
unct tur
s, nd
e tar iom
rr
nimal
Datc tion should not be applied to cuts, abrasions, eczematous, or sunburned skin.
7. Th
s med
te ep
atogen
ef ec snotwere
seenmed
in oa str ated
t or k doses
to 5.0o mg
8 oWax
lat o should
be perfo
n d e too the0 15
potential
sk nkge do yo sd
6 im the
s t early
e maximu
re therapy,
ommended
human ose
(MRHD of
b sed
m occur.
m c This
pari ons.
A apa
n the
ha
9. oDuring
weeks of
an apparent
exacerbation
acneonmay
may be
due to
een
ra ogen
s wh
d orab c tnsid
do red
es a 5easmg/
g depresen
act o own
of theo mb di at
n on p nev ats
ouslya dun abb
een les
on aadd nhos er
ld not
n to
scont n ne
2therapy.
and
®
m Interactions
crophthalmia Ae DIFFERIN
cephalocele
ske eth sl abnorm
li el toin nduce
the r o al
ndirru t bti nc ln erni
exophthalmos
Drug
G l,nd0.3%
the po nti
om pat
en s, concoma
nd skelet
l abno
es top
n the
t.
tan id
u yof other
po nt
ally ima
r t ng
calrab
pr ducts
(medicated or abrasive soaps and cleansers, soaps and cos
• Cut that
neous
te a olog
tudies effect,
in ra and
andproducts
rabbits atwith
doses
0.6, 2 0, and of6 0alco
mg/kg/da
exhib spices,
d no or
to
metics
have
stro g drying
highofconcentrations
ol, ast ingents,
to should
icity and
n ma with
incr ases
umerary
r b hou
in both
ayedprepa
oss aticat
in abb
lime)
be only
approm ched
autionn super
Particular
caution
d be sp
ex ci
rc edandn esing
onsonconta
n ngts
®
Systr mic
e AUCc 0ac2 hd) intocombin
adapal t on
e 0.3%
gel at topica
6.0 mg/kg
y n h ve
ts be
andn used,
abbit
sulfur,
sorc expos
nol, or salicyl
with DIFFERIN
Ge , 0doses
3% oIf these
prepa da ions
ented
5 7toand
7 times,
the exposure
pat en
ad hp ene
0.3% g
it isrepre
advi ab
e not
start28therapy
withespectively
DIFFERIN® Gel,
0 3%, untilintha ne
effects
of ut heated
pr pwrat ons
e subsided
2
in olved
applied to the fa
chest an Impairme
back (2 g at sf applied
1000nogenicity
cm of acne
Carcinogenesis,
M e,tagenesis,
Fert lityt Carc
stud
s withs n).
dapalene have been con
Nu singn Moth
rs topical
It is notdoses
knownofwhe
er his
ug smg/kg/day,
excreted nand
human
m k.
Bec doses
use man
drugs0.5,
ar and
exc 1.5
e ed
ducted
mice at
0.4, 1.3,
andd 4.0
in rats
at oral
of 0.15,
in human mT k,ese
caution
erc ss d(mic
wh )nand
DIFFE
IN Gel
s admi
stereddtoyatheursing
n.
mg/kg/day
doses hould
re up be
to e3 tim
2 imes
(rats)0 3%
in terms
of mg/m²
pot ntwom
al e posure
®
Use: Sr ety
andndef decti
enessdose
in pediatric
ients be to
owbethe2.5
agegrams
of 12DIFFERIN
have not been
atPediatric
the maximum
omm
h man
(MRHD),p ssumed
Gel, estab
0 3%. nedthe oral
®
Gel 0 pheochromocy
3% did not inc ude
65 yea med
s of llas
ge of
ndmo dl r otsdete
Geria ncreased
ric Use Clincn dcalnce
s udif benign
s of DIFFERIN
study,
and malignan
oma ub
in ects
the adrenal
wa
obm ne
ervwh
d
andphotocarcinogenicity
above have not be nstudies
estab ished
No
were conducted. Animal studies have shown an increased risk of skin neoplasms
with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or
to sunlight. Although the significance of these studies to human use is not clear, patients should be advised to avoid
or minimize exposure to either sunlight or artificial UV irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay,
mouse lymphoma TK assay) and in vivo (mouse micronucleus test).
Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts
up to 20 mg/kg/day (up to 26 times the MRHD based on mg/m² comparisons). No effects of adapalene were found
on the reproductive performance or fertility of the F0 males or females. There were also no detectable effects on the
growth, development and subsequent reproductive function of the F1 offspring.
Pregnancy: Teratogenic effects. Pregnancy Category C. Retinoids may cause fetal harm, when administered to
pregnant women. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal
Data below). There are no adequate and well controlled studies in pregnant women. DIFFERIN® Gel, 0.3% should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and efficacy of
DIFFERIN® Gel, 0.3% in pregnancy has not been established.
1 Human Data
In clinical trials involving DIFFERIN® Gel, 0.3% in the treatment of acne vulgaris, women of chi d bearing potential
initiated treatment only after having had a negative pregnancy test and used effective birth control measures during
therapy. However, 6 women treated with DIFFERIN® Gel, 0.3% became pregnant. One patient elected o terminate
the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the
babies remained in intensive care until reaching a healthy state and one patient was lost to follow up.
2. Animal Data
• No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up
to 6 times the maximum recommended human dose (MRHD) based on mg/m² comparisons. Adapalene has
been shown to be teratogenic in rats and rabbits when administered orally at doses 25 mg/kg representing
32 and 65 times, respectively, the MRHD based on mg/m² comparisons. Findings included cleft palate,
microphthalmia, encephalocele and skeletal abnormalities in the rat and umbilical hernia, exophthalmos and
kidney and skeletal abnormalities in the rabbit.
• Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no feto
toxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits.
Systemic exposure (AUC0 24h) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits
represented 5.7 and 28.7 times, respectively, the exposure in acne patients treated with adapalene 0.3% gel
applied to the face, chest and back (2 grams applied to 1000 cm2 of acne involved skin).
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted
in human milk, caution should be exercised when DIFFERIN® Gel, 0.3% is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Geriatric Use: Clinical studies of DIFFERIN® Gel, 0.3% did not include subjects 65 years of age and older to deter
mine whether they respond differently than younger subjects. Safety and effectiveness in geriatric patients age 65
and above have not been established.
ADVERSE REACTIONS: In the multi center, controlled clinical trial, signs and symptoms of local cutaneous irritation
were monitored in 258 acne patients who used DIFFERIN® Gel, 0.3% once daily for 12 weeks. Of the patients who
experienced cutaneous irritation (erythema, scaling, dryness, and/or burning/stinging), the majority of cases were
mild to moderate in severity, occurred early in treatment and decreased thereafter. The incidence of local cutaneous
irritation with DIFFERIN® Gel, 0.3% from the controlled clinical study is provided in the following table:
Table 2: Physician assessed local cutaneous irritation with DIFFERIN® Gel
Incidence of Local Cutaneous Irritation with DIFFERIN® Gel, 0.3% from Controlled Clinical Study
(N 253*)
Maximum Severity Scores Higher Than Baseline
Erythema
Scaling
Dryness
Burning/Stinging
Mild
66 (26.1%)
110 (43.5%)
113 (44.7%)
72 (28.5%)
Moderate
33 (13.0%)
47 (18.6%)
43 (17.0%)
36 (14.2%)
Severe
1 (0.4%)
3 (1.2%)
2 (0.8%)
9 (3.6%)
* Total number of subjects with local cutaneous data for at least one post Baseline evaluation.
Table 3: Patient reported local cutaneous adverse events with DIFFERIN® Gel
DIFFERIN® (adapalene) Gel, 0.3%
Related* Adverse Events
Dry Skin
Skin Discomfort
Desquamation
Vehicle Gel
N 258
N 134
57 (22.1%)
36 (14%)
15 (5.8%)
4 (1.6%)
6 (4.5%)
2 (1.5%)
0 (0.0%)
0 (0.0%)
* Selected adverse events defined by investigator as Possibly, Probably or Definitely Related
Related adverse events from the controlled clinical trial that occurred in greater than 1% of patients who used
DIFFERIN® Gel, 0.3% once daily included: dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation
(1.6%), and sunburn (1.2%). The following selected adverse events occurred in less than 1% of patients: acne flare,
contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.
In a one year, open label safety study of 551 patients with acne who received DIFFERIN® Gel, 0.3%, the pattern of
adverse events was similar to the 12 week controlled study.
OVERDOSAGE: DIFFERIN® Gel, 0.3% is intended for topical use only. If the medication is applied excessively, no
f
P
p l
f
more rapid or better results will be obtained and marked redness, scaling or skin discomfort may occur. Chronic
t t e t of
l
lt
t
d
d
b b d,
t l d h
II t
A
ingestion
the drug may lead
Dermatolof 2006;54:242
50to the same side effects as those associated with excessive oral intake of vitamin A.
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
DPT Laboratories, Ltd.
San Antonio, Texas 78215 USA
GALDERMA is a registered trademark.
Revised: June 2007 325089-0607
DI7-1
TRIM 7
BL ED: N
SAFETY
References: 1. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel
compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7
(6)(suppl):S3-S10. 2. Data on file. Galderma Laboratories, L.P. A 3-week, single-center, randomized,
investigator/evaluator-blinded, bilateral (split-face) comparison, clinical study of adults 18 years of age
and older with healthy skin (N=30).
Galderma is a registered trademark.
©2010 Galderma Laboratories, L.P.
Galderma Laboratories, L.P.
14501 N. Freeway
Fort Worth, TX 76177
DIFF-088
03/10
www.differin.com
Program Overview
Restricted Session open to dermatologist and adjunct (researcher,
corporate) members. A ticket is required for admittance
Practice Management Session open to eligible
office staff/registered nurses
Patient Safety Session
M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Leadership Institute — addresses leadership
competencies specific to dermatologists
Health Information Technology Sessions
Audience Response System Session
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U008 Quality and Customer Service
for a Better Practice. . . . . . . . . . . . . . . . . . . . . . . . . . 48
U009 Smoking and the Skin . . . . . . . . . . . . . . . . . . . . . . . 48
U010 Skin of Color. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
U011 From the Dermatology-Rheumatology Clinic:
Practical Tips and Advances in Management . . . . . . 49
Forums — 9:00 a.m. to 11:00 a.m.
F001 Nails. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Photoprotection. . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
F002 F003 Case-Based Challenges in
Consultative Dermatology. . . . . . . . . . . . . . . . . . . . 40
F004 Face to Face: Management of
Facial Dermatoses. . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Forums — 3:00 p.m. to 5:00 p.m.
F009 Review and Update of Regional Reconstruction. . . . 50
F010 Legal Dilemmas in Dermatology. . . . . . . . . . . . . . . 50
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U001 Your True Colors: Know Yourself and Understand
Others. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
U002
Asian American Skin . . . . . . . . . . . . . . . . . . . . . . . . 38
Hidradenitis Suppurativa: An Update. . . . . . . . . . . . 38
U003 U004 Medical Management of Actinic Keratoses. . . . . . . . 38
Workshop — 9:00 a.m. to 11:00 a.m.
W001 MOC Self-Assessment: Skin Cancer. . . . . . . . . . . . 41
Symposia
S001 S002 S003 — 9:00 a.m. to 12:00 p.m.
EADV/AAD Joint Symposium. . . . . . . . . . . . . . . . . 41
E.H.R. Physician Demonstration. . . . . . . . . . . . . . . 42
Negotiating Your Way to Great Leadership . . . . . . . 42
Forums — 12:00 p.m. to 2:00 p.m.
F005 Infectious Disease and Infestation Update . . . . . . . . 43
F006 What’s Boiling Over: Atopic Dermatitis and Other
Eczematous Conditions . . . . . . . . . . . . . . . . . . . . . . 43
F007 Case-Based Controversies: Procedural . . . . . . . . . . . 44
F008 Case-Based Controversies: Medical. . . . . . . . . . . . . . 44
Workshop — 12:00 p.m. to 2:00 p.m.
W002 MOC Self-Assessment: Office-Based Safety . . . 45
U005 Pitfalls in Dermatopathology. . . . . . . . . . . . . . . . . . 45
U006 Bringing out the Best in Others. . . . . . . . . . . . . . . . 46
U007 Neonatal Dermatology. . . . . . . . . . . . . . . . . . . . . . . 46
Course — 2:00 p.m. to 5:00 p.m.
C001 Live Patient Demonstration: Botulinum Toxin
and Fillers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Symposia — 2:00 p.m. to 5:00 p.m.
S004 Leading High Performance Teams . . . . . . . . . . . . . . 47
S005 Medication Monitoring and Complications. . . . . . . 48
Workshops — 3:00 p.m. to 5:00 p.m.
W003 MOC Self-Assessment: Acne, Psoriasis,
Eczema and Inflammatory Dermatosis. . . . . . . . . . 51
W004 Dermoscopy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Friday, August 5
U012 Patients Satisfaction:
Measurement and Improvement . . . . . . . . . . . . . . . 53
U013 What’s New in Non-Melanoma Skin Cancer. . . . . . 53
U014 Mastering Moles in Pediatric Patients. . . . . . . . . . . . 53
U015 Laser Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Plenary Session — 9:00 a.m. to 12:00 p.m.
9:00 a.m.Chair’s Welcome / Henry W. Lim, M.D. . . . . . . . . 54
9:05 a.m.President’s Address / Ronald L. Moy, M.D. . . . . . . 54
9:20 a.m.Everett C. Fox, M.D., Memorial Lectureship:
Sentinel Node Biopsy: Just the Facts, you Decide!
/ Timothy M. Johnson, M.D. . . . . . . . . . . . . . . . . . 54
9:50 a.m.Guest Speaker / Don Tapscott. . . . . . . . . . . . . . . . . 54
10:30 a.m.Overhauling CME and Dermatology Education:
Laps, Gaps, Maps, and Traps
/ Erik J. Stratman, M.D. . . . . . . . . . . . . . . . . . . . . 55
10:45 a.m.Contact Dermatitis / David Eric Cohen, M.D. . . . . . . 55
11:00 a.m.Update in CTCL: A Tale of Two Kinds of T-Cells
/ Sam T. Hwang, M.D., Ph.D. . . . . . . . . . . . . . . . 55
11:15 a.m.Comparative Effectiveness
/ David J. Margolis, M.D. . . . . . . . . . . . . . . . . . . . 55
11:30 a.m.Non-Ablative and Ablative Fractional Resurfacing:
Cosmetic and Medical Indications
/ Roy G. Geronemus, M.D. . . . . . . . . . . . . . . . . . . . 56
www.aad.org
|
17
Program Overview
Thursday, August 4
Program Overview
Course — 2:00 p.m. to 5:00 p.m.
C002 Live Patient Demoonstration - Neurotoxins
and Soft Tissue Augmentation. . . . . . . . . . . . . . . . . 57
S006 What’s Hot in Dermatopathology . . . . . . . . . . . . . . 57
S007 Effective Communications:
Delivering Key Messages . . . . . . . . . . . . . . . . . . . . . 58
U016 From Bench to Bedside:
Important Clinical Advances . . . . . . . . . . . . . . . . . . 58
U017 Photodynamic Therapy. . . . . . . . . . . . . . . . . . . . . . . 58
U018 Dermoscopy for the Non-Dermoscopist. . . . . . . . . . 59
Cellulitis: A Common (Mis)Diagnosis? . . . . . . . . . . 59
U019 Program Overview
Forums — 3:00 p.m. to 5:00 p.m.
F011 Using Technology to Improve
Dermatology Access. . . . . . . . . . . . . . . . . . . . . . . . . 59
F012 Case-Based Challenges for PA/NP’s. . . . . . . . . . . . . 60
Melanoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
F013 F014 Finessing Surgical Technique . . . . . . . . . . . . . . . . . . 61
W005 MOC Self-Assessment: Pediatric Dermatology. . . . 62
Saturday, August 6
U020 Exploring Evidence Based Cosmeceuticals. . . . . . . . 64
Controversies in “Dysplastic” Nevi. . . . . . . . . . . . . . 64
U021 U022 Patch Test Allergens 101:
A Detective’s Toolkit. . . . . . . . . . . . . . . . . . . . . . . . . 65
U023 Use of Light for Diagnosis and
Treatment in Dermatology. . . . . . . . . . . . . . . . . . . . 65
Forums — 9:00 a.m. to 11:00 a.m.
F015 Alopecia and Hair Loss. . . . . . . . . . . . . . . . . . . . . . . 66
Consultative Dermatology. . . . . . . . . . . . . . . . . . . . 66
F016 F017 Case-Based Controversies:
Dermatopathology. . . . . . . . . . . . . . . . . . . . . . . . . . 66
Symposia — 9:00 a.m. to 12:00 p.m.
S008 What’s Hot in Women’s Dermatology . . . . . . . . . . . 67
S009 Dermatology Grand Rounds: A Discussion of CaseBased Dilemmas. . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Course — 9:00 a.m. to 5:00 p.m.
C003 Derm Exam Prep Course: Refresher. . . . . . . . . . . . . 68
18
|
Forums — 12:00 p.m. to 2:00 p.m.
F018 Hypercoagulability, Purpura and the Skin . . . . . . . . 69
F019 Oral Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
F020 Tumor Board. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
W006 Practical Approaches to Patient Problems. . . . . . . . 70
Focus Session — 12:15 p.m. to 1:45 p.m.
U024 When Clinical and Histological Findings Converge:
Great Cases From a Dermatopathologist’s
Perspective. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
U025 Impact of Nanotechnology and Dermatology. . . . . . 71
U026 Pediatric Dermatology Jeopardy. . . . . . . . . . . . . . . . 71
Symposium — 2:00 p.m. to 5:00 p.m.
S010 Cutting Edge Surgery and Oncology. . . . . . . . . . . . 72
U027 Practical Dermoscopy. . . . . . . . . . . . . . . . . . . . . . . . 72
U028 Morphea: Not Just for Adults Anymore. . . . . . . . . . 72
Forums — 3:00 p.m. to 5:00 p.m.
F021 New Technologies in Minimally
Invasive Skin Rejuvenation. . . . . . . . . . . . . . . . . . . . 73
F022 Psoriasis Guidelines: Implementing
them in Your Practice. . . . . . . . . . . . . . . . . . . . . . . . 73
W007 Coding and Documentation. . . . . . . . . . . . . . . 74
Sunday, August 7
U029
Leprosy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
U030 Optimizing Management of Melanoma:
Recognizing and Responding to
Common Dilemmas in Patient Care . . . . . . . . . . . . 76
U031 The Interface of Skin and Psyche. . . . . . . . . . . . . . . 76
U032 Spitz’s Genodermatoses. . . . . . . . . . . . . . . . . . . . . . . 76
U033 Infectious Disease Update: What I Wouldn’t Have
Known Without Evidence-Based Medicine . . . . . . . 77
Forum — 9:00 a.m. to 11:00 a.m.
F023 Pathology and Procedures of the Aging Hand . . . . . 77
Symposia — 9:00 a.m. to 12:00 a.m.
S011 What’s Hot in Pediatric Dermatology. . . . . . . . . . . . 78
S012 What’s Breaking Out: Acne and Rosacea . . . . . . . . . 78
Personal Program Schedule
Thursday, August 4
Saturday, August 6
7:15 a.m. to 8:45 a.m.
7:15 a.m. to 8:45 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 12:00 p.m.
12:00 p.m. to 2:00 p.m.
9:00 a.m. to 5:00 p.m.
12:15 p.m. to 1:45 p.m.
12:00 p.m. to 2:00 p.m.
2:00 p.m. to 5:00 p.m.
12:15 p.m. to 1:45 p.m.
2:30 p.m. to 4:00 p.m.
2:00 p.m. to 5:00 p.m.
3:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
Friday, August 5
3:00 p.m. to 5:00 p.m.
Sunday, August 7
9:00 a.m. to 12:00 p.m.
7:15 a.m. to 8:45 a.m.
2:00 p.m. to 5:00 p.m.
9:00 a.m. to 11:00 a.m.
2:30 p.m. to 4:00 p.m.
9:00 a.m. to 12:00 p.m.
Personal Program Schedule
7:15 a.m. to 8:45 a.m.
3:00 p.m. to 5:00 p.m.
Notes
www.aad.org
|
19
General Information
MEETING LOCATION
NON-MEMBER REGISTRATION
New this year, non-member requests and required
documentation will only be accepted via the online
submission page located in the attendee registration area at
www.aad.org/meetings-and-events/summer-meeting.
Summer Academy Meeting 2011 will take place August 3-7
in New York, N.Y. On-site offices, exhibits, services, and all
educational sessions will be located at:
Hilton New York
1335 Avenue of the Americas
New York, NY 10019
www.hilton.com
Registration information
Early registration
Early registration and housing for Summer Academy
Meeting 2011 begins at 12:00 p.m. (CT), Wednesday,
May 11, 2011, according to the schedule below.
Registration and housing forms faxed in prior to the
opening of early registration will be held and processed
based on the date and time received and the schedule
listed below. Allow 3-5 business days for the processing of
faxed forms.
Non-members must submit an online request form for
registration approval and access ID number. See the chart on
page 23 for a list of non-member registration categories.
Once approved, the registration and housing brochure will
be sent via U.S. mail and an access ID number will be sent
to the e-mail address supplied online. The deadline for
submission and approval is Friday, July 15, 2011 at 12 p.m.
(CT). Please allow 10-12 days for approval, processing, and
receipt of materials, including access ID number.
Note: In an effort to make the meeting more
environmentally friendly, program books will no longer
be mailed out to non-member registrants. The complete
program book can be accessed online. Program books will be
available on-site for reference.
Questions:
[email protected] or [email protected]
Physician, life,
and honorary members........................Wednesday, May 11
Toll-free phone:
(866) 503-SKIN (7546)
Graduate members,
residents, research fellows,
and medical students............................Wednesday, May 18
Spouse/Guest registration includes spouses, family members
(children 16 years or older), and guests accompanying
registrants. A “guest” is defined as a significant other, friend,
or a child 16 years or older. Photo ID and proof of age
(driver’s license, student ID, birth certificate) will be
required. A co-worker or an associate within the industry
does not qualify for the guest registration category.
Adjunct members, physician assistants
and nurse practitioners, office
staff, registered nurses,
and non-members................................Wednesday, May 25
Early registration for members and approved non-members
closes at 12:00 p.m. (CT) on Wednesday, July 6, 2011. After
this date and time late registration will apply.
Between July 27 at 12 p.m. (CT) – August 3 at
12 p.m. (CT) all registration systems will be closed. On-site
registration will begin at 12 p.m. (CT) on Wednesday,
August 3, 2011.
SPOUSE / GUEST REGISTRATION
Spouse/Guest registration is available for one person per
physician registrant.
Registrants in this category may attend non-restricted
symposia, plenary sessions, electronic posters and technical
exhibits. This category will not be issued an ExpoCard or a
Certificate of Attendance.
www.aad.org
|
21
General Information
E-mail:
General Information
Registration instructions
Registration and housing for the Summer Academy Meeting 2011 may be completed online, by fax, or by mail.
Registration, including enrollment in specific sessions, is on a first-come, first-served basis. Registration forms are enclosed
with this book. All forms are non-transferable.
Registration
type
Registration
instructions
payment
method
processing
time
ONLINE REGISTRATION
To register and book housing online for Summer Academy Meeting 2011, go to:
www.aad.org/meetings-and-events/summer-meeting
Credit card only Instant
Credit card Three to five
business days
from receipt
Send payment, registration, and housing forms to:
Credit card
AAD Housing and Registration
568 Atrium Drive
Vernon Hills, IL 60061-1731
Registrants should retain a copy of both sides of the form for their
records before mailing. Only materials delivered to the above address will be accepted.
Five to seven
business days
from receipt
or check payable to: (Visa, Mastercard,
or American Express)
click on Attendee Registration and Housing and follow the instructions. You will need to input the ID number that is preprinted above your name on the back of the registration and housing brochure.
FAX REGISTRATION
To register by fax, complete all registration and housing forms and fax to:
(800) 521-6017 (U.S. and Canada)
(Visa, Mastercard,
(847) 996-5401 (International)
Registration and housing forms faxed in prior to the opening of early
registration will be held and processed based on the date and time
received and the schedule on the previous page.
Due to fax volume, confirmation of fax receipt will not be provided.
General Information
U.S. MAIL
(Visa, Mastercard,
AAD Housing and
Registration
CUSTOMER SERVICE
For additional assistance in completing your registration call the AAD Registration Office at (847) 996-5876 or (800) 974-3084 or call the AAD
Meetings and Conventions Department at (847) 330-0230.
ADA / SPECIAL ASSISTANCE
Academy staff will be available to help individuals with any special needs (i.e., physical). Please complete the appropriate section on the
registration form and a staff member will contact you.
TICKETED EVENTS
Registrants should identify sessions for which they are requesting tickets when they complete general registration (see chart page 24 for
information on session categories, including ticket requirements and tuition fees). Enrollment in ticketed sessions is on a first-come, first-served basis. Alternate choices should be identified. Enrollment in multiple sessions during the same time slot is not permitted.
Confirmations and changes
Confirmation letters will be sent to all registrants who register prior to the start of on-site registation. If an e-mail address is
provided, confirmation will be sent via e-mail. If no e-mail address is provided, the confirmation will be sent via fax. If
neither an e-mail address or fax number is supplied, confirmation will be sent via U.S. mail. Once you have received a
confirmation letter, you may review and print registration information online. To do so, take the following steps:
1. Visit www.aad.org/meetings-and-events/summer-meeting
2. Click on Attendee Registration and Housing
3. Click on Already Registered
4. Enter registration confirmation number and last name, then click Find Me
Once in your personal record, you may print a copy of your receipt, pay a balance due, or make changes to your registration
and housing. An updated confirmation will be sent after changes are processed.
22
|
General Information
Registration Categories, Access, and Fees
The chart below details fees and sessions access for all categories eligible to register for Summer Academy Meeting 2011. For
further information on membership eligibility, please refer to www.aad.org/member-tools-and-benefits/become-a-member or
e-mail [email protected].
Member categories
Registration Fees
SESSION ACCESS
Early
LATE
Open
Ticketed
Restricted
Physician member
$305
$325
Y
Y
Y
Adjunct (researcher, corporate)**
$305
$325
Y
Y
Y
Registration category
5/11/11 – 7/6/11
at 12:00 p.m. (CT)
7/6/11 at 12:01 p.m. (CT)
7/27/11 at 12:00 p.m. (CT)
Adjunct other**
$305
$325
Y
Y
N
Life member
$205
$240
Y
Y
Y
Honorary member
no fee
no fee
Y
Y
Y
Graduate member/Resident/Research Fellow**
$135
$160
Y
Y
Y – dermatologist N – non-dermatologist
Non-member categories
(See page 21 for information on obtaining a non-member request form for registration approval)
Registration category
EARLY
5/11/11 – 7/6/11
at 12:00 p.m. (CT)
SESSION ACCESS
LATE
Open
Ticketed
Restricted
7/6/11 at 12:01 p.m. (CT)
7/27/11 at 12:00 p.m. (CT)
Medical student* **
no fee
no fee
Y
Y
N
Non-dermatology resident**
$135
$160
Y
Y
N
Non-member physician +
(treating patients in an office-like setting)
$1,285
$1,410
Y
Y
Y – dermatologist N – non-dermatologist
Physician assistant/nurse practitioner* **
(working in an AAD member dermatologist’s office)
$305
$325
Y
Y
N
Resident/Research Fellow**
(outside U.S. and Canadian program)
$135
$160
Y
Y
Y – dermatologist
N – non-dermatologist
Office staff/registered nurse*
(working in a dermatologist’s office)
$205
$240
Y
Practice
management
sessions only
N
Non-member, non-physician (Non-member
corporate individuals and industry
representatives or scientists working
in field of the dermatology)* **++
$1,285
$1,410
Y
Y
N
Spouse/guest ++
$65
$85
Y
N
N
* This category is not eligible to register a spouse/guest along with registation.
** This category is not eligible to register office staff/RN along with registration.
+ Only dermatologists in this category may register office staff/RN along with registration.
++ This category of registration will not be issued an ExpoCard with registration.
www.aad.org
|
23
General Information
Registration Fees
General Information
Session Categories, Access and Fees
The chart below details session types at Summer Academy Meeting 2011 as well as session fees where applicable. Meeting
attendees should register for specific sessions requiring tickets when completing general registration. See page 25 for details
on distribution of tickets and other meeting materials.
tuition fee
SESSION
TYPE
SESSION
DESCRIPTION
TICKET
REQUIRED
Members
and PAs/NPs
Derm Exam Prep
Course: Refresher**
This couse is targeted at the Board Certified
Dermatologist preparing for the American
Board of Dermatology (ABD) Maintenance of
Certification in Dermatology (MOC-D) exam.
Y
$300
Non-Members and
Office Staff/RNs
Medical Students
and Residents
N/A
$150
General Information
Residents preparing for their Board exam may
also benefit, but this course is not designed as a Prep for initial board certification.
Live patient
demonstration**
Interactive session presenting live
demonstrations of botulinum toxin and soft
tissue filler injections; open to dermatologists
and adjunct (research, corporate) members only
Y
$100
$400
$60
Restricted
symposia*
Sessions comprised of individual presentations
focused on a specific subject; open to
dermatologists and adjunct (research, corporate)
members only
Y
No fee
No fee
No fee
Non-restricted
symposia*
Sessions comprised of individual presentations
focused on a specific subject
N
No fee
No fee
No fee
Workshops**
Sessions emphasizing media training, clinical
care, and technical skills
Y
$35
$95
$25
Forums*
Sessions exploring a single subject
Y
No fee
No fee
No fee
Focus sessions*
Sessions with an emphasis on discussion and
participant interaction
Y
No fee
No fee
No fee
* T
ickets for sessions with no fee will hold a seat for 15 minutes after the official start time, after which seats will be
available on a first-come first-served basis for eligible categories.
** Attendees attending sessions with a fee must have a ticket for admittance.
What’s New This Year!
CHARITABLE CONTRIBUTIONS
Donate to the AAD Shade Structure Program and/or the
AAD Camp Discovery Endowment! You can make a taxdeductible contribution when you register for the Summer
Academy Meeting 2011, or at the AAD Resource Center
located in Booth 906 in the Technical Exhibit Hall. See
page 26 for details.
Unopposed exhibit hours
In addition to the regularly scheduled exhibit hours:
Thursday............................................... 12 p.m. to 6 p.m.
Friday................................................... 12 p.m. to 6 p.m.
Saturday................................................ 10 a.m. to 2 p.m.
the Academy is offering two hours of unopposed exhibit
hours on:
Friday, August 5...............................12 p.m. to 2 p.m.
During this time, physicians may visit the technical exhibits,
without conflicts to their educational session schedule.
24
|
General Information
CANCELLATIONS
MEETING MATERIALS
Registrants who wish to cancel all of their general
registration should send a letter of cancellation via one of
the following methods:
U.S. / CANADIAN EARLY REGISTRANTS
[BY JULY 6, 2011 AT 12:00 P.M. (CT)]
General registration
E-mail:
[email protected]
Fax: (847) 996-5401 or (800) 521-6017
The following policies apply to cancellations:
Deadline:12 p.m. (CT), Wednesday,
July 27, 2011; no refund will be given
for cancellations received after this
date. No exceptions will be made.
Fee: $75 (fee will be deducted from refund
amount); $25 (fee will be deducted for
all spouse/guest cancellations)
Processing:Cancellations received by 12 p.m.
(CT), Wednesday, July 27, 2011 will
be processed and refunds issued prior
to the meeting.
No-shows:No-shows are considered to have
missed the Wednesday, July 27, 2011
deadline and are not eligible for a
refund.
Onsite:No refunds will be issued for on-site
registration.
Name change:
R
egistration is non-transferable. If you
cannot attend the meeting, you must
submit a cancellation; you may not
change the name on your registration.
For hotel reservation cancellation, please see hotel and
travel information section on page 26.
Session ticket cancellations
Session tickets must be returned prior to the start time of
the session in order to obtain a refund. To return session
tickets prior to the meeting, refer to the Meeting Materials
section.
Session tickets may be returned on site at the On-site
Registration Counter. Tickets cannot be returned or
exchanged after the start of the session. Refunds will not be
issued for late arrival or for non-attendance.
U.S. and Canadian registrants who complete registration by
12 p.m. (CT), on Wednesday, July 6, 2011, will have their
badges, tickets, and attendance verification/meeting bag
voucher sent by U.S. mail to U.S. registrants, and via
special courier service to Canadian registrants between July
11 and July 15, 2011. Materials will be mailed to the
address listed on your registration record, which will also be
listed on your ExpoCard.
In the event that you do not receive your materials prior
to the meeting, a new set can be picked up at the on-site
registration counters.
Ticketed event changes/cancellations for U.S. and Canadian
registrants who will be receiving their materials by mail will
only be accepted until Wednesday, July 6, 2011 at 12 p.m.
(CT). After this date and time, ticket cancellations and
changes will need to be made on site at the meeting. For
housing changes/cancellations, refer to the hotel and travel
information section of the program book page 27.
INTERNATIONAL REGISTRANTS AND INDIVIDUALS WHO REGISTER
AFTER wednesday, JULY 6, 2011 AT 12 P.M. (CT)
All international registrants and U.S. and Canadian registrants
who register after 12 p.m. (CT) on July 6, 2011, will need to
pick up badges, tickets, and vouchers on site at the On-site
Registration Counters. See page 28 for locations.
CORRECTIONS
Upon receipt, please review materials for accuracy.
If a discrepancy or error is found, send an e-mail to
[email protected] by 12 p.m. (CT), Wednesday,
July 27, 2011 with the following information:
• Full name
• Registration confirmation number
• Error or discrepancy found
The AAD will make every attempt to make corrections
received by the deadline prior to the start of the meeting.
Corrected tickets must be picked up at the On-site
Registration Counter (see page 28 for locations and times).
Corrections received after the deadline must be made
On-site at the Registration Counter.
ATTENDANCE VERIFICATION, MEETING BAGS, OTHER MATERIALS
Those who registered during the early registration phase and
received their meeting packet may redeem their attendance
verification/meeting bag voucher on site at the Attendance
Verification/Meeting Bag Counter. The attendance
verification/meeting bag voucher must be presented so that
attendance can be verified and CME credit claimed.
See page 28 for counter times and location.
www.aad.org
|
25
General Information
Tickets returned on-site will be processed and refunds
issued four to six weeks after the meeting.
Badges, tickets, vouchers
General Information
BADGE IDENTIFICATION
Registration categories will be indicated by badge color as
described below. Specific categories will appear in bold at
the bottom of each badge.
BADGE TYPE
BLUE
Physician members, life members, honorary
members, graduate members, residents, research
fellows, physician assistants/nurse practitioners,
non-dermatology residents, medical students, non-member physicians
Medical
personnel
YELLOW
Adjunct members, office staff/registered nurses,
and non-member non-physicians
GREEN
Spouses/guests (note: no badge will be issued to
children under 16 years)
RED
Exhibitors
BEIGE
Press
ORANGE
AAD staff
General Information
Allied health
personnel
Separate registration counters will be set up for medical
personnel and allied health personnel. Please utilize the
appropriate designated counters based on your registration
type. Please refer to the listing above.
Letters of Invitation
If you require a Letter of Invitation, please submit a written
request via e-mail to [email protected] once you have
completed your registration. Letters will be sent once
registration verification is complete. Due to security
concerns, letters will only be issued to registrants who have
completed their registration by the Wednesday, July 27, 2011,
12 p.m. (CT) deadline.
Certificate of Attendance
International registrants, physician assistants/nurse
practitioners, office staff/registered nurses, medical students,
and adjunct members may print a Certificate of Attendance
on site. To do so, take your ExpoCard to the registration
area located on the 2nd Floor Promenade of the Hilton
New York. Certificate of Attendance stations will be
available beginning Friday, August 5, 2011. Certificates will
not be issued for the spouse/guest & non-member nonphysician categories.
CHARITABLE CONTRIBUTIONS
You can make a tax-deductible contribution when you
register for the Summer Academy Meeting 2011, or at the
AAD Resource Center located in Booth 906 in the Technical
Exhibit Hall.
AAD Camp Discovery Endowment
Children with chronic skin conditions enjoy AAD Camp
Discovery, a summer camp where they can meet others with
similar conditions. You can help support this unique
summer camp opportunity! Six week-long sessions serve
more than 300 children each year.
AAD Shade Structure Program
You can be a part of the Academy’s efforts to reduce skin
cancer occurrences. More than 200 protective shade
structures have been built through this program, sheltering
more than 158,000 people from harmful UV rays each day.
Your help is needed to expand this important component of
our skin cancer prevention efforts.
Thank you for
Furthering Excellence in Dermatology…Today and Tomorrow
HOTEL AND TRAVEL INFORMATION
Hotel accommodations and reservations
Guest rooms are being held for Summer Academy Meeting
2011 registrants at the Hilton New York, Sheraton New York,
and The London, at AAD discounted meeting rates for those
booking through the AAD Housing Office. These rates are
lower than available hotel rack rates. See the registration and
housing brochure for information on hotel reservations.
Individuals who book reservations directly with the hotel are not
guaranteed the AAD discount. Additional hotels may be added
if needed.
Reservations may be made online, by fax, or by mail through
the AAD Housing Office in conjunction with registration
for the meeting and according to the registration schedule on
page 23. Hotel reservations for those not registered for the
meeting cannot be accommodated.
Be prepared to finalize your travel plans immediately as
hotel rooms go quickly. Availability cannot be guaranteed
for reservation requests received after the housing deadline
of July 12, 2011 at 12 p.m. (CT).
PAYMENT INFORMATION
Registration and housing fees may be paid by credit card
(Visa, Mastercard, or American Express) or by check,
payable to AAD Registration and Housing.
26
|
General Information
HOTEL RESERVATION CANCELLATION
Send a letter of cancellation to:
Association Travel Concepts
Registrants may book online, by phone or e-mail with the
AAD’s official travel agency, Association Travel Concepts
• E-mail: Online:
Deadline Tuesday, July 12, 2011 at 12 p.m. (CT)
[email protected] or
www.atcmeetings.com/aad
• Fax to AAD Housing Office: (847) 996-5401 or (800) 521-6017
New Users click “Create a New Account” to get started.
E-mail:
[email protected]
A full refund of your deposit will be issued.
Phone: (800) 458-9383
After Tuesday, July 12, 2011 at 12 p.m. (CT)
Requests for changes or cancellations will NOT be processed
by the AAD Housing Office after 12 p.m. (CT),
July 12, 2011. Refunds of deposits will NOT be issued for
cancellations received after 12 p.m. (CT), Tuesday,
July 12, 2011 regardless of method of cancellation
Hours:
Monday – Friday,
7:30 a.m. to 6 p.m. (CT)
Between Tuesday, July 12, 2011 and Friday, July 15, 2011
The Academy will be transferring reservation information to
hotels, and hotels will be processing reservations into their systems.
Booking fees:
Online: $7
e-mail: $35
phone: $35
(Fees apply to ticketed reservations)
United and American
You may also book through your own agency or contact the
airlines directly. Refer to the ID numbers indicated below
to receive applicable discounts.
Refund of deposits will NOT be issued for cancellations
received after 12 p.m. (CT), Tuesday, July 12, 2011
regardless of method of cancellation.
No late check-in
Failure to check in on the scheduled date of arrival will
result in the loss of deposit and cancellation of the room.
Travel information
American Airlines: (800) 433-1790
ID: 2971BC
CAR RENTAL
Discounts on vehicle rentals with Avis and Hertz are available
to meeting registrants.
Avis
Contact Avis directly and provide the Avis World Wide
discount number A723900 when making your reservation.
Reservations may be made on the Web or by phone.
Website: AIR TRAVEL
The following discounts and services have been negotiated for
registrants traveling to the Summer Academy Meeting 2011 in
New York, N.Y. through the Academy’s official travel agency,
Association Travel Concepts (ATC), on United Airlines and
American Airlines:
•Up to 5 percent off applicable classes of service for
United Airlines tickets purchased more than 30 days
prior to the meeting. Restrictions apply.
•5 percent off applicable classes of service for American
Airlines tickets purchased prior to the meeting.
• Personalized services.
• Low fare options.
• Advanced seat assignment and special meal requests.
• Frequent flyer program updates.
www.avis.com
Phone:(800) 831-8000 (U.S.)
(800) 879-2847 (Canada)
(Those outside U.S. and Canada should contact
their local Avis office.)
Hertz
Contact Hertz directly and provide the discount code
0010533 when making your reservation or submit a
coupon or promotional coupon number. Reservations may
be made on the Web or by phone.
Website: www.hertz.com
Phone:(800) 654-2210 (U.S.)
(800) 263-0600 (Canada)
(Those outside U.S. and Canada should contact
their local Hertz office.)
The above discounts apply for flights between July 31- August
10, 2011 to or from John F. Kennedy or LaGuardia Airports.
Additional services are available through Association Travel
Concepts when booking online, including airport parking,
event tickets, dining reservations, mobile device alerts, personal
profile, 24/7 online access, powerful search options, hold trips,
low fares search options.
www.aad.org
|
27
General Information
Starting July 16, 2011
Contact the hotel directly to cancel or change a reservation.
Refunds of deposits will NOT be issued for cancellations
received after 12 p.m. (CT), Tuesday, July 12, 2011
regardless of method of cancellation.
United Airlines:800) 521-4041
ID: 510CK
General Information
ON-SITE SERVICES AND EXHIBITS
ACADEMY OFFICES/EXHIBITS
All locations are in the Hilton New York unless otherwise indicated. Additional information, including hours of operation,
for these and other offices, exhibits, and services on site at Summer Academy Meeting 2011 follows.
AAD Resource Center...............................................................................................................................................Booth 906
Board of Directors’ Office.....................................................................................................................................Harlem Suite
Business Center........................................................................................................................................................... 2nd floor
Convention Office...................................................................................................................................... Gramercy Suite AB
Development Office............................................................................................................................................. Hudson Suite
Cyber Center............................................................................................................................................2nd floor Promenade
Poster Exhibits.......................................................................................................................................... 3rd floor Promenade
Registration . ............................................................................................................................................2nd floor Promenade
Press Registration......................................................................................................................................2nd floor Promenade
Speaker Ready Room................................................................................................................................. Murray Hill Suite A
General Information
Technical Exhibits............................................................................................ Rhinelander Gallery & Americas Halls I and II
Registration services
Exhibits
ON-SITE REGISTRATION COUNTER: 2ND FLOOR PROMENADE
TECHNICAL EXHIBITS: RHINELANDER GALLERY & AMERICAS
HALLS I AND II
On-site Registration will open on Wednesday, August 3 at
12 p.m. For those who have not registered prior to this date,
tickets for available sessions may be selected here.
A photo ID must be presented. Each individual can pick
up ONLY his or her own materials, with the exception of
the spouse/guest badge.
The Technical Exhibit Hall will be open during the
following hours:
Thursday, August 4....................................12 p.m. – 6 p.m.
Reception ............................................... 5 p.m. – 6 p.m.
The On-site Registration Counter will be open during the
following hours:
Friday, August 5.........................................12 p.m. – 6 p.m.
Wednesday, August 3.................................12 p.m. – 6 p.m.
Saturday, August 6..................................... 10 a.m. – 2 p.m.
Thursday, August 4...................................... 7 a.m. – 6 p.m.
Infants and children under age 16 will not be admitted to
the Technical Exhibit Hall. This policy was created for the
safety of the children of Academy members and guests. Your
compliance is appreciated.
Friday, August 5........................................... 7 a.m. – 6 p.m.
Saturday, August 6....................................... 7 a.m. – 5 p.m.
Sunday, August 7....................................... 7 a.m. – 12 p.m.
ATTENDANCE VERIFICATION/MEETING BAG PICKUP COUNTER:
2ND FLOOR PROMENADE
All registrants should redeem their attendance verification/
meeting bag voucher at the Attendance Verification/Meeting
Bag Counter during the on-site registration hours listed
above. This voucher must be redeemed in order to claim
CME credit.
28
|
Unopposed Exhibit Hours . .................. 12 p.m. – 2 p.m.
AAD RESOURCE CENTER: BOOTH #906
The AAD Resource Center contains information on
Academy membership as well as applications, and
information on Academy services and products. Staff will be
available during regular exhibit hours to answer questions.
General Information
ELECTRONIC POSTER EXHIBITS/POSTER PRESENTATIONS:
3RD FLOOR PROMENADE
BUSINESS SERVICE CENTER: 2ND FLOOR
The Business Service Center is available to all meeting
registrants. Available services include photocopying,
transparencies, fax transmissions and receipts, and FedEx
and U.S. mail drop-off. Payment is required at time of
service; major credit cards are accepted. The Business
Center will be open during the following hours:
Poster authors will conduct brief presentations of their
electronic posters at the Poster Presentation Centers in the
3rd floor Promenade during the meeting. A full schedule
of presentations will be available on the Summer Academy
Meeting 2011 website at www.aad.org in June, and posted
on-site at the meeting.
Electronic Poster Exhibits viewing stations will be open
during the following hours:
CYBER CENTER: 2ND FLOOR PROMENADE
Other Services
The Cyber Center will be open during the following hours:
EVALUATION AND CME VERIFICATION
The overall evaluation form and CME credit reporting form
will be provided in the registration bag distributed on site.
SPEAKER READY ROOM: MURRAY HILL SUITE A
The Speaker Ready Room will be open during the following
hours:
Thursday, August 4............................ 6:30 a.m. – 5:30 p.m.
Friday, August 5................................. 6:30 a.m. – 5:30 p.m.
Saturday, August 6............................. 6:30 a.m. – 5:30 p.m.
Sunday, August 7.................................. 6:30 a.m. – 12 p.m.
www.aad.org
|
29
General Information
Only those who have submitted their Attendance
Verification/Meeting Bag voucher are eligible
to claim CME credit.
General Information
PRESS REGISTRATION: 2ND FLOOR PROMENADE
Journalists who are working for and representing recognized
news organizations are encouraged to register to attend the
meeting as Press. Press may register to attend the Summer
Academy Meeting 2011 in advance or at the On-site Press
Registration Desk. To register, journalists must provide a business
card and samples of their work. All freelancers must present a
letter of assignment. Please note, the Academy will not be
hosting a Press Office at the Summer Academy Meeting 2011.
MOBILITY SERVICE
Twenty-four hour mobility service is available by contacting
ScootAround, Inc.
Toll-free phone:
(888) 441-7575
E-mail:
[email protected]
Fax:
(204) 478-1172
General Information
Mobility service during Summer Academy Meeting 2011
official meeting hours is available.
Should your needs require mobility service strictly during
official meeting hours, you may reserve a scooter through
the Academy, free of charge. To do so, check the “ADA
Mobile” box under the Personal Information page of your
online registration. You will be required to pick up and
drop off your scooter in the AAD Convention Office,
Gramercy Suite AB, each meeting day.
TOURS
The concierge at your hotel can assist with arrangements for
sightseeing tours. Should you require tour information after
you have arrived at the hotel, the Concierge Desk can be
reached from any house phone or sleeping room. The
Academy has no control over and assumes no responsibility
for the tours that are provided by independent tour
operators. This information is provided solely to assist
Summer Academy Meeting 2011 participants.
CHILD CARE SERVICES
Contact the Concierge Desk at your hotel to arrange for
child care services. Arrangements should be made as early as
possible prior to your anticipated arrival. The Academy has
no control over and assumes no responsibility for the care
provided through the hotels. This information is provided
solely as a service to help registrants identify possible
resources for child care services.
MEETING HANDOUTS
Meeting handouts will be available beginning July 1, 2011
on the Academy’s Website at www.aad.org/meetings-andevents/summer-meeting. Handouts will no longer be
distributed on site via DVD for Summer Academy
Meeting 2011.
30
|
AAD MEETING POLICIES
Independence in CME
The mission of the Academy’s continuing medical education
program is to improve patient care, and health care
outcomes by maintaining, developing and enhancing
medical knowledge, patient care, interpersonal and
communication skills and professionalism. As a provider
accredited by the Accreditation Council for Continuing
Medical Education (ACCME) and in support of this
mission, the Academy is dedicated to providing continuing
medical education that is independent, fair, balanced,
objective and free of commercial bias.
The Academy employs several strategies to ensure these
standards will be met. The planning committee members
submit and consider their own disclosure information and
recuse themselves from planning educational activities
should they have conflicts related to the subject area
presented. When developing an educational program, the
planning committee reviews applications and disclosure of
interest forms, along with needs assessment and evaluative
data from past activities in order to develop programming.
Potential participants are sent detailed guidelines that
provide direction on necessary components to ensure
independence in continuing medical education activities
and to resolve conflict, as itemized below.
Disclosure of Relevant Financial Relationships
The Board of Directors requires that all participants in the
Annual and Summer Meeting comply with all applicable
laws and regulations governing disclosure. Session directors
and speakers are required to provide the Academy with a
comprehensive disclosure of financial relationships with a
commercial interest producing health care goods or services
consumed by or used on patients. Individuals who refuse to
disclose relevant financial relationships are disqualified from
participation in the educational program(s).
Disclosure statements must include all financial
relationships occurring within 12 months of the educational
activity. If no financial relationships exist, the individual is
required to indicate such on the disclosure form.
A comprehensive disclosure of financial relationships is
published in the Program-At-A-Glance and is available
online on the Academy’s Website at www.aad.org.
In addition, directors/speakers are expected to make a verbal
disclosure of relevant financial relationships or indicate no
conflicts exist at the beginning of their presentation.
A PowerPoint-based slide with a disclosure template will be
provided to the speaker for inclusion in the presentation prior
to the meeting. Failure to disclose will result in a denial of
the opportunity to participate in the CME activity.
General Information
It is the responsibility of the session director to ensure
balance with regards to disclosure of potential conflicts of
interest. In addition, all speakers are required to complete
the speaker attestation form indicating compliance with
these policies.
Content Validation
Academy-sponsored educational activities are designed to
promote improvements or quality in health care and not
promote a specific proprietary business interest or a
commercial interest. Presentations and related materials
must be based on scientific methods generally accepted by
the medical community.
Presentations should be evidence-based and discuss the
validity of the evidence upon which they base the opinion(s).
(See Sackett et al, BMJ 1996;312:71-2.) This ensures the
audience that the recommendations are supported by the
evidence and contributes to management of any potential
conflicts of interest. Further, if the presentation includes
discussion of unlabeled or investigational use of a commercial
product, this also must be disclosed to the participants. CME
must give a balanced view of therapeutic options. Use of
generic names will contribute to this impartiality.
Outcomes Measurement
Several methods of evaluation are utilized in assessing the
educational program. Session directors, speakers, attendees,
and formal observers are all given the opportunity to
evaluate the educational content and speaker performance.
Included in this process are measures to rate the success of
the Academy’s policies regarding independence in
continuing medical education activities with particular
focus on the absence of commercial bias.
Infants and children under the age of 16 are not allowed
into educational sessions or the Technical Exhibit Hall. This
policy is due to the nature of some presentations and to
ensure the safety of registrants’ children. Your support and
compliance are appreciated.
CAMERA/VIDEO RECORDING
Use of cameras, camera phones, and video cameras is
prohibited in all educational sessions. Violations of this
policy will result in removal from the session and
confiscation of equipment. Directors and room monitors
will be closely monitoring adherence to this policy.
CELL PHONES
Cell phone usage during education sessions is disruptive
and is therefore prohibited. Session attendees are asked to
turn off cell phones or place them on vibrate prior to
entering a session room. Violations of the policy will
result in removal from the session room. Session directors
and room monitors will be closely monitoring adherence
to this policy.
g
SMOKING
All AAD educational programs within meeting rooms
and seated functions occurring during the meeting are
smoke free. Please also comply with the smoking policy
of each individual facility.
ALCOHOLIC BEVERAGES
The Academy’s official policy regarding the minimum
age for alcohol consumption is the age applicable to the
jurisdiction of the event venue.
In addition, the Academy may review speaker presentations
stored on the meeting servers to collect aggregate data
regarding disclosure. These data are only used to determine
effectiveness of the Academy’s policies and procedures
regarding disclosure.
Should it be determined that a member of the Academy’s
educational program violated the Academy’s “Policy to
Ensure Independence in Continuing Medical Education,”
the individual may not be asked to participate in future
educational programs.
www.aad.org
|
31
General Information
If CME educational material or content includes trade
names, trade names from several companies should be used
where available, as opposed to using trade names from just
a single company. Educational materials such as slides,
abstracts, and handouts cannot contain any advertising or
product-group messages.
AGE LIMITS
General Information
OFFICIAL LANGUAGE
The official language of the Summer Academy Meeting 2011
is English.
MEETING ROOM LOCATIONS
Please be aware that the room locations listed in this
program book may change prior to the meeting. Refer to
the Program Book Update under the Summer Academy
Meeting 2011 section of the AAD website at www.aad.org.
When on site, the Program-at-a-Glance will have updated
room changes. The Program-at-a-Glance will be distributed
to all registrants in the meeting bag.
scientific sessions/TICKETED SESSION LATE ARRIVALS
Tickets for sessions with no fee will hold a seat for a
registered attendee until 15 minutes after the official start
time of the session. After the first 15 minutes, seats will be
available on a first-come, first-serve basis to eligible
categories. Individuals attending sessions with a fee must
have a ticket for admittance.
AAD Staff
MEETINGS AND CONVENTIONS DEPARTMENT
The Meetings and Conventions Department administers the
Summer Academy Meeting 2011.
For further information, please contact the following staff
members by phone at (847) 330-0230, fax (847) 330-1090
or e-mail [email protected].
Timothy Moses, CMP...... Director, Meetings and Conventions
Debra Barrett...............................Senior Manager, Meetings
Robin Downey........................ Senior Manager, Registration
Sara Peterson, CEM...................... Senior Manager, Exhibits
Amanda Sage, CMP.....................Senior Manager, Meetings
Tamara Pundsack.........................Senior Meetings Specialist
Joni Taylor............................................... Exhibits Specialist
Susan Jackson................................. Administrative Specialist
Krysten Zarembski.............................Meetings Coordinator
General Information
Rachel Jamieson.................................. Registration Assistant
EDUCATION DEPARTMENT
The Education Department develops and administers the
educational program for the Summer Academy Meeting 2011.
For further information, please contact the following staff
members by phone at (847)330-0230, Fax (847)330-1135,
or e-mail [email protected].
Debra L. Gist, MPH, FACME.............. Director, Education
Jennifer Thompson, MS....... Senior Manager, Live Education
Jennifer Wahl........................................ Education Specialist
Michelle Michelotti.......................... Education Coordinator
CREATIVE AND PUBLISHING DEPARTMENT
The Creative and Publishing Department designs, edits, and
produces the Summer Academy Meeting 2011 Program Book.
Lara Lowery..................... Director, Creative and Publishing
Ed Wantuch................................................Design Manager
Nicole Torling................................................ Lead Designer
Joe Miller..................................................Graphic Designer
Katie Domanowski.................... Senior Manager, Publishing
Dean Monti ............. Managing Editor, Special Publications
Nate Jenkins......................................... Production Manager
Carrie Parratt...................................... Advertising Specialist
Jon Dudek...........................................Production Specialist
32
|
The American Academy of Dermatology
extends its most sincere appreciation
to our Sustaining Fund Donors!
Your support helps us expand and enhance our
educational and humanitarian mission.
Thank you for
Furthering Excellence in Dermatology…Today and Tomorrow!
Visit the Leaders in Giving Recognition Module
in the Level 3 Lobby.
Come visit the AAD Resource Center
Save $25 on the
Save $20 on
the 2011 Coding
and Documentation
Manual!
NEW PME Series Manual, Transition
into Practice, perfect
for the job seeker!
Save $25 on
Save 25%-35%
the newest skin cancer and sun-safe
presentation tool, the See SPOT CD.
on magazines and professional journals with this NEW member benefit!
Receive 5% off
AAD Apparel including
scrubs and lab coats!
Personalize it!
Pick up a FREE
sample pack of AAD’s
Patient Education
Pamphlets!
Booth 906 to demo these new products and save!
Save over 10%
NEW Patient
Communication
Surveys — learn
how to improve your practice and
help satisfy Component 4 of MOC-D.
Peer Communication Surveys coming soon!
on the Dermatology Self-Assessment Program Volume 4!
Satisfies
Component 2
of MOC-D!
Save $40 with
Demo the Clinical
Performance Assessment Tool (CPA and learn how it satisfies Component 4 of MOC-D.
the new Dialogues
in Dermatology
online format.
Great for iPods!
Save $25 on
Dermoscopy: A Guide
for the Physician.
View the Quality
Reporting System and find out how to earn a
1% CMS bonus! Over 8,000
slides and
400 cases!
Now replenish
skin at the
structural level
Visit
Galderma
BOOTH #5
06
to learn
more!
Cetaphil® RESTORADERM® Skin Restoring
Moisturizer and Body Wash formulated for atopic dermatitis
Patented technology helps restore hydration
in atopic skin1,2:
Ceramides help replenish the skin’s natural lipids
Filaggrin technology helps restore moisture to help rebuild the
damaged skin barrier
Clinically proven to help soothe itch and reduce redness,
dryness and irritation2
Highly tolerable; preservative and fragrance free2
cetaphil.com
References: 1. Sugarman JL. The epidermal barrier in atopic dermatitis. Semin
Cutan Med Surg. 2008;27:108-114. 2. Data on file. Galderma Laboratories.
Galderma, Cetaphil and RESTORADERM are registered trademarks.
© 2011 Galderma Laboratories, L.P.
Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
CETA-278 Printed in USA 03/11
Scientific Sessions
For a description of session categories, access and fees, see page 24.
Please note: meeting room locations are subject to change. See page 32 for more information.
M
O
C
Thursday, August 4
U001Your True Colors: Know Yourself and Understand
Others......................................................................38
U002
Asian American Skin................................................38
Hidradenitis Suppurativa: An Update.......................38
U003 U004 Medical Management of Actinic Keratoses...............38
Workshop — 9:00 a.m. to 11:00 a.m.
W001MOC Self-Assessment: Skin Cancer.........................41
Symposia
S001 S002 S003 — 9:00 a.m. to 12:00 p.m.
EADV/AAD Joint Symposium.................................41
EHR Physician Demonstration................................42
Negotiating Your Way to Great Leadership..............42
Forums — 12:00 p.m. to 2:00 p.m.
F005 Infectious Disease and Infestation Update................43
F006 What’s Boiling Over: Atopic Dermatitis and Other
Eczematous Conditions............................................43
F007 Case-Based Controversies: Procedural.......................44
F008 Case-Based Controversies: Medical...........................44
Course — 2:00 p.m. to 5:00 p.m.
C001 Live Patient Demonstration: Botulinum Toxin
and Fillers.................................................................47
S004 Leading High Performance Teams............................47
Medication Monitoring and Complications.............48
S005 Focus Sessions — 2:30 p.m. to 4:00 p.m.
U008 Quality and Customer Service for a Better Practice....48
Smoking and the Skin..............................................48
U009 U010 Skin of Color............................................................49
U011 From the Dermatology-Rheumatology Clinic:
Practical Tips and Advances in Management............49
Forums — 3:00 p.m. to 5:00 p.m.
F009 Review and Update of
Regional Reconstruction...........................................50
F010 Legal Dilemmas in Dermatology..............................50
Workshops — 3:00 p.m. to 5:00 p.m.
Eczema and Inflammatory Dermatosis....................51
W004 Dermoscopy.............................................................51
W002 MOC Self-Assessment: Office-Based Safety.......45
www.aad.org
|
37
Scientific Sessions, Thursday, August 4
Forums — 9:00 a.m. to 11:00 a.m.
Nails.........................................................................39
F001 F002 Photoprotection.......................................................39
F003 Case-Based Challenges in
Consultative Dermatology........................................40
F004 Face to Face: Management of
Facial Dermatoses.....................................................40
U005 Pitfalls in Dermatopathology....................................45
U006 Bringing out the Best in Others...............................46
Neonatal Dermatology.............................................46
U007 Scientific Sessions
Focus Sessions
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U001
Your True Colors: Know Yourself and
Understand Others
U003
Hidradenitis Suppurativa: An Update
Room: Clinton Suite
Room: Regent Parlor
Director Robert A. Lee, M.D., Ph.D.
Director Elizabeth Shannon Martin, M.D.
Thursday, August 4, Scientific Sessions
Learning Objectives
Following this focus session, the attendee should be able to:
1. Identify his/her own leadership strengths and weaknesses.
2. Improve the effectiveness of communications with others.
3. Implement core leadership competencies into daily practice.
Description
No matter the setting, dermatologists are faced with leadership
opportunities every day. Whether it be everyday staff management,
practice promotion/expansion, involvement in organized medicine,
or advancing an academic career, strong leadership skills allow a
physician to meet these challenges with aplomb. This interactive
session will allow participants to perform a personality selfassessment and focus on how information learned allows the
dermatologist to capitalize on his/her strengths and improve on
his/her weaknesses. How to improve communications with others
using personality assessment will also be discussed. This session
addresses the Leadership Institute Competencies Increasing
Self-Awareness and Communicating Effectively.
1.50 Category 1 CME Credits
U002
Asian American Skin
Room: Gibson Suite
Director Melvin W. Chiu, M.D.
Learning Objectives
1. Recognize the unique characteristics of Asian American skin.
2. Describe the presentation of particular dermatologic conditions
as they present in Asian Americans.
3. Discuss special considerations when treating Asian American
skin.
Description
The Asian American population is one of the fastest growing
segments of the U.S. population. An estimated 40 million Asian
Americans will be living in the U.S. by 2050. This session will
introduce the diversity of Asian skin, its unique characteristics,
and some of the dermatologic conditions that can manifest
differently in Asian skin. Furthermore, this session will cover
therapeutic considerations when managing skin disease in
Asian Americans.
38
|
Learning Objectives
1. Diagnose hidradenitis suppurativa, differentiate it from clinical
simulator and categorize it based on severity.
2. Summarize current medical and surgical therapeutic options.
3. Formulate and prescribe a treatment plan based on current the
medical literature.
Description
Hidradenitis suppurativa is a chronic, recurrent, scarring
inflammatory dermatosis. It is a common disease that is associated
with considerable morbidity and often poses significant challenges
for the practitioner. Its clinical presentation and corresponding
histopathology will be reviewed. Standard and newer therapeutic
options, including hormone therapy, immunomodulators, surgical
and laser procedures, will be discussed. After this presentation, the
audience will be able to diagnose and accurately stage the disease,
describe its natural history, and summarize current therapies.
They will be able to apply this information to develop a rational
treatment algorithm for this often difficult to treat disease.
U004
Medical Management of Actinic
Keratoses
Room: Sutton South
Director Neal D. Bhatia, M.D.
Learning Objectives
1. Review the fundamental pathogenesis and progression of
photodamage to actinic keratosis.
2. Apply the mechanisms of action of therapeutics to the disease
state and discuss current and future treatment options.
3. Identify the importance of incorporating medical management
of actinic keratosis into a treatment regimen.
Description
The medical management of actinic keratosis and the consequence
of photodamage requires a fundamental understanding of
the pathogenesis of mutations and the cutaneous neoplastic
changes that occur over time, as well as a basic knowledge of the
mechanisms of action of the many available therapeutic options.
The goals of the session are to review these concepts as well as
discuss current and future treatments, both topical and systemic,
to serve as part of the clinician’s regimen.
Scientific Sessions
Forums
9:00 a.m. to 11:00 a.m.
F001Nails
F002
Photoprotection
Room: Sutton North
Room: Nassau Suite A/B
Director Phoebe Rich, M.D.
Invited Speakers
C. Ralph Daniel, M.D.
Zoe Diana Draelos, M.D.
Nathaniel J. Jellinek, M.D.
Director Steven Q. Wang, M.D.
Richard K. Scher, M.D.
Dana W.K. Stern, M.D.
Learning Objectives
Following this forum, the attendee should be able to:
1. Apply techniques for performing a nail biopsy.
2. Diagnose and manage nail psoriasis, nail fungal infections and
other nail conditions.
3. Recognize and treat cosmetic nail problems.
Schedule
9:00 a.m. What You Need To Know About Nail Psoriasis and
More / Dr. Scher
9:15 a.m. What You Need: A Nail Tool Kit / Dr. Stern
9:25 a.m. How To Do It: Nail Surgery Procedures / Dr. Jellinek
9:45 a.m. Questions and Answers / All faculty
10:00 a.m. Hot Nail Topics - Tumors, Fungus, New Therapy
/ Dr. Rich
10:15 a.m. What You Need To Know About Candida in the
Nail / Dr. Daniel
10:30 a.m. The Latest and Greatest / Dr. Draelos
Henry W. Lim, M.D.
Uli Osterwalder
Learning Objectives
1. Discuss the current regulation and future trends in sunscreens
formulation.
2. Evaluate the impact of sunscreens on skin cancer prevention
and Vitamin D synthesis.
3. Explain the role of nanotechnology and antioxidants in
sunscreens formulation.
Description
Current technology and development in photoprotection,
specifically the role of sunscreen will be discussed by leading
experts in the field. The session will focus on the regulatory trends
and scientific research in sunscreen formulation. A discussion
of hot topics, such as skin cancer prevention and Vitamin D
synthesis, in photoprotection will also be presented.
Schedule
9:00 a.m. Introduction / Dr. Wang
9:05 a.m. The Ideal Sunscreen - Global Understanding,
Perspective and Direction on Sunscreen Regulation
/ Mr. Osterwalder
9:25 a.m. Photoprotection and Vitamin D: What’s New? / Dr. Lim
9:45 a.m. Does Sunscreen Prevent Skin Cancer? / Dr. Halpern
10:05 a.m. What is the Role of Antioxidants in Photoprotection?
/ Dr. Wang
10:25 a.m. The Impact of Nanotechnology in Photoprotection
/ Dr. Draelos
www.aad.org
|
39
Description
This session covers nail diagnosis, surgery and therapy, from
soup to nuts. Nail experts will discuss common and uncommon
nail problems with practical tips and strategies for management.
Detailed nail surgery know-how for the novice and experienced
will round out the program. There will be adequate time for
questions and discussion.
INVITED SPEAKERS
Zoe Diana Draelos, M.D.
Allan C. Halpern, M.D.
Scientific Sessions
Forums
9:00 a.m. to 11:00 a.m.
F003
Case-Based Challenges in Consultative
Dermatology
F004
Face to Face: Management of Facial
Dermatoses
Room: Beekman Parlor
Room: Sutton Center
Director Lauren C. Hughey, M.D.
Director Matthew Zirwas, M.D.
INVITED SPEAKERS
Jonathan Cotliar, M.D.
Lindy Peta Fox, M.D.
Kanade Shinkai, M.D., Ph.D.
INVITED Speaker
Joseph B. Bikowski, M.D.
Learning Objectives
1. Discuss controversies and challenges in the diagnosis of
inpatient dermatology cases.
2. Identify controversies and challenges in the treatment of
inpatient dermatology cases.
Description
Inpatient dermatology offers us challenging cases. On a daily
basis, we are making difficult decisions on rounds. This session
is designed to examine some of these challenging situations and
consider options for approaching these cases.
Schedule
9:00 a.m. Treatment of Inflammatory Skin Disease in the
Setting of Active Infection or Underlying Malignancy
/ Dr. Kroshinsky
9:30 a.m. Diagnosing Patients With Fever and Rash in the Bone
Marrow Unit / Dr. Cotliar
10:00 a.m. PCP Prophylaxis in Immunosuppressed Patient with
Skin Disease / Dr. Shinkai
10:30 a.m. Ethical Issues in Treatment of Hospitalized Patients
with Skin Disease / Dr. Fox
40
|
Learning Objectives
1. Diagnose unusual or unique presentations of facial dermatoses.
2. Develop unique treatment plans tailored to the presentation of
each patient.
Description
The session will consist of two lectures — one on follicularly
based facial dermatoses (demodex, acne, rosacea, pityrosporum
folliculitis, etc) and one on eczematous facial dermatoses
(seborrhea, atopic dermatitis, allergic contact, irritant contact, etc).
The lectures will not discuss typical presentations and therapies —
it is assumed that attendees are competent to diagnose and treat
these cases. Instead, the lectures will focus on difficult to diagnosis
cases and on unique presentations that predict response to specific
therapies.
Schedule
9:00 a.m. Follicularly Based Facial Dermatoses / Dr. Bikowski
10:00 a.m. Eczematous Facial Dermatoses / Dr. Zirwas
Scientific Sessions
Workshop
Symposium
W001
S001EADV/AAD Joint Symposium
9:00 a.m. to 11:00 a.m.
Tuition fee and ticket required for admission.
M
O
C
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
MOC Self-Assessment: Skin Cancer
Room: Rendezvous Trianon
Director Jerry D. Brewer, M.D.
INVITED SPEAKERS
Christian L. Baum, M.D.
Michael J. Camilleri, M.D.
Mark A. Cappel, M.D.
Room: Mercury Ballroom
Co-Director Jean L. Bolognia, M.D.
Co-Director Erwin Tschachler, M.D.
Oscar Colegio, M.D., Ph.D.
Shari Nemeth, M.D.
Learning Objectives
Following this workshop, the attendee should be able to:
1. Identify strengths and weaknesses in knowledge of cutaneous
oncology.
2. Demonstrate commitment to lifelong learning and selfassessment.
3. Practice increased self-directed learning to remain up-to-date
on current trends and information relating to cutaneous
malignancy.
Schedule
9:00 a.m. Questions on Basal Cell Carcinoma / Dr. Baum
9:20 a.m. Questions on Squamous Cell Carcinoma / Dr. Colegio
9:40 a.m. Questions on Malignant Melanoma / Dr. Nemeth
10:00 a.m. Questions on Merkel Cell Carcinoma / Dr. Nemeth
10:20 a.m. Questions on Adnexal Tumors / Dr. Camilleri
10:20 a.m. Questions on Rare Cutaneous Malignancy / Dr. Cappel
This session will be submitted to the American Board
of Dermatology for approval to satisfy Component 2,
commitment to lifelong learning and periodic
self-assessment, of the MOC-D program.
Rolf-Markus Szeimies, M.D.
Kenneth J. Tomecki, M.D.
Rein Willemze, M.D.
Learning Objectives
Following this symposium, the attendee should be able to:
1. Appreciate the bases for the new classification scheme for
cutaneous B-cell lymphomas.
2. Have an evidence-based treatment approach to bullous
pemphigoid.
3. Discuss new applications for photodynamic therapy.
Description
The EADV and AAD have joined forces in an effort to compliment
one another and provide the audience with an expanded perspective
of topics of interest to dermatologists. Speakers representing the
EADV will offer insights into the recent revisions in classification
and prognoses of cutaneous B-cell lymphomas, based in large part
upon the efforts of the EORTC. In addition to a review of newly
developed rapid diagnostic tests for sexually transmitted infections,
an evidence-based approach to the diagnosis and treatment of
bullous pemphigoid will be presented. The use of photodynamic
therapy for a range of disorders, from basal cell carcinomas to
inflammatory diseases, will be covered, as well as new light sources
and photosensitizers currently available in Europe. Because MRSA
is a significantly greater problem in the USA than in Europe,
speakers representing the AAD will provide an update on that
topic in addition to a review and critique of the recent Institute of
Medicine’s recommendations regarding vitamin D requirements.
References
1. Kirtschig G, Middleton P, Bennett C, et al. Interventions for
bullous pemphigoid. Cochrane Database of Systematic Reviews
2010, Issue 10. Art. No.: CD002292.
2. Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer.
Lancet 2010;375:673-85.
3. www.iom.edu/Reports/2010/Dietary-Reference-Intakes-forCalcium-and-Vitamin-D.aspx
Schedule
9:00 a.m. Bullous Pemphigoid: Clinical Spectrum and
Evidence-Based Practical Management / Dr. Borradori
9:30 a.m. Bad Bugs and New Drugs: MRSA Infections
/ Dr. Tomecki
10:00 a.m. Sexually Transmitted Infections: Update on Rapid
Diagnosis and Treatment / Mr. Barton
10:30 a.m. Cutaneous Lymphomas: What Dermatologists Should
Know / Dr. Willemze
11:00 a.m. Photodynamic Therapy: A European Perspective
/ Dr. Szeimies
11:30 a.m. Institute of Medicine’s Recommendations Regarding
Vitamin D Requirements / Dr. Lim
www.aad.org
|
41
Description
This session will focus on the completion of 25 questions. Answers
will be provided after the questions. The session is structured in a
question and answer format utilizing an audience response system
(ARS) and will cover skin cancer as a topic specific to MOC SelfAssessment. Participants will receive immediate feedback for each
question and identify areas of weakness that require further selfdirected study. Specific topics that will be covered include: basal
cell carcinoma, squamous cell carcinoma, malignant melanoma,
Merkel cell carcinoma, adnexal tumors, and rare cutaneous
malignancy (i.e. atypical fibroxanthoma, dermatofibrosarcoma
protuberans, etc).
Invited Speakers
Simon Barton, M.D.
Luca Borradori, M.D.
Henry W. Lim, M.D.
Scientific Sessions
Symposia
9:00 a.m. to 12:00 p.m.
S002EHR Physician Demonstration
Room: Grand Ballroom East/West
Director Mark D. Kaufmann, M.D.
Learning Objectives
1. Assess how other dermatologists in various practice settings
successfully adopted EHR systems.
2. Implement an EHR utilizing best practices.
3. Discuss how to enhance patient safety, strengthen care
coordination, and participate in quality improvements through
EHR systems.
Description
Live interactive physician-only (no vendors) demonstration of
how EHR implementation was done and pearls on strategies that
worked best. This session will provide members with an enhanced
understanding of the experiences of EHR dermatology champions.
Save the Date
Don’t miss the
2012 Volunteer Service Project
at next year’s
Annual Meeting in San Diego, CA.
Thursday, March 15, 2012
More information coming soon!
www.aad.org/dermatologyinaction
42
|
S003Negotiating Your Way to Great
Leadership
Room: Regent Parlor
Director David J. Goldberg, M.D., JD
Invited Speakers
David E. Cohen, M.D., M.P.H.
William P. Davey, M.D.
Joseph S. Eastern, M.D.
Michael H. Gold, M.D.
Stephen P. Stone, M.D.
Learning Objectives
1. Demonstrate effective negotiation skills.
2. Recognize the perspective of others involved in the negotiation
process; use alternative approaches to reach an optimal
outcome.
3. Identify skills that make participation in board/committee
meetings productive.
Description
“Getting the job done” in our daily lives requires that we negotiate
every day. Getting the job done at a committee level, on a board of
directors, in our offices, or even with industry, the academic setting
requires constant negotiation. Negotiation may be necessary to
accomplish what you need to get done with an insurance contract,
an academic department, a legislator, a building manager, industry,
your office staff, and even our patients. Insight into skills that help
you negotiate more effectively will be presented in this session.
Working in our universities, communities and organizations we
often serve on committees and boards. Skills that help you get the
job done effectively will be reviewed. Building a team that works
together to build strength, communication and efficiency for an
effective outcome is necessary in all of our work. Join our panel of
experts to learn from experience how to be an effective negotiator
and “get the job done.”
Schedule
9:00 a.m. Principles of Negotiation / Dr. Davey
9:30 a.m. Negotiating with Providers: Make It Fair / Dr. Gold
10:00 a.m. Negotiation with Patients: Control Your Day
/ Dr. Goldberg
10:30 a.m. Negotiation to Simplify our Daily Practices
/ Dr. Eastern
11:00 a.m. Negotiation with Influence on a Board of Directors
/ Dr. Stone
11:30 a.m. Negotiation In Academics: The Art and the Science
/ Dr. Cohen
Scientific Sessions
Forums
12:00 p.m. to 2:00 p.m.
F005
Infectious Disease and Infestation
Update
F006
What’s Boiling Over: Atopic Dermatitis
and Other Eczematous Conditions
Room: Sutton Center
Director Kenneth J. Tomecki, M.D.
Director Robert Sidbury, M.D.
INVITED SPEAKERS
Anne E. Burdick, M.D., M.P.H
Christopher C. Gasbarre, D.O.
Jose Dario Martinez, M.D.
INVITED SPEAKERS
Mary Wu Chang, M.D.
Lawrence F. Eichenfield, M.D.
Vincent Anthony DeLeo, M.D. Julie V. Schaffer, M.D.
Ronald P. Rapini, M.D.
Theodore Rosen, M.D.
Learning Objectives
1. Recognize recent trends and developments in infecttious
diseases and infestations.
2. Evaluate and treat affected patients more knowledgeably
and effectively.
Schedule
12:00 p.m. Insect Assaults / Dr. Rapini
12:20 p.m. Travelers’ Buggy Maladies: The Americas
/ Dr. Martinez
12:40 p.m. Are There Bed Bugs in Your Bed? / Dr. Rosen
1:00 p.m. Germs And Steel: Antibiotics In Derm Surgery
/ Dr. Gasbarre
1:20 p.m. Leprosy 2011 / Dr. Burdick
1:40 p.m. Resurgent Diseases / Dr. Tomecki
Description
This forum will update the learner on advances in the diagnosis
and management of patients with atopic dermatitis and related
conditions. We will specifically address the significance of new
food allergy guidelines and how they relate to eczema patients,
the unique challenges presented by infants with severe eczematous
eruptions, the role of patch testing and contact allergy in atopic
patients, and the appropriate use of systemic therapy.
Schedule
12:00 p.m. The Severely Affected Infant: What Should You Do
Differently? / Dr. Chang
12:24 p.m. The New NIAID Food Allergy Guidelines: How Do
They Affect my Practice? / Dr. Eichenfield
12:48 p.m. Contact Allergy and Patch Testing in Atopic Patients
/ Dr. DeLeo
1:12 p.m. The Appropriate Use of Systemic Therapy / Dr. Schaffer
1:36 p.m. The Rest of the Story / Dr. Sidbury
www.aad.org
|
43
Description
This session, essentially an infectious “what’s new,” will highlight
the following topics: Selected infestations, including bed bugs;
selected travel-related afflictions from the Americas; leprosy;
resurgent diseases; and antimicrobials used in surgey. Presentations
will emphasize trends and new developments, including diagnosis,
therapy, and changing patterns of disease. Session will be clinically
germane and directly applicable to patient care.
2 .00 Category 1 CME credits
Learning Objectives
1. Review the new NIAID food allergy guidelines and their
relevance to AD care.
2. Discuss the differential diagnosis and appropriate management
of severe infantile eczema.
3. Recognize the appropriate use of systemic therapy in atopic
dermatitis.
Scientific Sessions
Forums
12:00 p.m. to 2:00 p.m.
F007
Case-Based Controversies: Procedural
Room: Sutton North
F008
Case-Based Controversies: Medical
Director Mark D. P. Davis, M.D.
Learning Objectives
1. Develop treatment strategies for challenging skin cancers.
2. Manage reconstruction conundrums.
INVITED SPEAKERS
Dawn M. R. Davis, M.D.
Amer Nizar Kalaaji, M.D.
Kathleen Julie Hectorne, M.D. Catherine Clayton Newman,M.D.
David A. Wetter, M.D.
Description
The session is divided in two parts. The first part will focus
on controversies in the management of melanoma, the use
of adjuvant radiation in the treatment of SCC and role of
dermatologists in treating Merkel cell carcinoma. The second part
will highlight challenges in regional reconstruction.
Learning Objectives
1. Describe controversies in diagnosis of selected dermatologic
conditions.
2. Discuss controversies in the management of selected
dermatologic conditions.
Director Victor Allen Neel, M.D., Ph.D.
Description
We will explore cases seen by medical dermatologists that led to
some controversy either in diagnosis or management.
Schedule
12:00 p.m. Is Interstitial Granulomatous Dermatitis a Systemic
Disorder? / Dr. Newman
12:20 p.m. The Patient is Starting Prednisone 30 mg Daily for
Immunobullous Disease: Does PCP Prophylaxis Need
to be Initiated? / Dr. Kalaaji
12:40 p.m. The Patient is on Biologics for Rheumatoid Arthritis.
Now He has Developed What Looks Like Psoriasis on
the Hands and Feet: What to do Now? / Dr. Wetter
1:00 p.m. Controversial Cases Seen by the Pediatric
Dermatologist: A Pot-Pourri / Dr. Davis
1:20 p.m. This Male Patient Has Severe, Recalcitrant
Nodulocystic Acne. He has a History of Psychiatric
Illness: Should you Prescribe Isotretinoin?
/ Dr. Hectorne
1:40 p.m. The Patient Clearly has Delusions of Parasitosis:
What Now? / Dr. Davis
44
|
Scientific Sessions
Workshop
Focus Session
W002MOC Self-Assessment:
M
O
Office-Based Safety
C
U005
Pitfalls in Dermatopathology
Room: Gibson Suite
12:15 p.m. to 1:45 p.m.
12:00 p.m. to 2:00 p.m.
Director Hillary Johnson-Jahangir, M.D., Ph.D.
INVITED SPEAKERS
Jacques Michael Casparian, M.D. Divya Srivastava, M.D.
James Selwyn Taylor, M.D.
Oliver J. Wisco, D.O.
Learning Objectives
1. Identify strengths and weaknesses in one’s knowledge of issues
in patient safety that are relevant to dermatology.
2. Integrate and apply current concepts in patient safety to
improve patient care.
Learning Objectives
1. Recognize a variety of dermatopathology cases that are prone to
be misdiagnosed.
2. Identify histological features that are useful in preventing
pitfalls in diagnosis.
3. Determine appropriate ancillary studies that help arrive at the
correct diagnosis.
Description
This session is directed towards residents, dermatologists with an
interest in dermatopathology and dermatopathologists who enjoy
challenging cases. Pitfalls in the diagnosis of cutaneous neoplasms
that may result in diagnostic errors with significant clinical impact
will be presented. The session focuses on histological mimickers:
skin malignancies that resemble reactive conditions or benign
neoplasms, benign conditions that masquerade as malignancies
and tumors that are prone to be mistaken for other types of
cutaneous malignancies. The audience will be presented with the
salient features of each entity and with tips to avoid misdiagnosis.
* Self-assessment questions utilized in this session are
the same as those used for Workshop W013 offered at
Annual Meeting 2011 and Workshop W004 offered
at Summer Academy Meeting 2010. Physicians should
not claim CME/MOC credit for attending this session
if they attended Workshop W013 at Annual Meeting
2011 or Workshop W004 at Summer Academy
Meeting 2010.
www.aad.org
|
45
Description
This session will be structured as a question-and-answer format
using an automated response system. Current concepts in patient
safety that are relevant for dermatologists will be highlighted.
Safety issues important in procedural and medical dermatologic
practice will be addressed in order to better care for our patients.
This session does not qualify as a Patient Safety Module for MOC
Component 2: Commitment to Lifelong-Learning and Periodic
Self-Assessment.
Director Aleodor A. Andea, M.D.
Scientific Sessions
Focus Sessions
12:15 p.m. to 1:45 p.m.
U006
Bringing out the Best in Others
Room: Regent Parlor
Director Kathryn Schwarzenberger, M.D.
INVITED SPEAKERS
Jane M. Grant-Kels, M.D.
Joseph L. Jorizzo, M.D.
Learning Objectives
1. Describe and utilize mentorship skills to build teams at all
levels.
2. Identify and nurture qualities in individuals that help your
team grow.
Description
Regardless of practice setting, we all work closely with others:
partners, residents, nurses, assistants, and staff. One of the most
rewarding, and potentially difficult, aspects of leadership is helping
others mature and grow into their full potential. Join several
dedicated mentor-leaders in our field as they share their pearls
about how to help others reach their full potential. Audience
participation will be sought in this open-format session.
Develop the
Leader Within!
Leadership Institute sessions and
events offer you an opportunity
to strenthen your leadership skills
to benefit you in your career, the
specialty and your personal life.
Set aside time for you to enhance
and engage your inner leader at this
year’s Summer Academy Meeting.
U007Neonatal Dermatology
Room: Sutton South
Director Tor A. Shwayder, M.D.
Learning Objectives
1. Recognize normal newborn cutaneous variants so one can relax
and reassure the parents.
2. Identify abnormal newborn cutaneous variants and when to
yell for help!
3. Perform an examination on newborn skin at the hospital
or office.
All Leadership Institute sessions are marked
with
In between meetings, visit
www.aad.org/leadership to learn more.
Description
Love seeing those babies, but dread being asked about a rash?
Confused about normal newborn skin variations? How does one
approach the cutaneous signs of rare genetic diseases? And those
marks with rare systemic associations, do they need imaging or
follow up? Journey with me to explore the newborn skin, with
special emphasis on the normal, practical, everyday office visit
punctuated with only enough warnings to keep you on your toes.
Included at no extra charge: Hints from 30 years of keeping my
tie clear of poop and how to muffle ear-splitting cries.
46
|
throughout the Program Book.
Scientific Sessions
Course
Symposium
2:00 p.m. to 5:00 p.m.
C001
2:00 p.m. to 5:00 p.m.
Live Patient Demonstration: Botulinum
Toxin and Fillers
S004
Room: Trianon Ballroom
Director Margaret E. Parsons, M.D.
Director Thomas E. Rohrer, M.D.
INVITED SPEAKERS
Diane S. Berson, M.D.
Doris J. Day, M.D.
Lisa M. Donofrio, M.D.
Michael Kane, M.D.
Amy B. Lewis, M.D.
Ellen S. Marmur, M.D.
Alan Matarasso, M.D.
Seth L. Matarasso, M.D.
Roberta D. Sengelmann, M.D.
Description
This live interactive session will feature experts from around the
country demonstrating and commenting on soft tissue filler and
botulinum toxin injections. It is an opportunity for attendees to
virtually step into the office of these expert injectors and see how
they assess, interact with, and inject their patients. Each region of
the face will be addressed by two faculty members and audience
interaction is encouraged.
References
1. Kaminer M, Dover J, Arndt K, Rohrer T, eds. Atlas of
Cosmetic Surgery. Philadelphia: Elsevier, 2008
2. Carruthers A, Carruthers J. Botulinum Toxin in Procedures in
Cosmetic Dermatologic Surgery Series. Philadelphia: Elsevier,
2008
3. Carruthers A, Carruthers J. Soft Tissue Augmentation In
Cosmetic Dermatology Series. Philadelphia: Elsevier, 2008
Leading High Performance Teams
Room: Regent Parlor
INVITED SPEAKERS
Karen Collishaw, CAE
Jennifer Lucas, M.D.
Victor J. Marks, M.D.
Erik J. Stratman, M.D.
Learning Objectives
1. Identify key concepts of team-building.
2. Plan and execute effective team goals.
3. Utilize team member skills for effective outcomes.
Description
Getting your team to work together for maximum performance
requires insight, thought, preparation, and leadership. Join our
experts in this area to learn concrete concepts and valuable insight
and ideas on how to maximize your team’s performance for an
optimal result with a group that feels that they have worked
together and enjoyed the process to achieve success.
References
1. Lencioni, P. The Five Dysfunctions of a Team. Jossey-Bass.
2002
Schedule
2:00 p.m. Introduction / Dr. Parsons
2:05 p.m. Managing Teams: Principles / Ms.Collishaw
2:35 p.m. Questions and Answers / Ms.Collishaw
2:40 p.m. Leading Teams / Dr. Marks
3:20 p.m. Questions and Answers / Dr. Marks
3:30 p.m. Knowing the Personalities on Your Team / Dr. Stratman
4:00 p.m. Questions and Answers / Dr. Stratman
4:05 p.m. Being a Star Team Player / Dr. Lucas
4:30 p.m. Questions and Answers / Dr. Lucas
4:35 p.m. Getting the Work Done on Time / Dr. Parsons
4:55 p.m. Questions and Answers/Conclusion / Dr. Parsons
Schedule
2:00 p.m. Introduction
2:05 p.m. Upper Face Rejuvenation / Dr. Alan Matarasso
/ Dr. Seth Matarasso
2:30 p.m. Lower Face Rejuvenation / Dr. Marmur / Dr. Day
2:55 p.m. Filling the Temples / Dr. Berson / Dr. Marmur
3:20 p.m. Volumizing the Mid Face / Dr. Donofrio / Dr. Lewis
3:45 p.m. Creating the Perfect Lip / Dr. Seth Matarasso
/ Dr. Berson
4:10 p.m. Rejuvenating the Neck and Hands / Dr. Lewis
/ Dr. Day
4:30 p.m. Rejuvenating the Eyes and Tear Troughs / Dr. Kane
/ Dr. Donofrio
4:55 p.m. Questions and Answers
www.aad.org
|
47
Learning Objectives
Following this course, the attendee should be able to:
1. Assess the aging face and choose the most appropriate injection
techniques.
2. Identify soft tissue fillers appropriate for a variety of facial areas
and applications.
3. Identify new concepts in facial aging and how that applies to
rejuvenating procedures.
Scientific Sessions
Symposium
Focus Session
S005
Medication Monitoring and
Complications
U008
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
Quality and Customer Service for a Better
Practice
Room: Gibson Suite
Director Stephen E. Wolverton, M.D.
Director Charles N. Ellis, M.D.
INVITED SPEAKERS
James Q. Del Rosso, D.O.
Julie Claire Harper, M.D.
John A. Zic, M.D.
Learning Objectives
1. Recognize why Service Excellence is important and how it
represents quality in medicine.
2. Evaluate great service in the office setting.
3. Implement Service Excellence in dermatology offices.
Learning Objectives
1. Identify the safety issues concerning common systemic
therapies in acne and rosacea.
2. Describe the clinical relevance of selected chemotherapy drugs
in dermatology and the cutaneous risks of these drugs.
3. Assess the most current scientific information on the most
serious isotretinoin complications, focusing most on the
theoretical risk of inflammatory bowel disease.
Description
This highly interactive symposium will address important up-todate scientific information, as well as relevant controversies and
difficult questions concerning four common areas of systemic
dermatologic therapy. Experts in each of the four areas will
inform and challenge the audience concerning both the important
complications and monitoring required in order to maximize drug
safety. The schedule allows more than adequate time to answer
questions from the audience.
References
1. Wolverton SE editor, Controversies in Dermatologic Drug
Therapy. Dermatol Ther 22(5):397, 2009 Sep-Oct. (entire issue)
Schedule
2:00 p.m. Systemic Agents Used to Treat Acne and Rosacea:
Monitoring and Safety Consideration / Dr. Del Rosso
2:40 p.m. Questions and Answers / All faculty
2:45 p.m. Chemotherapy and Dermatologist: Some Dermatology
Uses and Unique Skin Complications / Dr. Zic
3:25 p.m. Questions and Answers / Dr. Zic
3:30 p.m. Isotretinoin Adverse Effects: An Update on the Most
Worrisome Complications / Dr. Harper
4:15 p.m. Drug Causation: How Do We Know the Drug Did
the Deed? / Dr. Wolverton
48
|
Description
Service Excellence (also called customer service) is a critical
competency for dermatologists. Studies show patient satisfaction is
driven by patient experiences, even more than patient outcomes.
There is evidence that patient satisfaction and quality medicine
are one and the same. Training in providing great service leads to
a more efficient and happier workforce. Service Excellence forms
a foundation for other projects and safety improvements. After
instituting Service Excellence, practitioners spend more time in
medical care and less in office problem-solving. Understanding
how to provide great service will be the best thing you ever did for
yourself. (For all practitioners).
U009
Smoking and the Skin
Room: Sutton South
Director Sergei A. Grando, M.D., Ph.D.
Learning Objectives
1. Diagnose smoking-related skin and mucosal changes.
2. Diagnose skin and mucosal diseases related to smoking.
Description
In addition to a well known harmful role of smoking in several
inflammatory skin diseases, such as psoriasis and hidradenitis
suppurativa, there is a high risk of developing skin cancers among
first- and second-hand smokers. Increased skin cancer rate and
precocious skin aging in smokers are the two arms of the same
pathophysiologic mechanism. On the other hand, there is a
negative association of smoking with certain skin diseases, such
as pyoderma gangrenosum and pemphigus. The dichotomous
effect of smoking can be explained through the nicotinic receptormediated action of nicotine on different cutaneous cell types
involved in a particular disease.
Scientific Sessions
Focus Sessions
2:30 p.m. to 4:00 p.m.
U010
Skin of Color
Room: Clinton Suite
Director Wendy E. Roberts, M.D.
Learning Objectives
1. Review the current peer reviewed literature in Ethnic Skin of
Color.
2. Discuss skin cancer, alopecia and inflammatory disorders in
Ethnic skin of Color.
3. Update our medical knowledgebase and treatments in Ethnic
Skin of Color.
U011
From the Dermatology-Rheumatology
Clinic: Practical Tips and Advances in
Management
Room: Madison Suite
Director Abrar A. Qureshi, M.D., M.P.H.
Description
This session will consist of a summary of clinic set-up with a
discussion of operational, patient flow and billing practices.
I will discuss approaches to the patient with cutaneous lupus,
dermatomyositis, pyoderma gangrenosum, scleroderma/fibrosis
and psoriasis/psoriatic arthritis including taking a history and
physical examination, laboratory investigations and therapy. As
examples, case studies from our multidisciplinary clinics will be
presented emphasizing management and decision making process
and referral back to the referring dermatologist. Therapeutic
approaches will focus on case examples to illustrate choice of
systemic therapies including biologics. We will spend time
on off-label treatment options and therapeutic pearls mainly,
emphasizing the treatment of skin disease in patients who also
have multi-organ disease.
Teach the fundamentals of skin cancer and sun-safety!
Adults
Pre-teens
and Teens
Children
Grades
3-5
Perfect for school
presentations and
screening events!
Children
Grades
K-2
The See SPOT CD contains four dynamic PowerPoint™ slide
presentations, each specially targeted to a different age group.
The CD includes:
• Scripts that follow along with each presentation, slide by slide
• Pre- and post-presentation evaluations to test your audience’s
sun safety knowledge
• Printable coloring pages and word finds – great giveaway for
your waiting room
Visit the Academy Resource Center
Booth 906 to demo.
www.aad.org
|
49
Description
This session will overview pertinent and current peer review
literature present regarding Skin and Hair of Color. Fact vs.
fiction will be reviewed regarding description, detection and
treatment options in persons with darker skin types. The session is
targeted as a data resource for those who teach, research, or treat
skin of color.
Learning Objectives
1. Design a combined clinic with physicians from multiple
specialties working together.
2. Evaluate and work up patients with cutaneous lupus,
dermatomyositis, pyoderma gangrenosum, scleroderma/fibrosis
and psoriasis/psoriatic arthritis in a multidisciplinary clinic
environment.
3. Treat patients with cutaneous lupus, dermatomyositis,
pyoderma gangrenosum, scleroderma/fibrosis and psoriasis/
psoriatic arthritis.
Scientific Sessions
Forums
3:00 p.m. to 5:00 p.m.
F009
Review and Update of Regional
Reconstruction
F010
Room: Sutton Center
Director Clifford Warren Lober, M.D., J.D.
Director Shang I. Brian Jiang, M.D.
INVITED SPEAKERS
Murad Alam, M.D.
John A. Carucci, M.D., Ph.D.
Hayes B. Gladstone, M.D.
Learning Objectives
1. Recognize the best reconstruction options for difficult anatomic
areas.
2. Identify different reconstructive options for various anatomic
locations.
3. Identify important recent literature related to regional
reconstruction.
Description
This session will focus on regional reconstruction for Mohs surgery
defects. The speakers will review and update different repair
options for difficult anatomic locations such as the nose, ear, lip/
perioral area as well as staged procedures for these same locations.
Schedule
3:00 p.m. Introduction / Dr. Jiang
3:05 p.m. Reconstruction of Nasal Defects / Dr. Jiang
3:30 p.m. Reconstruction of the Lip and Perioral Area / Dr. Alam
3:55 p.m. Reconstruction of the Ear / Dr. Gladstone
4:20 p.m. Staged Reconstruction: Regional Approach / Dr. Carucci
50
|
Legal Dilemmas in Dermatology
INVITED SPEAKERS
Rebecca B. Campen, M.D., J.D.
Jonathan Scott Sanders, M.D., J.D.
Learning Objectives
1. Analyze legal dilemmas to facilitate appropriate patient care.
2. Recognize legal implications of treatment alternatives.
Description
You are online in a social Internet site and one of the other people
starts to discuss the treatment of his unusual skin condition. You
can’t resist giving advice. Unfortunately, your advice is grossly
incorrect. What is your liability? You see a patient who adamantly
insists that his sutures be removed one week after they have been
placed, but you know medically that the patient will have an
unsatisfactory result if you comply with his demand. What should
you do? These and other legal dilemmas will be discussed by a
panel of MD/JDs, all of whom are practicing dermatologists.
Schedule
3:00 p.m. Presentation and Analysis of Legal Dilemmas
/ All faculty
4:15 p.m. Presentation and Analysis of Legal Dilemmas
/ All faculty
Scientific Sessions
Workshops
3:00 p.m. to 5:00 p.m.
W003
M
O
C
MOC Self-Assessment: Acne, Psoriasis,
Eczema and Inflammatory Dermatosis
W004
Dermoscopy
Room: Sutton North
Director Mary C. Martini, M.D.
Director Joslyn S. Kirby, M.D.
INVITED SPEAKERS
Mark Lebwohl, M.D.
Christen M. Mowad, M.D.
INVITED Speaker Ana M. Ciurea, M.D.
Misha Rosenbach, M.D.
Joshua Zeichner, M.D.
Learning Objectives
1. Identify the strengths and weaknesses in the attendee’s
dermatology knowledge and to make improvements as needed.
2. Demonstrate commitment to lifelong learning and selfassessment via completion of 25 questions and answers with
discussion.
DERMOSCOPY
Description
This session is geared for both the beginner dermoscopist and also
offers a good review for clinicians who incorporate dermoscopy
in their practices. The session will review terminology, current
dermatoscopes: polarized and non-polarized and the two step
algorithm. Following these presentations, the attendee will view
numerous images of benign and malignant melanocytic lesions,
with emphasis on melanoma and dysplastic nevi. Non-melanocytic
lesions will also be covered. The session will conclude with a series
of dermoscopy unknowns.
Schedule
3:00 p.m. Dermoscopy Basics: Equipment and Terminology
/ Dr. Ciurea
3:20 p.m. Questions / Dr. Ciurea
3:30 p.m. The two Step Algorithm: Defining Melanocytic and
Non-Melanocytic Lesions / Dr. Ciurea
3:50 p.m. Questions / Dr. Ciurea
4:00 p.m. Dysplastic Nevi and Melanoma / Dr. Martini
4:20 p.m. Questions / Dr. Martini
4:30 p.m. Dermoscopy Unknowns / Dr. Martini
4:50 p.m. Questions / Dr. Martini
A Guide for the Physician
Learn a technique that is less invasive and yields
faster results, both of which benefit the patient.
• View over 8,000 slides and 400 cases
• Identify and diagnose lesions of the skin
• Includes two DVDs – basic and advanced
Visit the Academy
Resource Center Booth
906 to purchase!
www.aad.org
|
51
Description
This session is structured as a question and answer forum using an
audience response system. This forum will allow for self-assessment
with immediate feedback and allows for identification of areas that
require further self-directed study. The forum will cover topics in
acne, psoriasis, eczema, and other inflammatory dermatoses. Due
to the timed framework of this session, please arrive on time.
This session will be submitted to the American Board
of Dermatology for approval to satisfy Component 2,
commitment to lifelong learning and periodic
self-assessment, of the MOC-D program.
Learning Objectives
1. Apply the two step method to identify melanocytic and
nonmelanocytic skin lesions with dermoscopy.
2. Distinguish benign and malignant melanocytic lesions using
dermoscopy.
3. Identify melanoma on dermoscopy.
Scientific Sessions
Friday, August 5
U012Patients Satisfaction:
Measurement and Improvement . . . . . . . . . . . . . .
U013
What’s New in Non-Melanoma Skin Cancer. . . . .
U014
Mastering Moles in Pediatric Patients . . . . . . . . . .
U015
Laser Update. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Friday, August 5, Scientific Sessions
M
O
C
53
53
53
53
Plenary Session — 9:00 a.m. to 12:00 p.m.
9:00 a.m. Chair’s Welcome / Henry W. Lim, M.D. . . . . . . . . 54
9:05 a.m. President’s Address / Ronald L. Moy, M.D. . . . . . . 54
9:20 a.m.Everett C. Fox, M.D., Memorial Lectureship:
Sentinel Node Biopsy: Just the Facts, You Decide
/ Timothy M. Johnson, M.D. . . . . . . . . . . . . . . . . . 54
9:50 a.m. Guest Speaker / Don Tapscott. . . . . . . . . . . . . . . . . 54
10:30 a.m.Overhauling CME and Dermatology Education:
Laps, Gaps, Maps, and Traps
/ Erik J. Stratman, M.D.. . . . . . . . . . . . . . . . . . . . 55
10:45 a.m. Contact Dermatitis / David Eric Cohen, M.D. . . . . . 55
11:00 a.m.Update in CTCL: A Tale of Two Kinds of T-Cells
/ Sam T. Hwang, M.D., Ph.D. . . . . . . . . . . . . . . . 55
11:15 a.m.Comparative Effectiveness
/ David J. Margolis, M.D.. . . . . . . . . . . . . . . . . . . 55
11:30 a.m.Non-Ablative and Ablative Fractional Resurfacing:
Cosmetic and Medical Indications
/ Roy G. Geronemus, M.D. . . . . . . . . . . . . . . . . . . 56
S006 What’s Hot in Dermatopathology. . . . . . . . . . . . . 57
Effective Communications:
S007 Delivering Key Messages. . . . . . . . . . . . . . . . . . . . 58
U016 From Bench to Bedside:
Important Clinical Advances. . . . . . . . . . . . . . . . .
U017 Photodynamic Therapy. . . . . . . . . . . . . . . . . . . . .
U018 Dermoscopy for the Non-Dermoscopist. . . . . . . .
Cellulitis: A Common (Mis)Diagnosis?. . . . . . . . .
U019 Forums —
F011 F012 F013 F014 3:00 p.m. to 5:00 p.m.
Using Technology to Improve Dermatology Access. . 59
Case-Based Challenges for PA/NPs. . . . . . . . . . . . 60
Melanoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Finessing Surgical Technique. . . . . . . . . . . . . . . . . 61
W005 MOC Self-Assessment: Pediatric Dermatology. . . . 62
Course — 2:00 p.m. to 5:00 p.m.
C002 Live Patient Demonstration: Neurotoxins and Soft
Tissue Augmentation. . . . . . . . . . . . . . . . . . . . . . . 57
52
|
58
58
59
59
Scientific Sessions
Focus Sessions
7:15 a.m. to 8:45 a.m.
U012
Patients Satisfaction: Measurement and
Improvement
Room: Gibson Suite
U014
Mastering Moles in Pediatric Patients
Room: Regent Parlor
Director Julie V. Schaffer, M.D.
Director Victor James Marks, M.D.
Learning Objectives
1. Recognize the difference between patient and physician
perception of excellence in care.
2. Apply Principles of Service Excellence to your practice setting.
3. Identify behavioral standards that can be adopted as office
standards.
U013
What’s New in Non-Melanoma Skin
Cancer
Room: Sutton South
Director Gary Goldenberg, M.D.
Learning Objectives
1. Identify and analyze new and important studies in nonmelanoma skin cancer.
2. Describe new findings in dermatopathology in relation to nonmelanoma skin cancer.
3. Identify new treatment approaches to non-melanoma skin
cancer.
Description
This session will focus on non-melanoma skin cancer, including
actinic keratosis, squamous cell carcinoma, basal cell carcinoma,
Merkel cell carcinoma, and Kaposi’s sarcoma. We will review
and analyze new studies, focusing on pathogenesis, epidemiology,
histopathology, and treatment.
Description
This session will review the clinical spectrum, natural history,
and management of melanocytic nevi in children, including
variants such as spitz, blue, and speckled lentiginous nevi. Current
concepts of the risks associated with congenital melanocytic nevi
of different sizes, numbers, and locations as well as individualized
strategies for their management (e.g. considering cosmesis and
ease of monitoring) will be discussed. Recent observations on the
dermatoscopic features and molecular hallmarks of childhoodacquired and congenital melanocytic nevi will be examined,
highlighting insights into pathways of melanocytic tumorigenesis.
Data on clinical presentations and biologic behavior of prepubertal
melanoma will also be presented.
U015
Laser Update
Room: Clinton Suite
Director Jerome M. Garden, M.D.
Learning Objectives
1. Choose appropriate laser systems for various conditions.
2. Determine a practical and safe approach for everyday practice.
3. Identify the latest developments in laser therapy.
Description
With so many devices being promoted for the treatment of the
skin, this forum will give an understanding to the science and
clinical outcome including the latest developments. A greater skill
as how to approach the patient will be developed.
www.aad.org
|
53
Scientific Sessions, Friday, August 5
Description
This session will focus on raising awareness of the importance
of an exceptional experience by patients as the basis for office
success. We will discuss patient versus physician perceptions of
care, outline principles of service excellence, and elucidate the
concept of behavioral (service) standards as a means of ensuring
consistently personal service delivery by all personnel in the office.
Learning Objectives
1. Recognize clinicopathologic variants of acquired and congenital
melanocytic nevi in children and their typical patterns of
evolution.
2. Identify and monitor children at risk for the development of
melanoma or neurocutaneous melanocytosis.
3. Formulate an individualized approach to management of
melanocytic nevi in children.
Scientific Sessions
P151 PLenary Session
9:00 a.m. to 12:00 p.m.
Up to 2.00 Category 1 CME Credits
9:05 a.m.
9:00 a.m.
Welcome
President’s Address
Henry W. Lim, M.D.
Chair, Scientific Assembly Committee
Ronald L. Moy, M.D.
“To help us succeed in today’s dynamic health care environment,
the Academy has developed a detailed plan of strategic priorities
aligned with our members’ top concerns … including addressing
challenges and opportunities that emerge as we work through the
impending health care revolution,” Dr. Moy stated earlier this year.
No CME Credit
For the Summer Academy Meeting 2011 in New York, Dr. Moy
will discuss the progress of these efforts and address current issues
affecting the profession. Dr. Moy will discuss how the Academy
is helping its members manage change, and update attendees on
plans for influencing positive change for the future.
No CME Credit
9:50 a.m.
9:20 a.m.
Guest Speaker
Everett C. Fox, M.D.,
Memorial Lectureship:
Sentinel Node Biopsy:
Just the Facts, You Decide!
Don Tapscott
Timothy M. Johnson, M.D
Sentinel node biopsy for melanoma remains controversial within
dermatology. This presentation will summarize the contemporary
data, found by and large outside the core dermatology literature.
It should be appreciated that variable interpretation of existing
evidence is certain, and final interpretations and opinions may
respectfully differ from one person to another.
54
|
Don Tapscott is an internationally renowned authority on
the strategic impact of information technology on innovation,
marketing and talent. Tapscott consistently identifies and explains
the next business imperatives and defines the business models
and strategies required for success.
Tapscott has authored or coauthored fourteen widely read books
on technology, business and the Net Generation, including
his newest book, Macrowikinomics: Rebooting Business and the
World, co-authored with Anthony D. Williams. His other books
include Grown Up Digital: How the Net Generation is Changing
Your World and Wikinomics: How Mass Collaboration Changes
Everything – an international bestseller, appearing on the New
York Times and BusinessWeek bestseller lists.
No CME Credit
Scientific Sessions
9:00 a.m. to 12:00 p.m.
10:30 a.m.
10:45 a.m.
Overhauling CME and
Dermatology Education: Laps,
Gaps, Maps, and Traps
Contact Dermatitis
David Eric Cohen, M.D.
The evaluation of contact dermatitis presents an often harrowing
challenge in the daily care of patients with eczematous dermatitis.
While the technique of patch testing has changed little in
the past decades, our recognition of important provocative
allergens and groups of chemicals regularly transforms and
evolves, a consequence of the great flux in exposure patterns
that patients experience through their work and routine
daily activities. Consequently, we have seen the emergence of
important and relevant allergens as participants in the genesis of
cutaneous delayed type hypersensitivity and the vanishing role
of previously commonly implicated chemicals. We will review
the epidemiologic journey of contact dermatitis and current
perspectives on the importance and relevance of patch testing.
0.25 Category 1 CME Credit
11:00 a.m.
11:15 a.m.
Update in CTCL:
A Tale of Two Kinds of T Cells
Comparative Effectiveness
David J. Margolis, M.D.
Sam T. Hwang, M.D., Ph.D.
In the dermatologic literature, Sézary syndrome (SS) is often
described as a variant of mycosis fungoides (MF). New
immunological data indicate that the malignant T cells in SS and
MF are derived from two distinct populations of T cells. This
information can help explain the clinical manifestations of these
two diseases and provide avenues for selective therapy.
Comparative effectiveness research is the comparison of existing
therapeutic options in order to determine which therapy
provides the greatest benefits, often in a real world setting.
His presentation will include a basic primer on comparative
effectiveness research and discuss why this type of research will
impact the provision of healthcare.
www.aad.org
|
55
Over 3 billion dollars is spent annually delivering CME education
to physicians in the United States, or just over $3700 per
US physician. Despite the expenditure, data suggest that the
traditional lecture-based CME does little to change physician
behavior when delivering subsequent patient care. With pressure
mounting to provide more outcomes-driven impactful education
during residency and during the continuing professional
development of the practicing physician, medical education
has begun to evolve. Residency training now has milestones in
addition to competencies. In CME education, we see shifts in
education delivery and focus, now with much greater emphasis
in performance improvement, point of care education, and
Maintenance of Certification. In many cases, these education
changes are becoming less optional and an expected means to
acquire education to maintain licensure and/or certification. This
session will provide the dermatologist with a glimpse at changes
underway and changes coming, and will explain how we all will
be impacted through CME sessions of the near future.
Scientific Sessions
9:00 a.m. to 12:00 p.m.
11:30 a.m.
Non-Ablative and Ablative
Fractional Resurfacing:
Cosmetic and Medical
Indications
Roy G. Geronemus, M.D.
Fractional resurfacing was developed in response to complications
and prolonged healing associated with non fractional resurfacing
for cosmetic conditions. Non-ablative fractional resurfacing
involves the delivery of thousands of microthermal zones
extending to various depths depending on the laser wavelength
and energy. The non-ablative treatments have shown dramatic
clinical benefit for rejuvenation, acne and surgical scars,
dyschromia and actinic keratoses.
The American Academy of Dermatology is
pleased to announce a Call for Nominations
for the 2013 Named Lectureships. These
distinguished awards are given in recognition
of outstanding dermatologic research.
Recipients receive cash awards and will
present their lecture at the 2013 Annual
Meeting in Miami, Fla.
Nominations are currently being accepted for
the following awards:
11:45 a.m.
Questions and Answers
• ClarenceS.Livingood,MD,
AwardandLectureship
• MarionB.Sulzberger,MD,
MemorialAwardandLectureship
• LilaGruberMemorialCancerResearch
AwardandLectureship
• EugeneJ.VanScottAwardforInnovative
TherapyoftheSkinandPhillipFrost
LeadershipLecture
If you would like to apply
or nominate someone visit
the Academy Resource Center
Booth 906 or visit
www.aad.org/namedlectureships
56
|
Scientific Sessions
Course
Symposium
2:00 p.m. to 5:00 p.m.
C002
2:00 p.m. to 5:00 p.m.
Live Patient Demonstration: Neurotoxins
and Soft Tissue Augmentation
S006
What’s Hot in Dermatopathology
Room: Mercury Ballroom
Director Shane A. Meehan, M.D.
Director Heidi A. Waldorf, M.D.
Invited Speakers
Rebecca L. Fitzgerald, M.D.
Jeannette O. Graf, M.D.
Michael Kane, M.D.
Seth L. Matarasso, M.D.
Cameron K. Rokhsar, M.D.
Neil S. Sadick, M.D.
Susan H. Weinkle, M.D.
Learning Objectives
1. Evaluate the aging face.
2. Develop a therapeutic rejuvenation plan utilizing a
combination of neurotoxin and soft tissue fillers and collagen
stimulators.
3. Avoid and manage complications.
Schedule
2:00 p.m. Introduction / Dr. Waldorf
2:05 p.m. The Upper Face: Shaping the Brow / Dr. Kane
/ Dr. Graf
2:25 p.m. The Upper Face: Focus on the Eyes and Tear Trough
/ Dr. Graf / Dr. Matarasso
2:45 p.m. The Upper Face: The Atrophic Temple
/ Dr. Fitzgerald / Dr. Kane
3:05 p.m. The Mid-Face: Volumizing the Cheeks / Dr. Sadick
/ Dr. Fitzgerald
3:25 p.m. Questions and Answers / Faculty
3:35 p.m. The Mid-Face: Approaching the Perioral Area and
Lips / Dr. Matarasso / Dr. Waldorf
3:55 p.m. The Lower Face: Managing Jowls and Jawline
/ Dr. Waldorf / Dr. Weinkle
4:15 p.m. The Hands: Rejuvenation / Dr. Weinkle
/ Dr. Rohksar
4:25 p.m. Refining the Nose / Dr. Rohksar / Dr. Sadick
4:45 p.m. Questions and Answers / Faculty
Learning Objectives
1. Discuss new developments in the understanding of various
disease processes from the perspective of dermatopathology as
they pertain to clinical practice of dermatology.
2. Describe advances in diagnostic studies as they pertain to the
diagnosis and pathogenesis of a variety of infectious, neoplastic
and inflammatory disease processes.
Description
This course is designed to provide dermatologists and
dermatopathologists with an overview of recent developments in
the diagnosis and pathogenesis of a wide variety of neoplastic and
inflammatory processes. Recently devised immunoperoxidase
markers for the diagnosis of melanoma, non-melanoma skin
cancers, and certain infectious diseases will be discussed. In
addition, advances in molecular diagnostic studies as they pertain
to the understanding and diagnosis of melanocytic neoplasms will
be reviewed. The session will also encompass newly recognized
inflammatory processes, such as cocaine-related retiform purpura
and challenges pertaining to the diagnosis of pustular psoriasis
versus acute generalized exanthematous pustulosis.
Schedule
2:00 p.m. Inflammatory Skin Disorders / Dr. Patel
2:40 p.m. Discussion / Dr. Patel
2:45 p.m. Today’s Immunohistochemistry / Dr. Ferringer
3:25 p.m. Discussion / Dr. Ferringer
3:30 p.m. What’s New In Non-Melanoma Skin Cancer?
/ Dr. Goldenberg
4:10 p.m. Discussion / Dr. Goldenberg
4:15 p.m. Atypical Melanocytic Nevi And Melanoma
/ Dr. Meehan
4:55 p.m. Discussion / Dr. Meehan
www.aad.org
|
57
Description
This session consists of live demonstrations of injectables for
facial rejuvenation including neuromodulators, soft tissue fillers
and collagen stimulators. During the demonstrations, the faculty
will review patient evaluation, anatomic considerations, product
selection, injection techniques and complications. Combination
therapies to enhance outcomes will be discussed.
INVITED SPEAKERS
Tammie C. Ferringer, M.D.
Gary Goldenberg, M.D.
Rishi R. Patel, M.D.
Scientific Sessions
Symposium
Focus Session
S007Effective Communications:
Delivering Key Messages
U016
From Bench to Bedside: Important
Clinical Advances
Room: Gibson Suite
2:00 p.m. to 5:00 p.m.
Room: Mercury Rotunda
Director Patricia Farris, M.D.
Director Oscar Colegio, M.D., Ph.D.
INVITED Speaker Ruth Mugalian
Learning Objectives
1. Describe molecular pathways recently discovered to be effective
targets for treating melanoma, basal cell carcinoma and
dermatofibrosarcoma protuberans.
2. Summarize the efficacy of recently approved therapies or
therapies currently in trials for the treatment of skin cancers.
Learning Objectives
1. Prepare compelling and relatable key messages.
2. Communicate key messages clearly, concisely and effectively.
3. Apply strategies for staying focused on key messages in
challenging situations such as media interviews.
2:30 p.m. to 4:00 p.m.
Description
The Academy has identified effective communication as a
core competency for leadership in dermatology. Learning how
to successfully craft and deliver key messages will help you
communicate effectively in any situation. Attendees will have
the opportunity to practice what they’ve learned about message
development in mock media interviews designed to challenge
participants to stay focused while delivering their message. The
course director is a previous chair of the council on communications.
She will be assisted by a communications consultant. This session is
recommended for dermatologists and graduate members. Seating will
be limited to 30 and available on a first-come first-served basis.
Schedule
2:00 p.m. Introduction / Dr. Farris
2:05 p.m. Key Message Training / Dr. Farris
2:40 p.m. Basics/Expectations of an Interview / Ms. Mugalian
3:00 p.m. Develop Key Messages / Ms. Mugalian
3:20 p.m. On-Camera Mock Media Interviews / Ms. Mugalian
4:50 p.m. Questions and Answers / All Faculty
Description
Systemic and topical targeted therapies are emerging as a rational
approach to the management of skin cancers. In this session, the
rationale behind and effectiveness of new molecules used in the
treatment of melanoma, basal cell carcinoma, actinic keratoses,
dermatofibrosarcoma protuberans and Kaposi’s sarcoma will be
reviewed. This session is designed for a broad audience, from
practicing dermatologists to basic scientists.
U017
Photodynamic Therapy
Room: Regent Parlor
Director Mollie A. MacCormack, M.D.
Learning Objectives
1. Describe the mechanism of action of photodynamic therapy.
2. Identify conditions that respond well to photodynamic therapy
as well as those that do not.
3. Incorporate photodynamic therapy into his or her practice.
Description
Photodynamic therapy is rapidly becoming a mainstay of
dermatologic therapy. Easily incorporated into clinical practice it
adds a new dimension to dermatologic care. Yet, as with any recent
advance, confusion exists regarding its actual efficacy for treating a
variety of skin diseases. This session will cover the science behind
photodynamic therapy, details on how the procedure is performed
and how you can easily incorporate it into your own practice as
well as an extensive review of the data supporting its efficacy in
treating a wide range of dermatologic conditions.
58
|
Scientific Sessions
Focus Sessions
Forum
U018
Dermoscopy for the Non-Dermoscopist
Room: Sutton South
F011Using Technology to Improve
Dermatology Access
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
Director Jennifer A. Stein, M.D., Ph.D.
Learning Objectives
1. Recognize characteristic dermoscopic structures of benign and
malignant lesions.
2. Use dermoscopy to distinguish benign from suspicious lesions
that require biopsy.
3. Formulate a simple pattern recognition system that can be
used in general dermatologic practice to minimize unnecessary
biopsies and improve detection of malignant lesions.
U019
Cellulitis: A Common (Mis)Diagnosis?
Room: Clinton Suite
Director Daniela Kroshinsky, M.D.
Learning Objectives
1. Define the clinical patterns and symptoms associated with the
different forms of true cellulitis.
2. Recognize the features that suggest another diagnosis,
specifically in atypical presentations or in patients who fail to
respond to routine therapy.
3. Formulate a broad differential diagnosis for healthy and
immunosuppressed patients.
Description
Dermatologists are often consulted to evaluate a patient with
presumed cellulitis. For routine cellulitis, an accurate diagnosis can
be obtained from the patient’s symptoms and clinical appearance.
However, when the clinical presentation is somewhat atypical, or
if the patient fails to respond to appropriate therapy for common
bacterial cellulitis, the differential diagnosis should be rapidly
expanded. This session will discuss the approach to the patient with
presumed cellulitis, with an emphasis on the differential diagnosis
of cellulitis in both healthy and immunocompromised patients.
Director Claudia Hernandez, M.D.
Invited Speakers
April W. Armstrong, M.D.
Jeffrey A. V. Benabio, M.D.
Noah A. Craft, M.D.
William D. James, M.D.
Amit Pandya, M.D.
Learning Objectives
1. Identify those who may have limited access to dermatologic
care and to identify possible barriers to providing this care.
2. Review innovative means for providing dermatologic care to
those in need, including use of online educational databases,
and teledermatology.
3. Discuss access to care issues and consider future means for
providing dermatologic care to underserved populations.
Description
Though the problem of inequality of dermatologic care has been
recognized, there is still a shortage of care. Inequality of care in
different regions of the United States and globally needs to be
addressed. With the increase in usage of teledermatology and other
new technologies, access to care should increase. Understanding
the tools available to dermatologist will help in closing this gap.
This course will provide professional development to the attendees
via new information on methods of providing care to those in
need. New technologies will aid in delivery of care for underserved
patients and communities.
Transition into Practice:
A Toolkit for Dermatologists
Entering into the Workforce
Whether you’re fresh out of residency or changing
practices mid-career, this manual will guide you every
step of the way into your new job.
!
NEW
• Assessing Practice Options
• Interview Process
• Structuring Your Contract
• Co-ownership/Buy-in
• Marketing Yourself to Patients
Visit the Academy
Resource Center
Booth 906 to purchase!
www.aad.org
|
59
Description
Novice dermoscopists will be taught recognizable dermoscopic
patterns to assist in the diagnosis of pigmented lesions. We
will discuss a simple pattern recognition system that can be
incorporated into routine dermatologic practice. The session
will also include dermoscopy of special sites, including the face
and acral surfaces. Participants will be shown unknown cases
throughout the session for self-assessment and the approach
to diagnosis of these cases will be reviewed. By incorporating
dermoscopy into everyday practice, participants will be able to
improve their diagnostic accuracy in detecting melanoma and
other skin cancers.
Room: Sutton North
Scientific Sessions
Forums
3:00 p.m. to 5:00 p.m.
F012
Case-Based Challenges for PA/NPs
F013
Melanoma
Room: Sutton Center
Director Eva A. Hurst, M.D.
Invited Speakers
Lynn Anne Cornelius, M.D.
Kimberly Dawn Morel, M.D.
Director Martin A. Weinstock, M.D., Ph.D.
Kara S. Nunley, M.D.
Manisha J. Patel, M.D.
Learning Objectives
1. Perform a broad differential diagnosis based on clinical findings
and lesion morphology.
2. Identify clinical and pathologic features of common and
challenging dermatologic diseases.
3. Identify the most appropriate management strategies and
formulate a practical treatment plan.
Description
This forum is designed for NPs and PAs practicing dermatology.
Using challenging case examples, participants will be guided
through differential diagnoses and therapeutic plans for a variety
of complex cases. Specifically, thought processes leading to the
differential diagnoses will be described, laboratory testing and
dermatopathology will be reviewed, and management will be
discussed. Related to presented cases, this session will review
advances and practical approaches to treatment. Topic highlights
include pigmented lesions and melanoma, pediatric dermatology,
transplant dermatology, and complex medical dermatology cases.
An audience response system will be used to facilitate learning.
Schedule
3:00 p.m. Introduction and Objectives / Dr. Hurst
3:10 p.m. Pediatric Dermatology Case Challenges / Dr. Morel
3:35 p.m. Pigmented Lesion and Melanoma Case Challenges
/ Dr. Cornelius
3:55 p.m. Transplant Dermatology Case Challenges / Dr. Patel
4:20 p.m. Complex Medical Dermatology Case Challenges
/ Dr. Nunley
4:45 p.m. Question and Answer / All faculty
60
|
Invited Speakers
Richard Carvajal, M.D.
Allan C. Halpern, M.D.
Darrell S. Rigel, M.D.
Nancy E. Thomas, M.D.
Learning Objectives
1. Assess and use technologies relevant to melanoma.
2. Identify the clinical features of genetically distinct types
of melanoma.
3. Decribe new therapies for metastatic melanoma.
Description
This session will focus on the interaction of technology and
melanoma, including assessing its effect on risk, its use in
diagnosis, and issues in its control. Melanoma is now recognized
as a collection of diseases, and we will also discuss their clinical
features and therapy in the metastatic setting.
Schedule
3:00 p.m. Assessing Impact of New Technology on Melanoma
Risk / Dr. Weinstock
3:12 p.m. Technological Aids to Melanoma Diagnosis
/ Dr. Halpern
3:39 p.m. BRAF and NRAS Mutant Melanomas:
Clinical Features, Risk, and Outcome / Dr. Thomas
4:06 p.m. A New Era in the Management of Metastatic
Melanoma / Dr. Carvajal
4:33 p.m. Indoor Tanning: Current Issues and Future
Challenges / Dr. Rigel
Scientific Sessions
Forum
3:00 p.m. to 5:00 p.m.
F014
Finessing Surgical Technique
Director David M. Ozog, M.D.
Invited Speakers
Brett M. Coldiron, M.D.
Emily J. Fisher, M.D.
Hayes B. Gladstone, M.D.
Hugh M. Gloster Jr., M.D.
Christopher James Miller, M.D.
Suzanne Olbricht, M.D.
Learning Objectives
1. Demonstrate simple yet essential surgical techniques to achieve
optimal cosmetic and functional outcomes.
2. Utilize proper surgical instruments and materials to enhance
healing and repair outcomes.
3. Assess common mistakes made when coding for surgical
procedures and how to avoid them.
Schedule
3:00 p.m. Painless Anesthesia Before Difficult Closures Made
Simple / Dr. Ozog
3:15 p.m. Instruments That Make My Day Easier / Dr. Gloster
3:30 p.m. When Aversion Ain’t Happening: Tips for Optimal
Suture Placement / Dr. Miller
3:45 p.m. The Ear of the Dog: Hangover Remedies
/ Dr. Olbricht
4:00 p.m. Essential Suturing Techniques: Beyond The Simple
Interrupted Stitch / Dr. Gladstone
4:15 p.m. Good Closures Gone Bad: A Short Story Of Blood,
Pus, And Tears / Dr. Fisher
4:30 p.m. I Can Get Paid for That? Tips To Optimize Surgical
Coding / Dr. Coldiron
Your feedback helped us design a website
that makes your job easier.
Enjoy some of these new features:
• Dermatology A to Z, which offers easy-todigest text and images for your patients.
• Easier navigation around the website to
get to the information you need quickly.
Description
This session provides essential surgical pearls for the general
dermatologist and intermediate dermatologic surgeon. A myriad
of topics will be discussed including tips for anesthesia, optimizing
suturing techniques and wound aversion, and the best use of
surgical instruments, wound dressings and suture materials.
Practical topics will be discussed, including surgical coding and
tips to avoid and treat wound complications.
The new www.AAD.org
is built around you!
• An improved search function that yields
accurate results faster than ever before.
These are just a few of the improvements;
be sure to visit often to explore new content
and continuing improvements.
Tell us what
you think at
www.aad.org/
feedback
today!
Make www.AAD.org
your home page.
www.aad.org
|
61
Scientific Sessions
Workshop
3:00 p.m. to 5:00 p.m.
W005
M
O
C
MOC Self-Assessment: Pediatric
Dermatology
Director Katherine B. Puttgen, M.D.
Invited Speakers
Bernard Cohen, M.D.
Moise L. Levy, M.D.
Teresa S. Wright, M.D.
Learning Objectives
1. Identify features of neurofibromatosis type 1 in the pediatric
population.
2. Differentiate among treatment options for function-threatening
infantile hemangiomas.
3. Discuss causes of and therapies for tinea capitis.
Description
Attendees will review clinical findings of important
genodermatoses in children including tuberous sclerosis,
neurofibramotosis type 1, and Rothmund-Thomson. An update
on vascular anomalies in children including infantile hemangiomas
and congenital hemangiomas will be reviewed. Epidemiology of
important pediatric dermatology infections and infestations will
be discussed.
Need Self-Assessment Points?
Try the AAD’s Dermatology
Self-Assessment Program
• S
atisfiespartofComponent2of
MaintenanceofCertification(MOC-D)
• 1 00Self-assessmentquestionsand
pointspervolume
• L
earningformatsinprint,online,
andCD -ROM
Schedule
3:00 p.m. Questions and Answers: 1st Portion / Dr. Wright
3:30 p.m. Questions and Answers: 2nd Portion / Dr. Puttgen
4:00 p.m. Questions and Answers: 3rd Portion / Dr. Cohen
4:30 p.m. Questions and Answers: 4th Portion / Dr. Levy
* Self-assessment questions utilized in this session are the
same as those used for Workshop W002 and W005
offered at Annual Meeting 2010 and 2011 and
Workshop W008 at Summer Academy Meeting 2010.
Physicians should not claim CME/MOC credit for
attending this session if they attended any of the sessions
listed above.
!
NEW
Volume 4
Volume 3
Dou
que ble th
stio e
ns!
Voluime 2 – Online only
VisittheAcademyResource
CenterBooth906topurchase.
62
|
Scientific Sessions
M
O
C
Saturday, August 6
Exploring Evidence-Based Cosmeceuticals............... 64
U020 Controversies in “Dysplastic” Nevi.......................... 64
U021 U022 Patch Test Allergens 101: A Detective’s Toolkit........ 65
U023 Use of Light for Diagnosis and
Treatment in Dermatology...................................... 65
S008 What’s Hot in Women’s Dermatology..................... 67
S009 Dermatology Grand Rounds: A Discussion of
Case-Based Dilemmas............................................. 68
Course — 9:00 a.m. to 5:00 p.m.
C003 Derm Exam Prep Course: Refresher........................ 68
Symposium — 2:00 p.m. to 5:00 p.m.
S010 Cutting Edge Surgery and Oncology....................... 72
U027 Practical Dermoscopy.............................................. 72
Morphea: Not Just for Adults Anymore.................. 72
U028 Forums — 3:00 p.m. to 5:00 p.m.
F021 New Technologies in Minimally
Invasive Skin Rejuvenation...................................... 73
F022 Psoriasis Guidelines: Implementing
them in Your Practice.............................................. 73
W007 Coding and Documentation............................. 74
Forums — 12:00 p.m. to 2:00 p.m.
F018 Hypercoagulability, Purpura and the Skin............... 69
F019 Oral Disease............................................................ 69
F020 Tumor Board........................................................... 70
W006 Practical Approaches to Patient Problems............... 70
www.aad.org
|
63
Scientific Sessions, Saturday, August 6
Forums — 9:00 a.m. to 11:00 a.m.
Alopecia and Hair Loss............................................ 66
F015 Consultative Dermatology....................................... 66
F016 F017 Case-Based Controversies:
Dermatopathology................................................... 66
Focus Session — 12:15 p.m. to 1:45 p.m.
U024 When Clinical and Histological Findings Converge:
Great Cases From a Dermatopathologist’s
Perspective............................................................... 71
Impact of Nanotechnology and Dermatology.......... 71
U025 Pediatric Dermatology Jeopardy.............................. 71
U026 Scientific Sessions
Focus Session
7:15 a.m. to 8:45 a.m.
U020Exploring Evidence-Based
Cosmeceuticals
U021
Controversies in “Dysplastic” Nevi
Room: Gibson Suite
Director Payam Abrishami, M.D.
Room: Sutton South
Director Zoe Diana Draelos, M.D.
Saturday, August 6, Scientific Sessions
Learning Objectives
1. Demonstrate an understanding of how cosmeceuticals can be
used meaningfully in dermatology.
2. Examine new research directing development of cosmeceuticals.
3. Recognize the different categories of cosmeceuticals and their
efficacy parameters.
Description
Cosmeceuticals can be of value in dermatology for the prevention
and maintenance of skin disease, in addition to addressing
photoaging issues. This session will examine the evidence behind
cosmeceuticals in the current marketplace while presenting new
research leading to cosmeceutical development in the future. Each
of the basic categories of cosmeceuticals will be discussed with
attention to the efficacy of individual technologies.
Learning Objectives
1. Examine historically the concept of the “lentiginous” and
“dysplastic” nevi.
2. Analyze the criteria for the “lentiginous,” “dysplastic,” Clark’s,
and architecturally disordered nevi.
3. Discuss recommendations for terminology to be adopted by
our specialty.
Description
Through a series of original photomicrographs the session will
validate the concept of the “lentiginous” nevus for the attendee.
The terms “dysplastic” nevus, “atypical” nevus, architecturally
disordered nevus, Clark’s nevus, and degrees of “atypia” will
be explored through historical review. The attendee will be
empowered to decide the legitimacy of these concepts, which have
emerged over the last 30 years; this session will promote a new
direction in the understanding of these common melanocytic nevi.
Search with Ease!
With a database of goods and services that are continually purchased by dermatologists, the AAD Buyer’s
Guide allows members to quickly find what they need without the clutter of general purpose search engines.
Start searching today at www.aaddermatologybuyersguide.com
64
|
Scientific Sessions
Focus Session
7:15 a.m. to 8:45 a.m.
U022
Patch Test Allergens 101:
A Detective’s Toolkit
U023Use of Light for Diagnosis and Treatment
in Dermatology
Room: Clinton Suite
Room: Regent Parlor
Director Peter C. Schalock, M.D.
Director Iltefat H. Hamzavi, M.D.
Learning Objectives
1. Recognize common allergens on product labels.
2. Counsel patients on likely sources of allergen exposures.
3. Determine an appropriate array of allergens to adequately test
your patients.
Learning Objectives
1. Demonstrate a basic understanding of skin optics.
2. Demonstrate the ability to formulate treatment plans using
different light sources.
3. Identify the staff and skills needed to administer light-based
treatments in your office.
Description
Light has become a more important part of treatment options for
dermatologists. A basic understanding of skin optics is needed
to implement light based treatments in any practice. With this
understanding complex diseases can be managed more effectively
with phototherapy, PDT and lasers. This course will explain the
theory behind photomedicine and then develop an approach to
customize treatment modalities to the needs of the patient. Lastly,
suggestions will be made on how to organize an office to start or
improve phototherapy options.
u
aa
Measurement
Tools
www.aad.org
|
65
Description
The baseline series of patch tests encompass many compounds to
which patients are exposed on a daily basis. Having knowledge
of potential allergens and their prospective sources of exposure
is essential for assessing those with suspected allergic contact
dermatitis in a general dermatology practice. This session is
for those interested in learning more about the most common
allergens. We will review the T.R.U.E. Test as well as the 50
Chemotechnique North American Standard Series allergens.
Sources of these allergens and patient counseling tips will be
suggested. Illustrative questions and cases will be discussed.
Scientific Sessions
Forum
9:00 a.m. to 11:00 a.m.
F015
Alopecia and Hair Loss
Room: Sutton North
Director Dirk Michael Elston, M.D.
F017
Case-Based Controversies:
Dermatopathology
Learning Objectives
1. Perform an appropriate evaluation for non-scarring alopecia.
2. Perform an appropriate evaluation for scarring alopecia.
3. Manage alopecia effectively.
Director Jacqueline M. Junkins-Hopkins, M.D.
Description
The evaluation and management of hair disorders can be
challenging. This session presents a practical, efficient and costeffective approach to the evaluation and management of alopecia
and hirsutism.
Learning Objectives
1. 1. Identify management options for cases with problematic
histopathologic findings.
2. Recognize limitations in the histopathologic assessment of
certain entities.
3. Identify controversial topics that may be encountered in
Dermatopathology.
F016
Consultative Dermatology
Room: Sutton Center
Director Jonathan Cotliar, M.D.
INVITED SPEAKERS
Lauren C. Hughey, M.D.
Daniela Kroshinsky, M.D.
Kanade Shinkai, M.D., Ph.D.
Learning Objectives
1. Recognize unique cutaneous toxicities associated with cancer
therapy.
2. Recognize unique paraneoplastic dermatoses.
3. Recognize cutaneous complications of stem cell transplantation.
Description
This case-based session is intended for physicians with an interest
in the consultative care of cancer in patients with skin disease.
Special attention will be paid to unique reactions to cancer
therapy, new and unusual paraneoplastic dermatoses, unique
presentations of neutrophilic dermatoses, as well as common and
uncommon complications of stem cell transplantation.
Schedule
9:00 a.m. Unique Paraneoplastic Dermatoses / Dr. Hughey
9:25 a.m. Unique Reactions to Cancer Therapy / Dr. Fox
9:50 a.m. Unusual Dermatoses in Cancer Patients
/ Dr. Kroshinsky
10:15 a.m. Neutrophilic Dermatoses / Dr. Shinkai
10:40 a.m. Dermatoses Associated with Stem Cell Transplantation
/ Dr. Cotliar
66
|
INVITED SPEAKERS
Aleodor A. Andea, M.D.
John Andrew Carlson, M.D.
Leonard C. Sperling, M.D.
Description
Some entities in Dermatopathology may be considered
controversial with regard to diagnosis, reporting and/or
recommendations supplied by the dermatopathologist. Many
of these issues have an impact on patient management. Selected
topics, such as alopecia biopsies, management and reporting of
atypical but non-malignant proliferations, including melanocytic
lesions, atypical spindle cell tumors, and atypical dermal
lymphocytic infiltrates, will be discussed by a panel of experienced
dermatopathologists. Audience participation is welcomed and
encouraged. This session will benefit both dermatologists and
dermatopathologists.
Schedule
9:00 a.m. Case Presentation / Dr. Carlson
9:25 a.m. Questions and Answers / Dr. Carlson
9:30 a.m. Case Presentation / Dr. Andea
9:55 a.m. Questions and Answers / Dr. Andea
10:00 a.m. Case Presentation / Dr. Sperling
10:25 a.m. Questions and Answers / Dr. Sperling
10:30 a.m. Case Presentation / Dr. Junkins-Hopkins
10:55 a.m. Questions and Answers / Dr. Junkins-Hopkins
Scientific Sessions
Symposium
9:00 a.m. to 12:00 p.m.
S008
What’s Hot in Women’s Dermatology
Director Boni E. Elewski, M.D.
INVITED SPEAKERS
Craig A. Elmets, M.D.
Marian Elizabeth Northington, M.D.
Vlada Groysman, M.D.
Darrell S. Rigel, M.D.
Mark Lebwohl, M.D.
Richard K. Scher, M.D.
Mary Gail Mercurio, M.D.
Learning Objectives
1. Discuss management of melanoma in women, vulvodynia and
vulvar dermatoses; recognize contact dermatitis in women and
pregnancy related dermatoses.
2. Effectively diagnose and treat women with nail disorders.
3. Select the best medical and aesthetic approach for management
of the aging female face.
Schedule
9:00 a.m. Introduction / Dr. Elewski
9:05 a.m. Nail Tips for Women / Dr. Scher
9:30 a.m. Treating Psoriasis in Women / Dr. Lebwohl
9:55 a.m. Dermatoses of Pregnancy / Dr. Mercurio
10:20 a.m. A Medical and Aesthetic Approach to the Aging Face
/ Dr. Northington
10:45 a.m. Management of Vulvodynia and Vulvar Dermatoses
/ Dr. Groysman
11:05 a.m. Contact Dermatitis in Women / Dr. Elmets
11:30 a.m. Melanoma in Women: Special Concerns / Dr. Rigel
Enjoy the virtual attendee experience and
convenience!
• O
ver700speakersrecordedwithtopicscovering
mosteveryaspectofdermatology
• Speaker’sslidessynchronizedwithaudioofselecttalks
• Accesstoonlineversionforeasylistening
anytime,anywhere
• LoadtalksdirectlytoanyMP3playingdevice,iPod,
oriTunesplaylist
• BothMACandPCCompatible
To place an order call Association Archives at
(858)704-8612orvisit
www.associationarchives.com/AAD
Visit the Academy Resource Center
Booth 906 to order.
www.aad.org
|
67
Annual Meeting
2011 Conference
Recordings available
on DVD!
Description
Certain skin diseases occur more commonly in women.
This symposium will focus on select skin disorders emphasizing
diagnostic clues, therapeutic challenges, and treatment.
Additionally, nail disorders, melanoma, diseases of pregnancy,
best medical and aesthetic approach for the aging face, and psoriasis
will be highlighted. Finally, there will be a discussion of vulvodynia
and vulvar dermatoses as well as contact dermatitis in women.
Scientific Sessions
Symposium
Course
S009
Dermatology Grand Rounds: A Discussion
of Case-Based Dilemmas
C003
Director Jeffrey J. Miller, M.D.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 5:00 p.m.
Director Amit Garg, M.D.
Invited Speakers
Jeffrey Phillip Callen, M.D.
Jennie T. Clarke, M.D.
Jane M. Grant-Kels, M.D.
Fiona O’Reilly Zwald, M.D.
Learning Objectives
1. Develop skills in differential diagnosis and evaluation of
complex dermatologic diseases, many with interdisciplinary
considerations.
2. Discuss the use of advanced systemic therapies for the
management of refractory dermatologic conditions.
Description
This session will offer a Grand Rounds style discussion. Evidenceand experience-based commentary among panelists and audience
members will be presented to offer practical considerations in
the diagnosis, specific evaluation, and advanced therapeutic
management of challenging clinical cases and representing a
breadth of complex diseases. An interactive case-based approach
will be utilized to highlight relevance for the experienced clinician.
Derm Exam Prep Course: Refresher
INVITED SPEAKERs
Bryan Erik Anderson, M.D.
Victor J. Marks, M.D.
Bethanee Jean Schlosser, M.D.
Andrea L. Zaenglein, M.D.
Learning Objectives
1. Review the 150 dermatologic diseases and conditions listed
by the American Board of Dermatology (ABD) as required
for the General Dermatology module of the Maintenance of
Certification in Dermatology (MOC).
2. Identify areas needing additional study in preparation for the
General Dermatology module of the MOC-D exam.
3. Recognize the format used on the MOC-D exam.
Description
This course is targeted to dermatologists preparing for the
American Board of Dermatology (ABD) Maintenance of
Certification in Dermatology (MOC-D) exam. Residents
preparing for their Board exam may also benefit. The course
will review the 150 diagnoses listed as covered in the General
Dermatology module of the MOC-D exam in a format similar
to the one used on the exam.
Save the Date
A M E R I C A N A C A D E M Y O F D E R M AT O L O G Y
Derm Exam Prep Course
THE ONLY preparatory course available for the American Board
of Dermatology’s Maintenance of Certification exam!
November 18 – 20, 2011 • Orlando, Fla.
Visit the Academy Resource Center Booth 906 for more information.
68
|
Scientific Sessions
Forum
12:00 p.m. to 2:00 p.m.
F018
Hypercoagulability, Purpura and the Skin
F019
Oral Disease
Room: Sutton North
Director Warren W. Piette, M.D.
Director Ginat W. Mirowski, M.D., D.M.D.
Learning Objectives
1. Recognize typical presentations of microvascular occlusion
syndromes in the skin.
2. Choose relevant laboratory screening exams critical for
diagnosis.
3. Define mechanisms of cutaneous occlusion.
INVITED SPEAKERS
Nasim Fazel, M.D.
Bethanee Jean Schlosser, M.D., Ph.D.
Janellen Smith, M.D.
Rochelle R. Torgerson, M.D., Ph.D.
Description
The session will cover the evaluation and treatment of numerous oral
conditions. The faculty will share with the audience their approach
and treatment of many common oral dermatoses including oral
ulcers, oral erosive lichen planus, burning mouth, oral conditions
in the immunocompromised host, as well as tongue lesions.
Schedule
12:00 p.m. Acute Oral Ulceration / Dr. Fazel
12:20 p.m. Oral Lichen Planus / Dr. Schlosser
12:40 p.m. Update on Burning Mouth Syndrome / Dr. Torgerson
1:00 p.m. Tongue Lesions / Dr. Smith
1:20 p.m. Challenging Oral Cases / Dr. Mirowski
www.aad.org
|
69
Description
This session begins with an outline of the differences in diagnoses
between venous thromboembolism and microvascular occlusion.
A brief discussion of relevant clotting and clot inhibition pathways
is followed by a targeted review of pertinent laboratory testing.
The session concludes with a presentation of unknown purpura
cases including simple hemorrhage, inflammatory hemorrhage,
and occlusion.
Learning Objectives
1. Evaluate the various presentations of common erosive/
ulcerative oral conditions including acute oral ulcers and
erosive lichen planus.
2. Evaluate and treat conditions of the tongue including burning
mouth.
3. Evaluate the various presentations of challenging conditions in
immunocompromised hosts.
Scientific Sessions
Forum
12:00 p.m. to 2:00 p.m.
F020
Tumor Board
Room: Sutton Center
Director Chrysalyne Delling Schmults, M.D.
Learning Objectives
1. Summarize available evidence that impacts management of
cutaneous cancers.
2. Apply current treatment recommendations to patient care as
appropriate.
3. Develop appropriate management strategies when scientific
evidence is lacking.
Description
Cases of cutaneous malignancy will be presented by the moderator
and discussed by a multi-disciplinary panel comprised of experts
in dermatology, dermatologic surgery, dermatopathology,
oncology, and radiation/surgical oncology. Audience questions
and participation will be encouraged. Cases will focus on
common tumors such as melanoma and SCC but will also
include more unusual tumors and interesting clinical scenarios.
Available evidence and current treatment recommendations will
be reviewed. Areas where data is lacking will be highlighted and
panelists will discuss how to make management decisions when
clear evidence does not exist.
70
|
Workshop
12:00 p.m. to 2:00 p.m.
W006
Practical Approaches to Patient
Problems
Director Jeffrey Phillip Callen, M.D.
INVITED SPEAKERS
Jerry D. Brewer, M.D.
Joseph L. Jorizzo, M.D.
Julie V. Schaffer, M.D.
Learning Objectives
1. Construct a plan for evaluation of patients with cutaneous
disease.
2. Develop a therapeutic ladder based upon the best evidence
available.
3. Diagnose systemic manifestations of skin disease.
Description
This session is an interactive session in which we will utilize an
audience response system. Patient cases will be presented followed
by a series of questions upon which audience input will be sought.
Following polling, an expert panel will discuss their approach to
the problem.
Scientific Sessions
Focus Session
12:15 p.m. to 1:45 p.m.
U024
When Clinical and Histological Findings
Converge: Great Cases From
a Dermatopathologist’s Perspective
Room: Regent Parlor
Director Paolo Romanelli, M.D.
Learning Objectives
1. Recognize the importance of representative skin biopsy to
diagnose skin disease more effectively.
2. Better communicate to their dermatopathologist for the
ultimate benefit of the patients.
3. Order appropriate IHC markers to optimize the therapeutic
approach.
U025
Impact of Nanotechnology and
Dermatology
Room: Sutton South
Pediatric Dermatology Jeopardy
Room: Clinton Suite
Director Victoria R. Barrio, M.D.
Learning Objectives
1. Recognize several important pediatric dermatology conditions.
2. Formulate appropriate treatment plans for certain pediatric
skin diseases.
Description
This will be an interactive review of important new and
fundamental concepts in pediatric dermatology. The format
will follow that of the popular game show “Jeopardy,” such
that each audience member can test their current knowledge in
selected areas. The session should both reinforce the audience
members previous knowledge and help work through scenarios
that may present in their future practice. It is aimed toward the
dermatology resident and the private practitioner.
Description
We will cover multiple clinically difficult cases that needed
a representative skin biopsy to obtain a correct diagnostic
clinicopathological correlation. Together with most of the cases,
some immunohistochemistry studies as potential therapeutic
biomarkers will also be discussed, in the effort to develop and
optimize an effective future “tailor-made” treatment for
every patient.
U026
Director Adnan Nasir, M.D., Ph.D.
Learning Objectives
1. Recognize the importance of nanotechnology in dermatology.
2. Identify the key benefits of nanotechnology for consumers and
patients in dermatology.
3. Identify potential hazards of nanotechnology.
Description
Nanotechnology is a burgeoning field with tremendous potential
for society and medicine. Currently, it is entering an exponential
growth phase in the number and variety of products soon to be or
already available for consumers and patients. The skin is the first
point of contact and the first line of defense for nanomaterials.
This presentation serves to educate attendees about the benefits
and pitfalls of a new and exciting technology with enormous
promise for the diagnosis and management of skin disease and for
the maintenance of skin health.
www.aad.org
|
71
Scientific Sessions
Symposium
Focus Session
S010
2:00 p.m. to 5:00 p.m.
Director
Cutting Edge Surgery and Oncology
U027
Practical Dermoscopy
Room: Regent Parlor
Jeremy S. Bordeaux, M.D., M.P.H.
Director
Steven Q. Wang, M.D.
Invited Speakers
Murad Alam, M.D.
Christopher K. Bichakjian, M.D.
Jerry D. Brewer, M.D.
2:30 p.m. to 4:00 p.m.
John A. Carucci, M.D., Ph.D.
Shang I. Brian Jiang, M.D.
Desiree Ratner, M.D.
Learning Objectives
1. Recognize the language of dermoscopy.
2. Recognize all of the global patterns and local criteria essential to
become a proficient dermoscopist.
3. Assess their ability to put the dermoscopic essentials into practice.
Learning Objectives
1. Diagnose and treat skin cancer more effectively.
2. Differentiate and utilize newer techniques and therapies in surgical
dermatology.
Description
There will be a complete review of the classic and not so classic global
patterns and local criteria used to diagnose melanocytic, non-melanocytic,
benign and malignant lesions. A self-assessment quiz will also be presented.
Description
The objective of this symposium is to update attendees on cutting edge topics in
dermatology related to the diagnosis and treatment of skin cancer and surgical
techniques. This session is directed to surgically oriented dermatologists.
U028
Morphea: Not Just for Adults Anymore
Director
Dawn M. R. Davis, M.D.
Schedule
2:00 p.m. Introduction / Dr. Bordeaux
2:05 p.m. Treatment of High Risk Squamous Cell Carcinoma With
Cetuximab / Dr. Ratner
2:25 p.m. Update On Merkel Cell Carcinoma / Dr. Bichakjian
2:45 p.m. In Situ Photoimmunotherapy for Metastatic Melanoma
/ Dr. Alam
3:05 p.m. Melanoma of the Head and Neck: Practical Challenges Based
on a Review of Greater Than 300 Cases at Penn / Dr. Miller
3:25 p.m. Questions
3:40 p.m. Non-Hodgkin’s Lymphoma and Skin Cancer / Dr. Brewer
4:00 p.m. Treatment of Basal Cell Carcinoma and Squamous Cell
Carcinoma In Situ With the Pulsed Dye Laser / Dr. Jian
4:20 p.m. What’s New In Translational Research of Skin Cancer
/ Dr. Carucci
4:40 p.m. Reconstructing a Full-Thickness Defect of the Eyelid
/ Dr. Bordeaux
4:50 p.m. Questions and Answers
Room: Sutton South
Learning Objectives
1. Recognize the clinical variants of morphea in the pediatric patient.
2. Formulate a multidisciplinary approach to patient evaluation and
management.
3. Select appropriate treatment methods.
Description
The recognition and management of morphea in the pediatric population
is primarily performed by dermatologists. This session will review the
various forms of morphea and discuss their similarities and unique
attributes as it pertains to children and adolescents. The opportunity
to coordinate a multidisciplinary approach to patient care to optimize
outcomes and satisfaction will be reviewed. A case portfolio will provide
interactive discussion of typical and difficult issues often encountered by
morphea patients and their physicians.
2:30 p.m. to 4:00 p.m.
S013 Procedural Safety in Dermatology
Director
Joseph Sobanko, M.D.
Learning Objectives
1. Recognize the problem of occupational exposures within the field of
medicine and those employees most suscept ble to percutaneous injuries and
mucocutaneous splashes.
2. Identify the procedures and behaviors that place dermatologists at highest risk
for occupational exposures.
3. Describe strategies to implement in daily practice that will help eliminate the
risk of occupational exposures.
Description
The number of needlesticks and mucocutaneous splashes that occur in the United
States is staggering. Dermatologists and their staff are particularly at risk due to
the high number of in-office procedures performed. Attendees of this session
will be able to identify and correct behaviors that place the practitioner and their
staff at risk before, during, and after in-office procedures. The subject of bloodborne pathogen transmission will be discussed in detail. Additionally, the large
problem of underreporting occupational exposures among students, residents, and
physicians will be addressed.
72
|
Scientific Sessions
Forum
3:00 p.m. to 5:00 p.m.
F021New Technologies in Minimally Invasive
Skin Rejuvenation
Room: Sutton North
F022
Psoriasis Guidelines: Implementing them
in Your Practice
Room: Sutton Center
Director Brooke A. Jackson, M.D.
Director Mark Lebwohl, M.D.
INVITED SPEAKERS
Cheryl M. Burgess, M.D.
Wendy E. Roberts, M.D.
INVITED SPEAKERS
Henry W. Lim, M.D.
Bruce Elliot Strober, M.D., Ph.D.
Abby S. Van Voorhees, M.D.
Hema A. Sundaram, M.D.
Heidi A. Waldorf, M.D.
Learning Objectives
1. Describe new and emerging technologies in minimally invasive
skin rejuvenation.
2. Discuss the role of these new technologies in the physician’s
armamentarium of treatment options.
3. Recognize the latest research supporting or negating these
emerging technologies.
Schedule
3:00 p.m. Fillers / Dr. Burgess
3:35 p.m. Lotions, Potions and Other Devices / Dr. Jackson
3:55 p.m. Neurotoxins / Dr. Roberts
4:15 p.m. Lasers / Dr. Waldorf
4:40 p.m. Fat / Dr. Sundaram
DESCRIPTION
The session will be helpful in expanding physician knowledge base
and improving clinical confidence and effectiveness in treating
psoriasis patients with a wide range of clinical presentations
including psoriatic arthritis. The session will consist of four
presentations, with time available after each talk for interaction
with the attendees. It will be structured in a question–and-answer
format when case studies are discussed. A short survey will be
conducted before and after the session, and a follow-up survey will
be conducted six months later to gauge and evaluate if guidelines/
implementation products and presentations were easy to translate
into daily clinical practice. Studies have shown that high-quality
guidelines can make important contribution to improving medical
care.
Schedule
3:00 p.m. Introduction and overview with survey / Dr. Lebwohl
3:10 p.m. Topical Therapy for Psoriasis with case study
/ Dr. Van Voorhees
3:35 p.m. Phototherapy for Psoriasis with case study / Dr. Lim
4:00 p.m. Systemic Therapy with case study / Dr. Lebwohl
4:25 p.m. Biologic Therapy with case study / Dr. Strober
4:50 p.m. Panel Discussion with survey / All Faculty
www.aad.org
|
73
Description
With the rapid proliferation of rejuvenation technologies, it is
important for the physician to be familiar with these emerging
technologies and their possible roles in the armamentarium of
treatment modalities offered to patients.
LEARNING OBJECTIVES
1. Develop skills to manage patients with psoriasis and psoriatic
arthritis with an emphasis on decision making criteria that will
enable the clinician to individualize therapy based upon disease
type, extent, response to previous treatments, quality of life
issues, and co-morbidities.
2. Recognize and diagnose challenging clinical cases and select
evidence-based treatment using the recently published AAD
psoriasis evidence-based guidelines, which includes best
practices.
3. Address gaps in clinical knowledge and care.
Scientific Sessions
Workshop
3:00 p.m. to 5:00 p.m.
W007
Coding and Documentation
Psoriasis Guidelines:
Implementing them in
Your Practice
Director Allan S. Wirtzer, M.D.
Invited SPeakers
Paul Lizzul, M.D., Ph.D.
Wayne M. Marley, M.D.
Howard Woodling Rogers, M.D.
Saturday, August 6
3:00 p.m. – 5:00 p.m.
Learning Objectives
1. Reduce errors in CPT coding.
2. Develop the necessary documentation required for CPT codes.
3. Identify how the audit process can affect your practice.
Invited Speakers:
Mark Lebwohl, M.D. – Director
Abby S. Van Voorhees, M.D.
Henry W. Lim, M.D.
Bruce Elliot Strober, M.D., Ph.D.
Description
Inappropriate and inaccurate coding can adversely affect your
practice’s financial well-being. This session will provide information
that will not only guide you in the selection of proper CPT codes
but, through the use of audited records, provide insight into what
constitutes acceptable documentation of your services.
AAD Live Coding
Webinars and
On-Demand Webinars
Get your coding updates
throughout the year from the
Academy’s expert coding team.
Tune in for LIVE webinars quarterly and get
your questions answered in real-time or check
out our library of webcasts for any previously
recorded sessions you may have missed or
want to watch again.
Visit www.aad.org/webinars
for a schedule of upcoming webinars
as well as a list of those past.
74
|
This forum will provide the opportunity
to learn best practices in the complex
management of psoriasis and psoriatic
arthritis. Experts in the field will review
the latest clinical guidelines with four
question-and-answer presentations.
Attendees receive a full set of recently
published AAD Guidelines together with
implementation products, which will
assist in using the evidence-based AAD
psoriasis guidelines in practice — FREE
of charge!
Visit www.aad.org/
meetings-and-events/
summer-meeting to register.
Scientific Sessions
M
O
C
Sunday, August 7
U029 Leprosy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Recognizing and Responding to
Common Dilemmas in Patient Care. . . . . . . . . . . . . . . 76
U031 The Interface of Skin and Psyche. . . . . . . . . . . . . . . . . . 76
U032 Spitz’s Genodermatoses . . . . . . . . . . . . . . . . . . . . . . . . . 76
U033 Infectious Disease Update: What I Wouldn’t Have
Known Without Evidence-Based Medicine. . . . . . . . . . 77
Forum — 9:00 a.m. to 11:00 a.m.
F023 Pathology and Procedures
of the Aging Hand. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
S011 What’s Hot in Pediatric Dermatology . . . . . . . . . . . . . . 78
S012 What’s Breaking Out: Acne and Rosacea. . . . . . . . . . . . 78
Your Sustaining Fund gift helps to…
• Protect the Public
• Expand Quality Dermatologic Care
• Translate Evidence into Practice
• Support Leaders in Dermatology
Thank you for Furthering Excellence in Dermatology…Today and Tomorrow
Learn more at the Academy Resource Center
Booth 906 or visit www.AADdevelopment.org
www.aad.org
|
75
Scientific Sessions, Sunday, August 7
Invest in the Academy’s mission of excellence!
Scientific Sessions
Focus Session
7:15 a.m. to 8:45 a.m.
U029
Sunday, August 7, Scientific Sessions
Leprosy
U031
The Interface of Skin and Psyche
Room: Gibson Suite
Room: Sutton South
Director Danielle M. Miller, M.D., Ph.D.
Director Richard G. Fried, M.D., Ph.D.
Learning Objectives
1. Diagnose the different presentations of Hansen’s Disease.
2. Treat the reactions seen in Hansen’s Disease.
3. Manage the disabilities and comorbidities seen in Leprosy.
Learning Objectives
1. Discuss the common burden of chronic skin disease and its
contributors to psychological distress in adults.
2. Define different types of stressors.
Description
The Leprosy Focus Session describes the clinical spectrum of
Hansen’s disease and its diagnosis. Standard treatment protocols
developed by the WHO and the National Hansen’s Disease
Program will be presented. The reactions seen in Hansen’s disease
and their treatment and management will be described. Also
presented will be the comorbidities and long term disabilities that
are encountered in this patient population and the surrounding
socio-economic challenges associated with Leprosy.
Description
There is an abundant and ever growing body of research
documenting the inextricable link between the skin and psyche.
Common skin disorders such as eczema, rosacea, psoriasis, acne,
urticaria, itch, and aging can all be influenced by the skin-psyche
connection. This session will review the most compelling data
and provide suggestions on how patients can incorporate
mind-body techniques.
U030Optimizing Management of Melanoma:
Recognizing and Responding to Common
Dilemmas in Patient Care
U032
Spitz’s Genodermatoses
Room: Sutton Center
Room: Regent Parlor
Director Christopher James Miller, M.D.
Learning Objectives
1. Develop effective management strategies to optimize outcomes
of patients with melanoma.
2. Recognize and respond to common dilemmas in which
adherence to consensus guidelines is not possible.
3. Evaluate the most current evidence to identify opportunities to
enhance management of patients with melanoma.
Description
Dermatologists frequently assume the primary role in managing
patients with melanoma. Although consensus guidelines are
useful for most steps of the management process, dermatologists
frequently encounter patients that challenge the simplicity
of treatment algorithms. This session will use case studies to
demonstrate common dilemmas encountered while managing
patients with melanoma and review current literature to develop
evidence-based responses. Controversial topics addressed in this
session will include biopsy technique, the role of sentinel lymph
node biopsy, the necessity of bloodwork or imaging, the role of
Mohs surgery, and optimal follow-up strategies.
76
|
Director Joel L. Spitz, M.D.
Learning Objectives
1. Recognize the main clinical features and be able to diagnose
the more common genodermatoses.
2. Treat and manage the most common genodermatoses.
Description
This session will be a clinical overview of genodermatoses directed
towards residents, clinicians, and physician extenders. Clinical
photos, mutation updates and management will be stressed in this
session based on Spitz’s Genodermatoses textbook. The presentation
will be in an interactive, fun, “game-show” format to maximize
learning and retention for board preparation and to gain a better
understanding of these syndromes.
Scientific Sessions
Focus Session
Forum
U033
Infectious Disease Update: What I
Wouldn’t Have Known Without EvidenceBased Medicine
F023
Room: Clinton Suite
Director Emily J. Fisher, M.D.
7:15 a.m. to 8:45 a.m.
Director Miguel R. Sanchez, M.D.
Learning Objectives
1. Examine data from studies of infectious diseases affecting the
skin and mucous membranes.
2. Use information to develop best practices to diagnose and treat
mucocutaneous infectious diseases.
3. Evaluate evidence behind new therapeutic strategies.
Pathology and Procedures of the
Aging Hand
Room: Sutton North
Invited Speakers
Dee Anna Glaser, M.D.
Hugh M. Gloster, Jr., M.D.
Ann G. Neff, M.D.
Learning Objectives
1. Diagnose common benign and malignant tumors of the hand
and formulate treatment plans.
2. Describe key anatomic features of the hands and utilize
appropriate surgical techniques.
3. Discuss methods for the treatment of common cosmetic
concerns of the aging hand as well as evaluating and treating
hyperhidrosis.
Description
Following this session, the participant should be able to identify,
diagnose and formulate appropriate treatment plans based on
outcomes for the most common benign and malignant tumors
found on the hands. Participants should be able to describe the
anatomy of the hand, as well as utilize appropriate anesthetic
and surgical techniques when performing surgery on the hand
to avoid potential complications. Participants should be able to
address common cosmetic concerns of the aging hand and various
methods for treating and improving these changes. Finally the
treatment of hyperhidrosis of the hands will be covered.
Schedule
9:00 a.m. Benign Tumors of the Hand / Dr. Neff
9:20 a.m. Malignant Tumors of the Hand / Dr. Gloster
9:50 a.m. Surgical Procedures of the Hand / Dr. Fisher
10:20 a.m. Cosmetic Procedures for the Aging Hand and
Hyperhidrosis Treatment / Dr. Glaser
www.aad.org
|
77
Scientific Sessions, Sunday, August 7
Description
From antibiotic resistance, to vaccines, to impending epidemics,
infectious diseases often capture the headlines of medical
news. But there is hardly another subspecialty in medicine or
dermatology in which differentiating fact from anecdote is more
crucial. This session will review evidence from scientific studies to
update the laboratory diagnosis and guide empirically supported
treatment of bacterial, fungal, viral and parasitic infections, as well
as develop more effective strategies to manage these diseases.
9:00 a.m. to 11:00 a.m.
Scientific Sessions
Symposium
9:00 a.m. to 12:00 a.m.
S011
What’s Hot in Pediatric Dermatology
S012
What’s Breaking Out: Acne and Rosacea
Director Nanette Blythe Silverberg, M.D.
Director Jonette Elizabeth Keri, M.D., Ph.D.
INVITED SPEAKERS
Helen Shin, M.D.
Robert Sidbury, M.D.
INVITED SPEAKERS
Hilary E. Baldwin, M.D.
Alan R. Shalita, M.D.
James Q. Del Rosso, D.O. Heather Clare Woolery-Lloyd, M.D.
Joely Anne Kaufman, M.D. Andrea L. Zaenglein, M.D.
Robert Silverberg, M.D.
Jonathan I. Silverberg, M.D.
Sunday, August 7, Scientific Sessions
Learning Objectives
1. Analyze recent data on the role of diet and weight in pediatric
skin disease.
2. Identify new diagnostic and therapeutic paradigms for
hemangiomas of infancy.
3. Analyze recent data on the role of genetics in pediatric skin
disease and new techniques in the therapy of genetic illnesses of
childhood.
Description
The session will cover several newer concepts and therapies in
pediatric dermatology. The lectures will include newer diagnostic
paradigms and therapeutic options in hemangiomas of infancy.
The role of diet, vitamins, and weight in pediatric skin disease will
be reviewed in light of recent literature. A lecture will review the
data on recent controversies in isotretinoin usage. There will also
be a lecture on new disease findings and pediatric dermatological
implications.
References
1. Iacobas I, Burrows PE, Frieden IJ, Liang MG, Mulliken JB,
Mancini AJ, Kramer D, Paller AS, Silverman R, Wagner AM,
Metry DW. LUMBAR: association between cutaneous infantile
hemangiomas of the lower body and regional congenital
anomalies. J Pediatr. 2010; 157: 795-801.
2. Murray CS, Canoy D, Buchan I, Woodcock A, Simpson A,
Custovic A. Body mass index in young children and allergic
disease: gender differences in a longitudinal study. Clin Exp
Allergy. 2011; 41: 78-85.
3. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman
MD. Isotretinoin use and the risk of inflammatory bowel
disease: a case-control study. Am J Gastroenterol. 2010;
105:1986-93.
Schedule
9:00 a.m. Acne, Isotretinoin And Autoimmunity / Dr. Silverberg
9:30 a.m. The Role Of Obesity In Atopic Dermatitis
/ Dr. Silverberg
10:10 a.m. What’s New In The World Of Pediatric Dermatology
/ Dr. Sidbury
10:45 a.m. New Concepts In Clinical Pediatric Dermatology
/ Dr. Silverman
11:20 a.m. Acne And Diet / Dr. Shin
78
|
Learning Objectives
1. Apply the latest evidence to treat acne and rosacea patients
with conventional and emerging therapies.
2. Treat acne in special populations including younger patients
and ethnic skin patients.
3. Identify common patient questions regarding diet and over the
counter products.
Description
The goal of this symposium will be to make practitioners better
able to treat all acne and rosacea patients with an emphasis on
providing good answers to commonly asked questions in day to
day practice. The session will begin with an update of the latest
information on these conditions and will follow with specific
insight into the role of diet in acne. A good review of sunscreens
and cosmetics as well as other non-prescription products will be
reviewed including home based light technology. A thorough
review on lasers/lights for acne and rosacea will be done, as well as
lecture on specific populations of early and ethnic acne patients.
Finally, a review of clinical pearls from contact dermatitis in these
patients to acne surgery hints will complete the symposium.
Schedule
9:00 a.m. Perspectives on the Management of Acne and
Rosacea: A Glance At The Past and A Peek At The
Future / Dr. Del Rosso
9:25 a.m. The Role of Diet in Acne and Rosacea / Dr. Shalita
9:50 a.m. Ethnic Skin Acne and Rosacea / Dr. Woolery-Lloyd
10:15 a.m. Cosmetics, Sunscreens, and Other Interesting
Topicals for Acne and Rosacea / Dr. Baldwin
10:40 a.m. Update on Lasers and Lights for Acne and Rosacea
/ Dr. Kaufman
11:05 a.m. Treating Early Acne: From Neonate to Adolescent
/ Dr. Zaenglein
11:30 a.m. Acne and Rosacea Treatment Pearls: Lessons from
Challenging Patients / Dr. Keri
The cycle of inflammatory rosacea warrants
the only FDA-approved oral treatment...
Formulated for an Effective
Anti-inflammatory Response
• Significant reduction in inflammatory lesion count seen as early as week 3
(vs placebo [P=.005]; 61% mean reduction at week 16 [N=251; P<.001])1,2
• In a large community-based trial, 75% of patients were clear or near clear
at week 12 (change in IGA* score; n=826)3
• Favorable tolerability vs doxycycline 100 mg with 5x less gastrointestinal upset4
• No evidence of bacterial resistance in a long-term safety study 5
*Investigator’s Global Assessment.
Oracea® (doxycycline, USP) is indicated for the treatment of only inflammatory lesions
(papules and pustules) of rosacea in adult patients.
In clinical trials, the most common adverse events reported were gastrointestinal upsets,
nasopharyngitis/pain, and nasal congestion/sinusitis. Oracea® should not be used to treat microbial
infections, and should be used only as indicated. This drug is contraindicated in people who have shown
hypersensitivity to any of the tetracyclines, and, like other tetracycline drugs, may cause fetal harm when
administered to a pregnant woman. Oracea® should not be used during pregnancy, by nursing mothers,
or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in
clinical trials, Oracea® patients should minimize or avoid exposure to natural or artificial sunlight. All
contraindications, warnings, and precautions associated with tetracyclines must be considered before
prescribing Oracea®. The safety of Oracea® treatment beyond 9 months has not been established.
Please see brief summary of Prescribing Information on next page.
*
*
References: 1. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol.
2007;56(5):791-802. 2. Data on file. Galderma Laboratories, L.P. 3. Webster GF. An open label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40-mg (30-mg immediate-release and 10-mg delayed-release beads).
Cutis. 2010;86(suppl 5[i]):7-15. 4. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576. 5. Preshaw PM, Novak MJ, Mellonig J, et al.
Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79(3):440-452.
Oracea and Galderma are registered trademarks of Galderma Laboratories, L.P.
14501 N. Freeway
ORA-525 Printed in USA 01/11
hcp.oracea.com
Rx Only
Keep out of reach of children.
Brief Summary of Full Prescribing Information
ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in
adult patients.
The dosage of ORACEA differs from that of doxycycline used to treat infections. To reduce the development
of resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be
used only as indicated.
CLINICAL PHARMACOLOGY
Pharmacokinetics
ORACEA capsules are not bioequivalent to other doxycycline products.
CONTRAINDICATIONS
This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other
tetracyclines.
WARNINGS
Teratogenic effects: 1) Doxycycline, like other tetracycline-class antibiotics, can cause fetal harm
when administered to a pregnant woman. If any tetracycline is used during pregnancy or if the
patient becomes pregnant while taking these drugs, the patient should be informed of the potential
hazard to the fetus and treatment stopped immediately.
ORACEA should not be used during pregnancy (see PRECAUTIONS: Pregnancy).
2) The use of drugs of the tetracycline class during tooth development (last half of pregnancy,
infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth
(yellow-gray-brown). This adverse reaction is more common during long-term use of the drug but has been
observed following repeated short-term courses. Enamel hypoplasia has also been reported. Tetracycline
drugs, therefore, should not be used during tooth development unless other drugs are not likely to
be effective or are contraindicated.
3) All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate
has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours.
This reaction was shown to be reversible when the drug was discontinued.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can
cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted
in animals treated early in pregnancy (see PRECAUTIONS: Pregnancy section).
Gastrointestinal effects: Pseudomembranous colitis has been reported with nearly all antibacterial
agents and may range from mild to life-threatening. Therefore, it is important to consider this diagnosis
in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia.
Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis”.
If a diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild
cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe
cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and
treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.
Metabolic effects: The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this
is not a problem in those with normal renal function, in patients with significantly impaired function, higher
serum levels of tetracycline-class antibiotics may lead to azotemia, hyperphosphatemia, and acidosis. If renal
impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the
drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy
is prolonged, serum level determinations of the drug may be advisable.
Photosensitivity: Photosensitivity manifested by an exaggerated sunburn reaction has been observed in
some individuals taking tetracyclines. Although this was not observed during the duration of the clinical studies
with ORACEA, patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or
UVA/B treatment) while using ORACEA. If patients need to be outdoors while using ORACEA, they should
wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures
with their physician.
PRECAUTIONS
General: Safety of ORACEA beyond 9 months has not been established.
As with other antibiotic preparations, use of ORACEA may result in overgrowth of non-susceptible microorganisms, including fungi. If superinfection occurs, ORACEA should be discontinued and appropriate therapy
instituted. Although not observed in clinical trials with ORACEA, the use of tetracyclines may increase the
incidence of vaginal candidiasis.
ORACEA should be used with caution in patients with a history of or predisposition to candidiasis overgrowth.
Bacterial resistance to tetracyclines may develop in patients using ORACEA. Because of the potential for drugresistant bacteria to develop during the use of ORACEA, it should be used only as indicated.
Autoimmune Syndromes: Tetracyclines have been associated with the development of autoimmune
syndromes. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients,
liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use
of all tetracycline-class drugs should be discontinued immediately.
Tissue Hyperpigmentation: Tetracycline class antibiotics are known to cause hyperpigmentation. Tetracycline
therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral
tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has
been reported to occur independently of time or amount of drug administration, whereas other pigmentation
has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation
as well as over sites of scars or injury.
Pseudotumor cerebri: Bulging fontanels in infants and benign intracranial hypertension in adults have
been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was
discontinued.
Laboratory Tests: Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic
studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.
Drug Interactions: 1. Because tetracyclines have been shown to depress plasma prothrombin activity,
patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
2. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid
giving tetracycline-class drugs in conjunction with penicillin. 3. The concurrent use of tetracycline and
methoxyflurane has been reported to result in fatal renal toxicity. 4. Absorption of tetracyclines is impaired by
bismuth subsalicylate, proton pump inhibitors, antacids containing aluminum, calcium or magnesium and ironcontaining preparations. 5. Doxycycline may interfere with the effectiveness of low dose oral contraceptives. To
avoid contraceptive failure, females are advised to use a second form of contraceptive during treatment with
doxycycline. 6. There have been reports of pseudotumor cerebri (benign intracranial hypertension) associated
with the concomitant use of isotretinoin and tetracyclines. Since both oral retinoids, including isotretinoin
and acitretin, and the tetracyclines, primarily minocycline, can cause increased intracranial pressure, the
concurrent use of an oral retinoid and a tetracycline should be avoided.
MICROBIOLOGY
The plasma concentrations of doxycycline achieved with ORACEA during administration (see DOSAGE AND
ADMINISTRATION) are less than the concentration required to treat bacterial diseases. In vivo microbiological
studies utilizing a similar drug exposure for up to 18 months demonstrated no detectable long-term effects on
bacterial flora of the oral cavity, skin, intestinal tract, and vagina.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Doxycycline was assessed for potential to induce
carcinogenesis in a study in which the compound was administered to Sprague-Dawley rats by gavage at
dosages of 20, 75, and 200 mg/kg/day for two years. An increased incidence of uterine polyps was observed
in female rats that received 200 mg/kg/day, a dosage that resulted in a systemic exposure to doxycycline
approximately 12.2 times that observed in female humans who use ORACEA (exposure comparison based upon
area under the curve (AUC) values). No impact upon tumor incidence was observed in male rats at 200 mg/kg/
day, or in either gender at the other dosages studied. Evidence of oncogenic activity was obtained in studies with
related compounds, i.e., oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors).
Doxycycline demonstrated no potential to cause genetic toxicity in an in vitro point mutation study with
mammalian cells (CHO/HGPRT forward mutation assay) or in an in vivo micronucleus assay conducted in CD-1
mice. However, data from an in vitro assay with CHO cells for potential to cause chromosomal aberrations
suggest that doxycycline is a weak clastogen.
Oral administration of doxycycline to male and female Sprague-Dawley rats adversely affected fertility and
reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity,
and concentration, abnormal sperm morphology, and increased pre-and post-implantation losses. Doxycycline
induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage
tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. Note that 50 mg/kg/day is
approximately 3.6 times the amount of doxycycline contained in the recommended daily dose of ORACEA for a
60-kg human when compared on the basis of AUC estimates. Although doxycycline impairs the fertility of rats
when administered at sufficient dosage, the effect of ORACEA on human fertility is unknown.
Pregnancy: Teratogenic Effects: Pregnancy Category D. (see WARNINGS section). Results from animal
studies indicate that doxycycline crosses the placenta and is found in fetal tissues.
Nonteratogenic effects: (see WARNINGS section).
Labor and Delivery: The effect of tetracyclines on labor and delivery is unknown.
Nursing Mothers: Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions
in infants from doxycycline, ORACEA should not be used in mothers who breastfeed. (see WARNINGS section).
Pediatric Use: ORACEA should not be used in infants and children less than 8 years of age (see WARNINGS
section). ORACEA has not been studied in children of any age with regard to safety or efficacy, therefore use
in children is not recommended.
ADVERSE REACTIONS
Adverse Reactions in Clinical Trials of ORACEA: In controlled clinical trials of adult patients with mild to
moderate rosacea, 537 patients received ORACEA or placebo over a 16-week period. The most frequent
adverse reactions occurring in these studies are listed in the table below.
Incidence (%) of Selected Adverse Reactions in Clinical Trials of ORACEA (n=269) vs. Placebo (n=268)
Nasopharyngitis
Pharyngolaryngeal Pain
Sinusitis
Nasal Congestion
Fungal Infection
Influenza
Diarrhea
Abdominal Pain Upper
Abdominal Distention
Abdominal Pain
Stomach Discomfort
ORACEA
13 (4.8)
3 (1.1)
7 (2.6)
4 (1.5)
5 (1.9)
5 (1.9)
12 (4.5)
5 (1.9)
3 (1.1)
3 (1.1)
3 (1.1)
Placebo
9 (3.4)
2 (0.7)
2 (0.7)
2 (0.7)
1 (0.4)
3 (1.1)
7 (2.6)
1 (0.4)
1 (0.4)
1 (0.4)
2 (0.7)
Note: Percentages based on total number of study participants in each treatment group.
Adverse Reactions for Tetracyclines: The following adverse reactions have been observed in patients
receiving tetracyclines at higher, antimicrobial doses:
Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory
lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity has been reported rarely. Rare instances
of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the
drugs in the tetracycline class. Most of the patients experiencing esophagitis and/or esophageal ulceration took
their medication immediately before lying down. (see DOSAGE AND ADMINISTRATION section).
Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon.
Photosensitivity is discussed above. (see WARNINGS section).
Renal toxicity: Rise in BUN has been reported and is apparently dose-related.(see WARNINGS section).
Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness,
pericarditis, and exacerbation of systemic lupus erythematosus.
Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.
OVERDOSAGE
In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures.
Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose.
DOSAGE AND ADMINISTRATION
THE DOSAGE OF ORACEA DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS.
EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE
EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.
One ORACEA Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at
least one hour prior to or two hours after meals.
Efficacy beyond 16 weeks and safety beyond 9 months have not been established.
Administration of adequate amounts of fluid along with the capsules is recommended to wash down the
capsule to reduce the risk of esophageal irritation and ulceration. (see ADVERSE REACTIONS section).
HOW SUPPLIED
ORACEA (beige opaque capsule printed with CGPI 40) containing doxycycline, USP in an amount equivalent to
40 mg of anhydrous doxycycline. Bottle of 30 (NDC 64682-009-01).
Storage: All products are to be stored at controlled room temperatures of 15°C-30°C (59°F-86°F) and
dispensed in tight, light-resistant containers (USP). Keep out of reach of children.
Patent Information: U.S. Patents 5,789,395; 5,919,775; 7,232,572; 7,211,267 and patents pending.
ORACEA is a registered trademark of CollaGenex Pharmaceuticals, Inc.
Manufactured by:
Marketed by:
CardinalHealth
Winchester, KY 40391 Fort Worth, TX 76177
7961-01 BPI 06/08
Brief Summary of Prescribing Information for STELARA™ (ustekinumab)
STELARA™ Injection, for subcutaneous use
See package insert for Full Prescribing Information
INDICATIONS AND USAGE: STELARA™ is indicated for the treatment of adult
patients (18 years or older) with moderate to severe plaque psoriasis who are
candidates for phototherapy or systemic therapy. CONTRAINDICATIONS: None.
WARNINGS AND PRECAUTIONS: Infections STELARA™ may increase the risk
of infections and reactivation of latent infections. Serious bacterial, fungal, and
viral infections were observed in subjects receiving STELARA™ (see Adverse
Reactions). STELARA™ should not be given to patients with any clinically
important active infection. STELARA™ should not be administered until the
infection resolves or is adequately treated. Instruct patients to seek medical
advice if signs or symptoms suggestive of an infection occur. Exercise caution
when considering the use of STELARA™ in patients with a chronic infection or
a history of recurrent infection. Serious infections requiring hospitalization
occurred in the psoriasis development program. These serious infections
included cellulitis, diverticulitis, osteomyelitis, viral infections, gastroenteritis,
pneumonia, and urinary tract infections. Theoretical Risk for Vulnerability to
Particular Infections Individuals genetically deficient in IL-12/IL-23 are
particularly vulnerable to disseminated infections from mycobacteria (including
nontuberculous, environmental mycobacteria), salmonella (including nontyphi
strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and
fatal outcomes have been reported in such patients. It is not known whether
patients with pharmacologic blockade of IL-12/IL-23 from treatment with
STELARA™ will be susceptible to these types of infections. Appropriate
diagnostic testing should be considered, e.g., tissue culture, stool culture, as
dictated by clinical circumstances. Pre-treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis infection prior to initiating treatment with
STELARA™. Do not administer STELARA™ to patients with active tuberculosis.
Initiate treatment of latent tuberculosis prior to administering STELARA™.
Consider anti-tuberculosis therapy prior to initiation of STELARA™ in patients
with a past history of latent or active tuberculosis in whom an adequate course
of treatment cannot be confirmed. Patients receiving STELARA™ should be
monitored closely for signs and symptoms of active tuberculosis during and after
treatment. Malignancies STELARA™ is an immunosuppressant and may
increase the risk of malignancy. Malignancies were reported among subjects
who received STELARA™ in clinical studies (see Adverse Reactions). In rodent
models, inhibition of IL-12/IL-23p40 increased the risk of malignancy (see
Nonclinical Toxicology). The safety of STELARA™ has not been evaluated in
patients who have a history of malignancy or who have a known malignancy.
Hypersensitivity Reactions Serious allergic reactions, including angioedema
and possible anaphylaxis, have been reported post-marketing. If an anaphylactic
or other serious allergic reaction occurs, discontinue STELARA™ and institute
appropriate therapy [see Adverse Reactions]. Reversible Posterior
Leukoencephalopathy Syndrome One case of reversible posterior
leukoencephalopathy syndrome (RPLS) was observed during the clinical
development program which included 3523 STELARA™-treated subjects. The
subject, who had received 12 doses of STELARA™ over approximately two
years, presented with headache, seizures and confusion. No additional
STELARA™ injections were administered and the subject fully recovered with
appropriate treatment. RPLS is a neurological disorder, which is not caused by
demyelination or a known infectious agent. RPLS can present with headache,
seizures, confusion and visual disturbances. Conditions with which it has been
associated include preeclampsia, eclampsia, acute hypertension, cytotoxic
agents and immunosuppressive therapy. Fatal outcomes have been reported. If
RPLS is suspected, STELARA™ should be discontinued and appropriate
treatment administered. Immunizations Prior to initiating therapy with
STELARA™, patients should receive all immunizations appropriate for age as
recommended by current immunization guidelines. Patients being treated with
STELARA™ should not receive live vaccines. BCG vaccines should not be given
during treatment with STELARA™ or for one year prior to initiating treatment or
one year following discontinuation of treatment. Caution is advised when
administering live vaccines to household contacts of patients receiving
STELARA™ because of the potential risk for shedding from the household
contact and transmission to patient. Non-live vaccinations received during a
course of STELARA™ may not elicit an immune response sufficient to prevent
disease. Concomitant Therapies The safety of STELARA™ in combination with
other immunosuppressive agents or phototherapy has not been evaluated.
Ultraviolet-induced skin cancers developed earlier and more frequently in mice
genetically manipulated to be deficient in both IL-12 and IL-23 or IL-12 alone
(see Nonclinical Toxicology). Theoretical Risk of Immunotherapy STELARA™
has not been evaluated in patients who have undergone allergy immunotherapy.
STELARA™ may decrease the protective effect of allergy immunotherapy and
may increase the risk of an allergic reaction to a dose of allergen immunotherapy.
Therefore, caution should be exercised in patients receiving or who have
received allergy immunotherapy, particularly for anaphylaxis. ADVERSE
REACTIONS: The following serious adverse reactions are discussed elsewhere
in the label: Infections (see Warnings and Precautions); Malignancies (see
Warnings and Precautions); and RPLS (see Warnings and Precautions).
STELARA™ (ustekinumab)
Clinical Studies Experience The safety data reflect exposure to STELARA™ in
2266 psoriasis subjects, including 1970 exposed for at least 6 months, 1285
exposed for at least one year, and 373 exposed for at least 18 months. Because
clinical trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly compared to rates
in the clinical trials of another drug and may not reflect the rates observed in
practice. Adverse reactions listed below are those that occurred at a rate of at
least 1% and at a higher rate in the STELARA™ groups than the placebo group
during the placebo-controlled period of STUDY 1 and STUDY 2. The numbers
(percentages) of adverse reactions reported for placebo-treated patients
(n=665), patients treated with 45 mg STELARA™ (n=664), and patients treated
with 90 mg STELARA™ (n=666), respectively, were: Nasopharyngitis: 51 (8%),
56 (8%), 49 (7%); Upper respiratory tract infection: 30 (5%), 36 (5%), 28 (4%);
Headache: 23 (3%), 33 (5%), 32 (5%); Fatigue: 14 (2%), 18 (3%), 17 (3%);
Diarrhea: 12 (2%), 13 (2%), 13 (2%); Back pain: 8 (1%), 9 (1%), 14 (2%);
Dizziness: 8 (1%), 8 (1%), 14 (2%); Pharyngolaryngeal pain: 7 (1%), 9 (1%),
12 (2%); Pruritus: 9 (1%), 10 (2%), 9 (1%); Injection site erythema: 3 (<1%),
6 (1%), 13 (2%); Myalgia: 4 (1%), 7 (1%), 8 (1%); Depression: 3 (<1%), 8 (1%),
4 (1%). Adverse drug reactions that occurred at rates less than 1% included:
cellulitis and certain injection site reactions (pain, swelling, pruritus, induration,
hemorrhage, bruising, and irritation). One case of RPLS occurred during clinical
trials (see Warnings and Precautions). Infections In the placebo-controlled period
of clinical studies of psoriasis subjects (average follow-up of 12.6 weeks for
placebo-treated subjects and 13.4 weeks for STELARA™-treated subjects),
27% of STELARA™-treated subjects reported infections (1.39 per subject-year
of follow-up) compared with 24% of placebo-treated subjects (1.21 per subjectyear of follow-up). Serious infections occurred in 0.3% of STELARA™-treated
subjects (0.01 per subject-year of follow-up) and in 0.4% of placebo-treated
subjects (0.02 per subject-year of follow-up) (see Warnings and Precautions). In
the controlled and non-controlled portions of psoriasis clinical trials, 61% of
STELARA™-treated subjects reported infections (1.24 per subject-year of
follow-up). Serious infections were reported in 0.9% of subjects (0.01 per
subject-year of follow-up). Malignancies In the controlled and non-controlled
portions of psoriasis clinical trials, 0.4% of STELARA™-treated subjects reported
malignancies excluding non-melanoma skin cancers (0.36 per 100 subjectyears of follow-up). Non-melanoma skin cancer was reported in 0.8% of
STELARA™-treated subjects (0.80 per 100 subject-years of follow-up) (see
Warnings and Precautions). Serious malignancies included breast, colon, head
and neck, kidney, prostate, and thyroid cancers. Immunogenicity The presence
of ustekinumab in the serum can interfere with the detection of anti-ustekinumab
antibodies resulting in inconclusive results due to assay interference. In STUDIES
1 and 2, antibody testing was done at time points when ustekinumab may have
been present in the serum. In STUDY 1 the last ustekinumab injection was
between Weeks 28 and 48 and the last test for anti-ustekinumab antibodies was
at Week 52. In STUDY 2 the last ustekinumab injection was at Week 16 and the
last test for anti-ustekinumab antibodies was at Week 24. In STUDY 1 (N=743),
antibody results were found to be positive, negative, and inconclusive in 38 (5%),
351 (47%), and 354 (48%) patients, respectively. In STUDY 2 (N=1198), antibody
results were found to be positive, negative, and inconclusive in 33 (3%), 90 (8%),
and 1075 (90%) patients, respectively. The data reflect the percentage of
subjects whose test results were positive for antibodies to ustekinumab in a
bridging immunoassay, and are highly dependent on the sensitivity and
specificity of the assay. Additionally, the observed incidence of antibody positivity
in an assay may be influenced by several factors, including sample handling,
timing of sample collection, concomitant medications and underlying disease.
For these reasons, comparison of the incidence of antibodies to ustekinumab
with the incidence of antibodies to other products may be misleading.
Post-marketing Experience Adverse reactions have been reported during postapproval use with STELARA™. Because these events are reported voluntarily
from a population of uncertain size, it is not always possible to reliably estimate
their frequency or establish a causal relationship to STELARA™ exposure.
Immune system disorders: Serious allergic reactions (including angioedema,
dyspnea and hypotension), hypersensitivity reactions (including rash and
urticaria). DRUG INTERACTIONS: Drug interaction studies have not been
conducted with STELARA™. Live Vaccines Live vaccines should not be given
concurrently with STELARA™ (see Warnings and Precautions). Concomitant
Therapies The safety of STELARA™ in combination with immunosuppressive
agents or phototherapy has not been evaluated (see Warnings and Precautions).
CYP450 Substrates The formation of CYP450 enzymes can be altered by
increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during
chronic inflammation. Thus, ustekinumab could normalize the formation of
CYP450 enzymes. A role for IL-12 or IL-23 in the regulation of CYP450 enzymes
has not been reported. However, upon initiation of ustekinumab in patients who
are receiving concomitant CYP450 substrates, particularly those with a narrow
therapeutic index, monitoring for therapeutic effect (e.g., for warfarin) or
drug concentration (e.g., for cyclosporine) should be considered and the
individual dose of the drug adjusted as needed (see Clinical Pharmacology).
STELARA™ (ustekinumab)
USE IN SPECIFIC POPULATIONS: Pregnancy Pregnancy Category B There
are no studies of STELARA™ in pregnant women. STELARA™ should be used
during pregnancy only if the potential benefit justifies the potential risk to the
fetus. No teratogenic effects were observed in the developmental and
reproductive toxicology studies performed in cynomolgus monkeys at doses up
to 45 mg/kg ustekinumab, which is 45 times (based on mg/kg) the highest
intended clinical dose in psoriasis patients (approximately 1 mg/kg based on
administration of a 90 mg dose to a 90 kg psoriasis patient). Ustekinumab was
tested in two embryo-fetal development toxicity studies. Pregnant cynomolgus
monkeys were administered ustekinumab at doses up to 45 mg/kg during the
period of organogenesis either twice weekly via subcutaneous injections or
weekly by intravenous injections. No significant adverse developmental effects
were noted in either study. In an embryo-fetal development and pre- and postnatal development toxicity study, three groups of 20 pregnant cynomolgus
monkeys were administered subcutaneous doses of 0, 22.5, or 45 mg/kg
ustekinumab twice weekly from the beginning of organogenesis in cynomolgus
monkeys to Day 33 after delivery. There were no treatment-related effects on
mortality, clinical signs, body weight, food consumption, hematology, or serum
biochemistry in dams. Fetal losses occurred in six control monkeys, six
22.5 mg/kg-treated monkeys, and five 45 mg/kg-treated monkeys. Neonatal
deaths occurred in one 22.5 mg/kg-treated monkey and in one 45 mg/kgtreated monkey. No ustekinumab-related abnormalities were observed in the
neonates from birth through six months of age in clinical signs, body weight,
hematology, or serum biochemistry. There were no treatment-related effects on
functional development until weaning, functional development after weaning,
morphological development, immunological development, and gross and
histopathological examinations of offsprings by the age of 6 months. Nursing
Mothers Caution should be exercised when STELARA™ is administered to a
nursing woman. The unknown risks to the infant from gastrointestinal or
systemic exposure to ustekinumab should be weighed against the known
benefits of breast-feeding. Ustekinumab is excreted in the milk of lactating
monkeys administered ustekinumab. IgG is excreted in human milk, so it is
expected that STELARA™ will be present in human milk. It is not known if
ustekinumab is absorbed systemically after ingestion; however, published data
suggest that antibodies in breast milk do not enter the neonatal and infant
circulation in substantial amounts. Pediatric Use Safety and effectiveness of
STELARA™ in pediatric patients have not been evaluated. Geriatric Use Of the
2266 psoriasis subjects exposed to STELARA™, a total of 131 were 65 years or
older, and 14 subjects were 75 years or older. Although no differences in safety
or efficacy were observed between older and younger subjects, the number of
subjects aged 65 and over is not sufficient to determine whether they respond
differently from younger subjects. OVERDOSAGE: Single doses up to 4.5 mg/kg
intravenously have been administered in clinical studies without dose-limiting
toxicity. In case of overdosage, it is recommended that the patient be monitored
for any signs or symptoms of adverse reactions or effects and appropriate
symptomatic treatment be instituted immediately. PATIENT COUNSELING
INFORMATION: Instruct patients to read the Medication Guide before starting
STELARA™ therapy and to reread the Medication Guide each time the
prescription is renewed. Infections Inform patients that STELARA™ may lower
the ability of their immune system to fight infections. Instruct patients of the
importance of communicating any history of infections to the doctor, and
contacting their doctor if they develop any symptoms of infection. Malignancies
Patients should be counseled about the risk of malignancies while receiving
STELARA™. Allergic Reactions Advise patients to seek immediate medical
attention if they experience any symptoms of serious allergic reactions.
Prefilled Syringe Manufactured by:
Centocor Ortho Biotech Inc.,
Horsham, PA 19044,
License No. 1821 at
Baxter Pharmaceutical Solutions,
Bloomington, IN 47403
© Centocor Ortho Biotech Inc. 2010
Vial Manufactured by:
Centocor Ortho Biotech Inc.,
Horsham, PA 19044,
License No. 1821 at
Cilag AG,
Schaffhausen, Switzerland
25ST10221
Save the Date
This activity has been approved for AMA PRA
Category 1 CreditsTM
Poster Exhibits
poster exhibits
Electronic Poster Exhibits/Poster Presentations: 3rd Level Lobby
Electronic Poster Exhibits viewing stations will be open during the following hours:
Thursday, August 4 ........................................ 7 a.m. – 6 p.m.
Saturday, August 6........................................7 a.m. – 5 p.m.
Friday, August 5............................................ 7 a.m. – 6 p.m.
Poster authors will conduct brief presentations of their electronic posters at the Poster Presentation Center in the 3rd Level Lobby during the
meeting. A full schedule of presentations will be available on the Summer Academy Meeting website at www.aad.org, and posted on-site at
the meeting.
Acne
P100
A double-blind, placebo-controlled, pilot study to determine the
efficacy and safety of a clindamycin 1.2% and tretinoin 0.025%
combination gel for the treatment of acne rosacea
P102
In vitro release of tretinoin from two clindamycin and tretinoin
combination gel formulations
P103
Bioavailability of clindamycin from a new clindamycin 1% –
benzoyl peroxide 3% low dose gel
P103
An open-label, split-face study evaluating efficacy and safety of
photopneumatic therapy for the treatment of acne
P200
Clinical evaluation of cutaneous xerosis in elderly
Arts, History, and Humanities of
Dermatology
P300
On the 25th birthday of psychosomatic dermatology
Basic Science
P400
The contribution of the lysine residue in the dermatological
activities of GHK-Cu
Clinical Dermatology and Other
Cutaneous Disorders
P500
Raynaud’s phenomenon of the nipple in breastfeeding mothers:
An underdiagnosed cause of nipple pain
P501
Health-related quality of life among Darier’s disease patients
P502
Plasma histamine concentrations and diamine oxidase activities in
chronic idiopathic urticaria
P503
Shitake dermatitis and other flagellate dermatoses
P505
Unusual presentation of pleurocutaneous fistula
P506
Trauma-induced neutrophilic dermatosis of the dorsal hands
P507
Cutaneous metastasis to the head from prostate adenocarcinoma:
Case report
P508
Poems syndrome identified in a patient with multiple atypical
hemangiomas
P509
Sweet syndrome associated with chlamydia pneumoniae pneumonia
P510
A case of plasma cell cheilitis arising from actinic cheilitis
P511
Mycosis fungoides palmaris et plantaris in childhood
Connective Tissue Diseases
P600
A case of atypical scleromyxedema
P601
Tumid lupus erythematosus with progression to discoid lupus
erythematosus
Dermatitis, Atopic
P700
The effect of parenting practices to behavior problems in children
with atopic dermatitis
P701
Involvement of human histamine N-methyltransferase gene
polymorphisms in susceptibility to atopic dermatitis in Korean
children
P702
A safe, effective, and novel topical herbal preparation for the
treatment of atopic dermatitis
Dermatitis, Contact, Allergic
and Irritant
P800
Dermatitis in patients undergoing the Nuss procedure for
correction of pectus excavatum
www.aad.org
|
83
Poster Exhibits
Aging/Geriatrics
P504
Review: Timing of office visits can be a powerful tool to improve
adherence in the treatment of dermatologic conditions
Poster Exhibits
Dermatopharmacology/Cosmeceuticals
Infection – Bacterial and Parasitic
P901
Efficacy and safety of a novel dual resurfacing product that combines
the benefits of manual microdermabrasion and chemical peeling
P1501
Case reports of lip leshmaniasis in pediatric patients
P900
Single-center, double-blinded study comparing the long-term
UV protective effects of three topical antioxidant products
Digital/Electronic Technology
P1000
A pilot study to evaluate high resolution skin imaging technology
(HRSIT) in dermatology clinical practice
Education AND Community Service
P1100
Assessing and improving patient knowledge about keloid scars
Epidemiology and Health Services
Administration
Poster Exhibits
P1200
Identifying risk factors via a skin cancer screening program: The
Moffitt Mole Patrol experience
P1201
Increased dermatologist density associated with reduction in
melanoma mortality
P1202
Cosmetic and non-cosmetic skin-related procedures performed
in the United States: A 12-year analysis
P1203
Time series study of reasons for non-compliance with biologic
treatments in psoriasis patients over three years
P1204
Psoriasis patient preference study on injectable biologic
medications and concerns about self-injection
P1205
Adherence to prescription oral or topical treatments in mild,
moderate, and severe psoriasis patients
P1206
Are urgent referrals actually urgent? Findings from a newlyestablished dermatology urgent care clinic
Genodermatoses
P1300
A case of lipoid proteinosis with oral ulcerative lesion
Hair and Nail Disorders
P1500
Efficacy of topical imiquimod 5% with cryotherapy for treatment
of anthroponotic cutaneous leishmaniasis, compared with
intralesional meglumine antimoniate
P1502
Secondary syphilis presenting with clinical features of adulthood
atopic dermatitis
P1503
Mixed cutaneous infection after work accident – the importance
of making cultures for different agents
Infection – Fungal
P1600
Naftifine 2% cream has demonstrated safety in the treatment of
tinea pedis, tinea cruris and tinea corporis
P1601
Naftifine 2% cream demonstrates a low propensity for irritation
and no evidence of phototoxicity or photoallergenicity potential
P1602
Naftifine 2% cream has demonstrated effectiveness in the
treatment of tinea pedis and tinea cruris
Internal Medicine Dermatology
P1700
Necrolytic acral erythema sine hepatitis C infection: A distinct
entity or clue to etiology?
P1701
Sweet syndrome with vasculitic pattern in a patient with POEMS
syndrome
P1702
Reactive perforating collagenosis: A case study
Lymphoma, Cutaneous/Mycosis
Fungoides
P1800
Abnormal B-cell clone in the setting of cutaneous T-cell lymphoma
P1801
Paniculitic-like T cell lymphoma of unusual presentation
Melanoma AND Pigmented Lesions
P1900
Neonatal blue light phototherapy and melanocytic nevi: A twin study
P1400
Oral supplementation of silicon and its impact on quality of hair
P1901
Mitotic rate as a marker to assess tumor biology in single versus
multiple primary melanoma
P1401
Investigation of serum vitamin D levels in patients with scarring
and nonscarring alopecia
P1902
A case of common blue nevus of the upper lip
P1402
Assessing vitamin D levels in alopecia areata patients
84
|
Poster Exhibits
Non-melanoma Skin Cancer
P2406
Efficacy and feasibility of combination excimer laser therapy,
clobetasol spray, and calcitriol ointment in the treatment of
generalized plaque psoriasis
P2001
Practice trends in the treatment of actinic keratosis in the United
States: 0.5% fluorouracil and combination cryotherapy plus
fluorouracil are underutilized despite evidence of benefit
P2407
A qualitative analysis on treatment expectations and experiences
among psoriasis patients in the United States
P2000
Low frequency of EGFR mutations but high frequency of EGFR
copy number anomalies in cutaneous squamous cell carcinoma
P2002
A recurred case of malignant eccrine poroma on the ear
Pediatric Dermatology
P2100
Subcutaneous fat necrosis of the newborn following iatrogenic
hypothermia
Photobiology, Phototherapy AND
Photosensitivity Diseases
P2200
Anatomically differentiated dosimetry for optimal phototherapy
of generalized psoriasis
Pigmentary Disorders AND Vitiligo
P2300
Treatment of melasma with a hydroquinone skin care system plus
0.025% tretinoin cream
Psoriasis AND Other
Papulosquamous Disorders
Skin Anatomy, Embryology AND
Physiology
P2500
The role of adenomatous polyposis coli (APC) in epidermal
development and hair follicle morphogenesis
P2501
Central sensitisation: An under-reported cause of chronic pain
in vascular malformations
Surgery – Cosmetic
P2600
Academic physicians’ attitudes towards implementation
of multidisciplinary cosmetic centers and the challenges of
subspecialties working together
P2601
Development and use of a submental fat rating scale
Surgery – Laser
P2700
Treatment of various epidermal-dermal skin lesions with fractional
er:yag laser: A Turkish experience
P2400
Health-related quality of life in patients undergoing etanercept
therapy for moderate to severe plaque psoriasis with involvement
of the scalp
P2701
The use of the 1450-nm diode laser in the nonablative treatment
of acne scarring in Fitzpatrick skin types IV-VI: A prospective
clinical study
P2401
An assessment of evidence from two phase III randomized
placebo-controlled trials in the treatment of moderate-to-severe
psoriasis: Benefit-risk analysis of ustekinumab
P2702
Correction of acne scars with fractional CO2 laser in darker skin assessment results and side effects
P2402
Response to retreatment with ustekinumab after withdrawal from
therapy in moderate-to- severe psoriasis patients: Results from the
PHOENIX 1 and ACCEPT phase 3 clinical trials
P2403
Consistency of responses across different ethnic populations
with moderate-to-severe psoriasis: Results from the ustekinumab
psoriasis clinical development program
P2404
Efficacy and safety of methotrexate in two fixed doses of 10mg or
25mg orally once weekly in patients with severe plaque type psoriasis:
A prospective, randomized, double blind, dose ranging study
P2703
Treatment of photoaging with CO2 fractional laser – evaluation
of results and complication in ten dark-skinned patients
P2704
Croll technique: Surgical reconstruction with localized laser in
acne scars
P2705
Effectiveness of 595nm pulsed dye laser in the treatment of basal
cell carcinoma and squamous cell carcinoma in situ
P2405
Psoriasis and palmoplantar pustulosis attributable to tumor necrosis
factor alpha inhibitors: The Mayo Clinic experience, 1998-2010
www.aad.org
|
85
Poster Exhibits
P2201
An analysis of chronic actinic dermatitis over a period of 25 years
P2408
Patient characteristics of ustekinumab utilization in a specialty
pharmacy provider (SPP) setting
When dry skin calls for a serious solution…
Recommend AmLactin
®
recommended by dermatologists
for rough, dry skin1
AmLactin® Rejuvenating Moisturizers
Nourishing formulas— combine emollients, humectants, and alpha-hydroxy acid to
exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP)
●
AmLactin Moisturizing Body Lotion & Cream
®
Everyday hydration— 12% lactic acid provides powerful therapy leaving skin
noticeably soft and smooth
●
AmLactin XL® Moisturizing Lotion
Visit us online at
www.amlactin.com
for samples, coupons
& more information!
Targets severely dry skin— features ULTRAPLEX,® an extra-strength blend of three
alpha-hydroxy compounds, clinically proven to improve smoothness and hydration
Serious care for softer skin
TM
For complete directions and cautions, please refer to individual product labels.
Reference: 1. Most recommended moisturizing product for rough, dry skin. Omnibus Study. Dermatology Times. May 2009.
1-800-654-2299 www.upsher-smith.com
©2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369
103985.02
Technical Exhibits
Technical Exhibit Hours
Thursday, August 4..............................................12 p.m. to 6 p.m.
Friday, August 5..................................................12 p.m. to 6 p.m.
Unopposed exhibit hours.................................12 p.m. to 2 p.m.
Saturday, August 6............................................... 10 a.m. to 2 p.m.
The American Academy of Dermatology invites you to visit the technical exhibits as part of your educational experience at the Summer
Academy Meeting 2011. The products displayed in the technical exhibits area and their uses, suggested by the manufacturers, do not
represent an endorsement nor imply that the products have been evaluated or approved by the American Academy of Dermatology.
For your convenience, the technical exhibiting companies are listed alphabetically and the products/services they offer are identified
as follows:
• Associations, Foundations and Medical Societies
• Medical Lighting Equipment
• Clothing
• Office Equipment and Supplies
• Computer Software and Hardware
• Practice Management
• Cosmetics and Skin Care
• Other Medical Equipment and Supplies
• Disposable Medical Supplies
• Pharmaceutical
• EMR/EHR Systems
• Photographic Equipment and Imaging Services
• Laboratory Services
• Phototherapy Supplies and Equipment
• Laser and Laser Supplies
• Publishing and Educational Materials
• Market Research
• Surgical Instruments
A listing by product/services can be found beginning on page 98.
Companies confirmed as of January 7, 2011.
3Gen, LLC/DermLite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405
31521 Rancho Viejo Rd, #104
San Juan Capistrano, CA 92675
Phone: (949)481-6384
Fax: (949)240-7492
Email: [email protected]
Product Category: Computer Software and Hardware, Office
Equipment and Supplies, Other Medical Equipment and Supplies,
Photographic Equipment and Imaging Services
3M Drug Delivery Systems. . . . . . . . . . . . . . . . . . . . . . . . 302
3M Center, Bldg 275-3E-10
St. Paul, MN 55144
Phone: (800)228-3957
Product Category: Disposable Medical Supplies
A
Abbott. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706
200 Abbott Park Rd
Abbott Park, IL 60064
Phone: (847)937-6100
Product Category: Pharmaceutical
Acuderm, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509
5370 NW 35th Terrace,
Ft. Lauderdale, FL 33309
Phone: (954)733-6935
Fax: (954)486-3602
Product Category: Disposable Medical Supplies, Other Medical
Equipment and Supplies
Acupath Laboratories. . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
285 Terminal Drive
Plainview, NY 11803
Phone: (888)228-7284
Fax: (516)326-3452
Aerolase. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
777 Old Saw Mill River Rd
Tarrytown, NY 10591
Phone: (914)345-8300
Fax: (914)345-8303
Product Category: Laser and Laser Supplies
Allergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
2525 Dupont Drive
Irvine, CA 92612
Phone: (714)246-4500
Fax: (714)246-4971
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833
485 Half Day Road, Suite 100
Buffalo Grove, IL 60089
Phone: (224)377-2000
Fax: (646)805-1312
Product Category: Laser and Laser Supplies, Other Medical
Equipment and Supplies
American Academy of Dermatology. . . . . . . . . . . . . . . . . . 906
930 E Woodfield Rd
Schaumburg, IL 60173
Phone: (866)503-SKIN (7546)
Fax: (847)240-1859
Product Category: Associations, Foundations, and Medical
Societies
American Acne and Rosacea Society. . . . . . . . . . . . . . . . 433
201 Claremont Ave.
Montclair, NJ
Phone: (973)783-4575
Fax: (973)783-4576
Societies
www.aad.org
|
87
Technical Exhibits
Alphabetical Directory of
Exhibiting Companies
Technical Exhibits
Amgen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606
One Amgen Center Drive
Thousand Oaks, CA 91320
Phone: (805)447-1000
Email: www.amgen.com
Axia Medical Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . 316
2015 Camino Vida Roble, Ste L
Carlsbad, CA 92011
Phone: (866)494-4466
Product Category: Cosmetics and Skin Care, Pharmaceutical
B
Technical Exhibits
Beiersdorf Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
187 Danbury Road
Wilton, CT 06897
Phone: (203)563-5800
Fax: (203)563-5800
Email: www.eucerinus.com
Product Category: Cosmetics and Skin Care
Bio - Oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
25800 Commercentre Drive
Lake Forest, CA 92630
Phone: (949)598-2400 x257
Fax: (949)598-2424
Biopelle, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
780 W 8 Mile Road
Ferndale, MI 48220
Phone: (866)424-6735
Fax: (877)548-7100
Bovie Medical Corporation. . . . . . . . . . . . . . . . . . . . . . . . 329
5115 Ulmerton Road
Clearwater, FL 33760
Phone: (800)537-2790
Fax: (800)323-1640
Product Category: Disposable Medical Supplies, Other Medical
Equipment and Supplies, Surgical Instruments
Brymill Cryogenic Systems. . . . . . . . . . . . . . . . . . . . . . . . 826
105 Windermere Ave
Ellington, CT 06029
Phone: (800)779-2796
Fax: (860)872-2371
Product Category: Office Equipment and Supplies, Other Medical
C
Canfield Imaging Systems . . . . . . . . . . . . . . . . . . . . . . . . 805
253 Passaic Ave
Fairfield, NJ 07004
Phone: (973)276-0300
Fax: (973)575-9914
Product Category: Computer Software and Hardware,
Photographic Equipment and Imaging Services, Medical Lighting
Equipment
88
|
CareCredit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
2995 Red Hill Ave, Ste 100
Costa Mesa, CA 92626
Phone: (866)247-3049 x2
Fax: (866)874-4093
Product Category: Practice Management
Caris Life Sciences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
6655 N. MacArthur Blvd
Irving, TX 75039
Phone: (800)979-8292
Fax: (214)596-2229
Product Category: Laboratory Services
Centocor Ortho Biotech, Inc. . . . . . . . . . . . . . . . . . . . . . . 702
800 Ridgeview Drive
Horsham, PA 19044
Phone: (610)651-6000
Fax: (215)325-4087
Cobalt Medical Supply. . . . . . . . . . . . . . . . . . . . . . . . . . . 415
P O Box 367
Pequannock, NJ 07440
Phone: (888)350-3790
Fax: (201)465-3041
Product Category: Disposable Medical Supplies, Medical Lighting
Equipment, Office Equipment and Supplies, Other Medical
Equipment and Supplies, Surgical Instruments, Pharmaceutical
Compulink Business Systems, Inc. . . . . . . . . . . . . . . . . . . 425
2645 Townsgate Road, Ste 200
Westlake Village, CA 91361
Phone: (800)456-4522
Fax: (208)979-7789
Product Category: Computer Software and Hardware, EMR/
EHR, Systems, Practice Management
Conmed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
525 French Rd
Utica, NY 13502
Phone: (800)448-6506
Fax: (800)438-3051
Product Category: Office Equipment and Supplies
Coria Laboratories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623
3909 Hulen Street
Phone: (817)501-0372
Cosmetic Surgery Times/Dermatology Times. . . . . . . . . . . 221
485F US Hwy 1 South, Suite 100
Iselin, NJ 08830
Phone: (732)346-3089
Fax: (732)596-0016
Product Category: Publishing and Educational Materials
Cutis and Cosmetic Dermatology . . . . . . . . . . . . . . . . . . . 310
7 Century Drive, Suite 302
Parsippany, NJ 07054
Phone: (973)206-8015
Fax: (973)206-9378
Technical Exhibits
D
Daavlin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519
205 W Bement St.
Bryan, OH 43506
Phone: (800)322-8546
Fax: (419)636-1739
Product Category: Phototherapy Supplies and Equipment
Dalos BioPharma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
421 S Lynnhaven Rd, Ste 101
Virginia Beach, VA 23452
Phone: (888)321-6772
Fax: (757)631-2114
DEKA Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407
665 Third Street
Suite 20
San Francisco, CA 94107
Phone: (877)844-5552
Fax: (415)358-8800
DERMAdoctor, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834
1901 McGee Street
Kansas City, MO 64108
Phone: (816)472-5700
Fax: (816)472-5752
Dermatology Foundation. . . . . . . . . . . . . . . . . . . . . . . . . . 818
1560 Sherman Avenue, Suite 870
Evanston, IL 60201-4808
Phone: (847)328-2256
Fax: (847)328-0509
Societies
Dermpath Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . 510
7111 Fairway Drive, Suite 400
Palm Beach Gardens, FL 33418
Phone: (866)467-7546
Fax: (214)975-1301
Dusa Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . 208
25 Upton Drive
Wilmington, MA 01887
Phone: (978)657-7500
Fax: (978)657-9193
Ellman International. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 806
3333 Royal Ave
Oceanside, NY 11572
Phone: (516) 594-3333
Fax: (516)569-0054
Product Category: Other Medical Equipment and Supplies,
Surgical Instruments
EltaMD Skincare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817
2055 Luna Road # 126
Carrollton, TX 75006
Phone: (800)633-8872
Fax: (972)385-7930
EZ Derm, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
90 Cypress Way East
Naples, FL 34110
Phone: (800)44-EZDERM
Fax: (239)598-0233
Product Category: Computer Software and Hardware, EMR/EHR
Systems
F
Fallene Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
2555 Industry Lane
Norristown, PA 19403
Phone: (800)332-5536
Ferndale Healthcare, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . 526
780 W Eight Mile Rd
Ferndale, MI 48220
Phone: (800)621-6003
Fax: (877)548-7100
Foamix Ltd.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230
PO Box 4038
Weizman Science Park
Ness Ziona, Israel 74740
Phone: (972)8-9316233
Fax: (972)8-9474356
Product Category: Cosmetics and Skin Care,Pharmaceutical
G
Galderma Laboratories, LP. . . . . . . . . . . . . . . . . . . . . . . . 506
14501 North Freeway
Phone: (817)961-5000
Fax: (817)961-5507
Genentech. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
1 DNA Way
So. San Francisco, CA 94080
Phone: (650)225-2064
www.aad.org
|
89
Technical Exhibits
Delasco. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808
608 13th Ave
Council Bluffs, IA 51501
Phone: (800)831-6273
Fax: (800)320-9612
Product Category: Cosmetics and Skin Care, Disposable Medical
Supplies, Laser and Laser Supplies, Medical Lighting Equipment,
Other Medical Equipment and Supplies, Pharmaceutical,
Publishing and Educational Materials, Surgical Instruments
E
Technical Exhibits
Graceway Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . 432
222 Valley Creek Blvd, Suite 300
Exton, PA 19341
Phone: (267)948-0400
Iredale Mineral Cosmetics. . . . . . . . . . . . . . . . . . . . . . . . 224
51 Church St
Great Barrington, MA 01230
Phone: (800)762-1132
H
IRIDEX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513
1212 Terra Bella Avenue
Mountain View, CA 94043
Phone: (800)388-4747
Fax: (650)962-0486
Henry Schein. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915
135 Duryea Road
Melville, NY 11747
Phone: (800)P-Schein
Fax: (800)329-9109
Product Category: Clothing, Computer Software and Hardware,
Cosmetics and Skin Care, Disposable Medical Supplies, EMR/
EHR Systems, Laboratory Services, Medical Lighting Equipment,
Office Equipment and Supplies, Pharmaceutical, Practice
Management Surgical Instruments
Technical Exhibits
Hill Dermaceuticals, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . 827
2650 S. Mellonville Ave
Sanford, FL 32773
Phone: (800)344-5707
Fax: (407)649-9213
Histopath Lab PA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
2671 W Norvell Bryant Hwy
Lecanto, FL 34461
Phone: (352)527-1344
HRA Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307
400 Lanidex Plaza
Parsippany, NJ 07054
Phone: (973)240-1204
Fax: (973)463-1888
Product Category: Market Research
I
Inga Ellzey Practice Group, Inc.. . . . . . . . . . . . . . . . . . . . 426
1211 State Road 436, Suite 297
Casselberry, FL 32707
Phone: (407)571-5536
Fax: (407)678-5751
Innocutis - A JSJ Pharmaceuticals Co. . . . . . . . . . . . . . . . 212
171 Church St.
Suite 140
Charleston, SC 29401
Phone: (800)499-4468
Fax: (843)965-8333
Product Category: Pharmaceutical, Associations, Foundations,
and Medical Societies, Surgical Instruments
Intendis, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801
PO Box 1941
Morristown, NJ 07962-1941
Phone: (866)463-3634
Fax: (973)966-3378
90
|
J
Jan Marini Skin Research, Inc. . . . . . . . . . . . . . . . . . . . . 802
6951 Via Del Oro
San Jose, CA 95119
Phone: (800)347-2223
Fax: (408)362-0140
Johnson and Johnson Consumer Products Company. . . . . . 505
199 Grandview Rd
Skillman, NJ 08558
Phone: (800)325-9821
Journal of Clinical and Aesthetic Dermatology. . . . . . . . . . 325
1595 Paoli Pike #103
Westchester, PA 19380
Phone: (866)325-9907
Fax: (484)266-0726
Journal of Drugs in Dermatology/ETAS. . . . . . . . . . . . . . . . 421
377 Park Ave South, 6th Floor
New York, NY 10016
Phone: (646)736-4333
Fax: (212)213-5435
K
Kaiser Permanente . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308
1800 Harrison St, 7th Floor
Oakland, CA 94612
Phone: (800)777-4912
Fax: (510)625-5487
L
La Roche-Posay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605
575 Fifth Avenue
New York, NY 10017
Phone: (888)577-5226
Leo Pharma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
Industriparken 55
Ballerup, 2750
Phone: (45)44945888
SKIN CARE
MANAGEMENT
SYSTEM
EA
UTY
CHO
IC
E
B
TM
PRODUCT
NE WBEAUT Y
WITH LAYERED TECHNOLOGY
WINNER
AW
ARD
1
2
3
5
4
CLEANSE
R E J U V E N AT E
R E S U R FA C E
H Y D R AT E
PROTECT
The 5-step system utilizes layered technology to measurably improve
the appearance of common skin conditions such as fine lines and
wrinkles, acne, rosacea and skin discoloration.
JANMARINI.COM
© 2011 Jan Marini Skin Research, Inc - NBSS211
Technical Exhibits
Lippincott, Williams and Wilkins . . . . . . . . . . . . . . . . . . . 303
172 W. 109th St.
Apt 5E
New York, NY 10025
Phone: (914)400-9964
Lucid, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
2320 Brighton Henrietta TL Rd
Rochester, NY 14623
Phone: (585)239-9800
Fax: (585)239-9800
Product Category: Laboratory Services, Other Medical Equipment
and Supplies, Photographic Equipment and Imaging Services
M
Technical Exhibits
MD Moms. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424
9051 Goldenwest St, #106-136
Huntington Beach, CA 92648
Phone: (888)636-6672
Fax: (619)374-7121
Medelita Scrubs and Lab Coats . . . . . . . . . . . . . . . . . . . . 413
1046 Calle Recodo, Suite D
San Clemente, CA 92673
Phone: (877)987-7979
Fax: (949)542-4101
Product Category: Clothing, Other Medical Equipment and
Supplies
Medesthetics Magazine. . . . . . . . . . . . . . . . . . . . . . . . . . 324
7628 Densmore Ave
Van Nuys, CA 91406
Phone: (800)442-5667
Medicis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520
7720 N Dobson Rd
Scottsdale, AZ 85256
Phone: (602)808-8800
Fax: (602)808-0822
Medimetriks Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . 322
363 Route 46 West
Fairfield, NJ 07004
Phone: (973)882-7512
Fax: (973)882-7502
Product Category: Pharmaceutical, Cosmetics and Skin Care
Mednet Technologies, Inc.. . . . . . . . . . . . . . . . . . . . . . . . 321
1975 Linden Blvd, Ste 407
Elmont, NY 11003
Phone: (516)285-2200
Fax: (516)285-1685
Product Category: Computer Software and Hardware, Practice
Management, Publishing and Educational Materials
92
|
MELA Sciences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409
50 S Buckhout St, Suite 1
Irvington, NY 10533
Phone: (914)591-3783
Fax: (914)591-3701
Product Category: Other Medical Equipment and Supplies,
Photographic Equipment and Imaging Services
Merz Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . 619
4215 Tudor Lane
Greensboro, NC 27410
Phone: (888)merzusa
Fax: (336)856-0107
Product Category: Pharmaceutical, Cosmetics and Skin Care
Micro4, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
7118 I-40 West, Bldg. D
Amarillo, TX 79106
Phone: (800)235-1856
Fax: (806)463-7021
Systems, Practice Management
Microsurgery Instruments, Inc.. . . . . . . . . . . . . . . . . . . . . 422
PO Box 1378
Bellaire, TX 77402-1378
Phone: (713)664-4707
Fax: (713)664-8873
Product Category: Medical Lighting Equipment, Other Medical
MJD Patient Communications. . . . . . . . . . . . . . . . . . . . . . 419
4915 St Elmo Ave, Suite 306
Bethesda, MD 20814
Phone: (301)657-8010
Fax: (301)657-8023
Product Category: Computer Software and Hardware, Office
Equipment and Supplies, Practice Management
MoleSafe USA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330
328 W St Georges Ave
Linden, NJ 07036
Phone: (908)925-7519
Fax: (908)925-2841
Product Category: Photographic Equipment and Imaging Services
Molluscum Rx. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420
5349 Lake Jessamine Dr
Orlando, FL 32839
Phone: (407)538-5654
Fax: (407)557-3493
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
3655 West Ninigret Dr
Salt Lake City, UT 84104
Phone: (800)924-4655
Fax: (801)952-0548
Product Category: Medical Lighting Equipment, Office
Equipment and Supplies, Other Medical Equipment and Supplies
When they come to you ...
On average, over 20 million people will board airplanes each month around the world.1
Some will walk barefooted through airport security which may expose them to tinea pedis.
Many eligible patients will receive the Naftin 90gm
size at No Out-of-Pocket Cost!**
UP TO $100 OFF *
INSTANTLY FOR ANY
NAFTIN (naftifine HCl 1%)
Instant Coupon available at www.NaftinCoupons.com
or by calling 1 888 296 1852
• 90g Pump
• 90g Cream
• 90g Gel Rx product
Indication
Naftin® (naftifine HCl 1%) Cream and Gel are indicated for the topical treatment
of tinea pedis, tinea cruris and tinea corporis caused by Trichophyton rubrum,
Trichophyton mentagrophytes, Epidermophyton floccosum and Trichophyton
tonsurans (Gel only).
* Subject to eligibility. Restrictions apply.
Naftin® Cream and Gel are contraindicated in individuals who have shown
hypersensitivity to any of their components and are for topical use only.
The most commonly reported side effects of Naftin® are burning/stinging,
dryness, redness, itching, and local irritation.
** Average co-pay shown verified as of August 2010 based on
reports from 380 health plans (eg. HMO, PPO, IPA, etc.) inclusive
of all benefit designs/co-pay tiers.
Please see adjacent page for Full Prescribing Information
1
RITA. Research and Innovative Technology Administration, Bureau of Transportation
Statistics.http://www.transtats.bts.gov/Oneway.asp? Display_Flag=0&Percent_Flag=0.
Accessed Aug 24, 2010.
GEL CREAM
Rx ONLY
DESCRIPTION: Naftin® Cream, 1% and Naftin® Gel, 1% contain the
synthetic, broad-spectrum, antifungal agent naftifine hydrochloride.
Naftin® Cream and Gel, 1% are for topical use only.
CHEMICAL NAME:
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride.
Naftifine hydrochloride has an empirical formula of C21H21N•HCl and
a molecular weight of 323.86.
Structural Formula:
CH 3
CH 2 NCH 2
H
C= C
H
HCI
Contains:
naftifine hydrochloride
Active Ingredient:
Naftifine hydrochloride………… 1%.
Inactive Ingredients: Naftin® Cream, 1% contains benzyl alcohol,
cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60,
purified water, sodium hydroxide, sorbitan monostearate, and stearyl
alcohol. Hydrochloric acid may be added to adjust pH. Naftin® Gel, 1%
contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate
disodium, alcohol (52%v/v), and purified water.
CLINICAL PHARMACOLOGY: Naftifine Hydrochloride is a synthetic
allylamine derivative. The following in vitro data are available but
their clinical significance is unknown. Naftifine hydrochloride has
been shown to exhibit fungicidal activity in vitro against a broad
spectrum of organisms, including Trichophyton rubrum, Trichophyton
mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum,
Microsporum canis, Microsporum audouini, and microsporum
gypseum, and fungistatic activity against Candida species, including
Candida albicans. Naftin® Cream and Gel, 1% have only been shown
to be clinically effective against the disease entities listed in the
INDICATIONS AND USAGE section.
PRECAUTIONS:
General: Naftin® Cream and Gel, 1%, are for external use only. If
irritation or sensitivity develops with the use of Naftin® Cream or
Gel, 1%, treatment should be discontinued and appropriate therapy
instituted. Diagnosis of the disease should be confirmed either by direct
microscopic examination of a mounting of infected tissue in a solution
of potassium hydroxide or by culture on an appropriate medium.
Information for patients: The patient should be told to:
1. Avoid the use of occlusive dressings or wrappings unless otherwise
directed by the physician.
2. Keep Naftin® Cream and Gel, 1% away from the eyes, nose, mouth
and other mucous membranes.
Carcinogenesis, mutagenesis, impairment of fertility:
Long-term studies to evaluate the carcinogenic potential of Naftin®
Cream and Gel, 1% have not been performed. In vitro and animal
studies have not demonstrated any mutagenic effect or effect on
fertility.
Pregnancy: Teratogenic Effects: Pregnancy Category B:
Reproduction studies have been performed in rats and rabbits (via oral
administration) at doses 150 times or more than the topical human
dose and have revealed no evidence of impaired fertility or harm to
the fetus due to naftifine. There are, however, no adequate and wellcontrolled studies in pregnant women. Because animal reproduction
studies are not always predictive of human response, this drug should
be used during pregnancy only if clearly needed.
Nursing mothers: It is not known whether this drug is excreted in
human milk. Because many drugs are excreted in human milk, caution
should be exercised when Naftin® Cream or Gel,1% are administered
to a nursing woman.
Pediatric use: Safety and effectiveness in pediatric patients have not
been established.
ADVERSE REACTIONS: During clinical trials with Naftin® Cream, 1%,
Although the exact mechanism of action against fungi is not known,
naftifine hydrochloride appears to interfere with sterol biosynthesis
by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of
enzyme activity results in decreased amounts of sterols, especially
ergosterol, and a corresponding accumulation of squalene in the cells.
the incidence of adverse reactions was as follows: burning/stinging
(6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%).
During clinical trials with Naftin® Gel, 1%, the incidence of adverse
reactions was as follows: burning /stinging (5.0%), itching (1.0%),
erythema (0.5%), rash (0.5%), skin tenderness (0.5%).
Pharmacokinetics: In vitro and in vivo bioavailability studies have
demonstrated that naftifine penetrates the stratum corneum in sufficient
concentration to inhibit the growth of dermatophytes.
DOSAGE AND ADMINISTRATION: A sufficient quantity of Naftin®
Following a single topical application of 1% of naftifine cream to
the skin of healthy subjects, systemic absorption of naftifine was
approximately 6% of the applied dose. Following single topical
applications of 3H- labeled naftifine gel 1% to the skin of healthy
subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/
or its metabolites are excreted via the urine and feces with a half-life of
approximately two to three days.
Naftin®
INDICATIONS AND USAGE:
Cream, 1% is indicated for the
topical treatment of tinea pedis, tinea cruris, and tinea corporis caused
by the organisms Trichophyton rubrum, Trichophyton mentagrophytes,
and Epidermophyton floccosum. Naftin® Gel, 1% is indicated for the
topical treatment of tinea pedis, tinea cruris, and tinea corporis caused
by the organisms Trichophyton rubrum, Trichophyton mentagrophytes,
Trichophyton tonsurans*, Epidermophyton floccosum*.
*Efficacy for this organism in this organ system was studied in fewer
than 10 infections.
CONTRAINDICATIONS: Naftin® Cream and Gel, 1% are contraindicated
in individuals who have shown hypersensitivity to any of their components.
WARNINGS: Naftin® Cream and Gel, 1% are for topical use only and
not for ophthalmic use.
Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410
© 2009 Merz Pharmaceuticals Rev 2/09
Cream, 1% should be gently massaged into the affected and
surrounding skin areas once a day. A sufficient quantity of Naftin® Gel,
1% should be gently massaged into the affected and surrounding skin
areas twice a day, in the morning and evening. The hands should be
washed after application. If no clinical improvement is seen after four
weeks of treatment with Naftin® Cream or Gel, 1%, the patient should
be re-evaluated.
HOW SUPPLIED:
Naftin® (naftifine hydrochloride) Cream, 1% is supplied in collapsible
tubes in the following sizes:
30g – NDC 0259-4126-30
60g – NDC 0259-4126-60
90g – NDC 0259-4126-90
30g – NDC 0259-4126-03 (pump)
90g – NDC 0259-4126-09 (pump)
Naftin® (naftifine hydrochloride) Gel, 1% is supplied in
collapsible tubes in the following sizes:
40g – NDC 0259-4770-40
60g – NDC 0259-4770-60
90g – NDC 0259-4770-90
Note: Store Naftin® Cream, 1% below 30˚C (86˚F).
Store Naftin® Gel, 1% at room temperature.
Technical Exhibits
Muhlbauer Dermatopahology Lab. . . . . . . . . . . . . . . . . . . 416
61 B Monroe Ave
Pittsford, NY 14534
Phone: (585)586-5166
Fax: (585)586-1370
N
National Biological Corporation. . . . . . . . . . . . . . . . . . . . 613
23700 Mercantile Road
Beachwood, OH 44122
Phone: (800)338-5045 x1
Fax: (216)765-0271
Product Category: Laser and Laser Supplies, Photographic
Equipment and Imaging Services, Phototherapy Supplies and
Equipment
Neocutis, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410
512 E. Eleven Mile Rd. #100
Royal Oak, MI 48067
Phone: (866)636-2884
Fax: (313)664-0668
NeoStrata Company. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 807
307 College Road East
Princeton, NJ 08540
Phone: (800)628-9904
Fax: (800)636-7872
Neutrogena. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502
5760 W 96th St
Los Angeles, CA 90045
Phone: (310)642-1150
Fax: (310)410-1631
NexTech. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820
5550 W. Executive Dr, Ste 350
Tampa, FL 33609
Phone: (813)425-9200
Fax: (813)425-9292
Systems, Practice Management
Niadyne NIA24/Strivectin. . . . . . . . . . . . . . . . . . . . . . . . 1013
4208 Six Forks Road 9th Floor
Raleigh, NC 27609
Phone: (919)838-7800
Fax: (919)838-7812
Obagi Medical Products. . . . . . . . . . . . . . . . . . . . . . . . . . 523
3760 Kilroy Airport Way
Long Beach, CA 90806
Phone: (562)628-1007
Fax: (562)628-1008
Onset Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
400 Highland Corporate Drive
Cumberland, RI 02864
Phone: (310)503-4621
Organization of Teratology Information Specialists . . . . . . 411
9500 Gilman Dr, MC0828
La Jolla, CA 92093
Phone: (877)311-8972
Fax: (619)294-6191
Societies, Publishing and Educational Materials
Ortho Dermatologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602
5760 West 96th Street
Los Angeles, CA 90045
Phone: (310)410-5813
Fax: (310)410-5945
P
Pharmaceutical Specialties, Inc. (PSI). . . . . . . . . . . . . . . 823
1620 Industrial Dr. NW
Rochester, MN 55901
Phone: (800)325-8232
Fax: (507)288-7603
Product Category: Cosmetics and Skin Care,Pharmaceutical
PharmaDerm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705
210 Park Avenue
Florham Park, NJ 07932
Phone: (866)337-6001
Photocure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
100 Overlook Center, 2nd Flr
Princeton, NJ 08540
Phone: (609) 375-2263
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524
147 Keystone Drive
Montgomeryville, PA 18936
Phone: (800)366-4758
Fax: (215)619-3208
Product Category: Cosmetics and Skin Care, Laser and Laser
Supplies, Phototherapy Supplies and Equipment
www.aad.org
|
95
Technical Exhibits
NeoGenomics Laboratories. . . . . . . . . . . . . . . . . . . . . . . . 231
12701 Commonwealth Dr
Ft Myers, FL 33913
Phone: (866)776-5907
O
Technical Exhibits
Practical Dermatology. . . . . . . . . . . . . . . . . . . . . . . . . . . 311
c/o Bryn Mawr Communications, LLC
Wayne, PA 19087
Phone: (484)581-1800
Product Category: Computer Software and Hardware, Practice
Management, Publishing and Educational Materials
Procter and Gamble. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515
1 PandG Plaza
Cincinnati, OH 45202
Phone: (513) 983-1100
Promius Pharma, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . 323
200 Somerset Corporate Blvd
Bridgewater, NJ 08807
Phone: (908)429-4500
Technical Exhibits
ProPath. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427
1355 River Bend Drive
Dallas, TX 75247
Phone: (800)258-1253
Fax: (214)237-1844
R
Ra Medical Systems, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . 216
2270-L Camino Vida Roble
Carlsbad, CA 92011
Phone: (760)804-1648
Fax: (760)804-1657
Product Category: Laser and Laser Supplies, Phototherapy
Supplies and Equipment
Revision Skincare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
9019 Premier Row
Dallas, TX 75247
Phone: (800)385-6652
Fax: (214)630-1806
Revitalash
6295 McLead
Las Vegas, NV 89120
S
Salvona Technologies. . . . . . . . . . . . . . . . . . . . . . . . . . . 332
65 Stults Rd
Dayton, NJ 08810
Phone: (609)655-0173
Fax: (609)655-9291
Sandstone Medical Technologies. . . . . . . . . . . . . . . . . . . 313
105 Citation Court
Homewood, AL 35209
Phone: (205)290-8251
Fax: (205)290-4269
96
|
Saunders/Mosby-Elsevier. . . . . . . . . . . . . . . . . . . . . . . . . 830
1600 JFK Blvd. #1800
Philadelphia, PA 19103
Phone: (800)325-4177
Skin and Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
83 General Warren Blvd, Ste 100
Malvern, PA 19355
Phone: (800)237-7285
Fax: (610)560-0501
Skin and Cancer Associates/Advanced Dermatology Mgmt. . . . 318
1111 Park Centre Blvd, Suite 300
Miami Gardens, FL 33169
Phone: (305)623-5595
Fax: (305)623-1937
Skin Cancer Foundation, The. . . . . . . . . . . . . . . . . . . . . . 734
149 Madison, Suite 901
New York, NY 10016
Phone: (212)725-5176
Fax: (212)725-5751
Societies, Publishing and Educational Materials
Skin Disease Education Foundation . . . . . . . . . . . . . . . . . 222
5635 Fishers Lane, Suite 6000
Rockville, MD 20852
Phone: (240)221-4405
Fax: (240)221-4400
SkinCeuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730
3402 West Miller Road
Garland, TX 75041
Phone: (800)811-1660
Fax: (972)926-2950
SkinMedica, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
5909 Sea Lion Place, Ste H
Carlsbad, CA 92010
Phone: (866)867-0110
Fax: (760)448-3604
Smile Reminder. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
3098 Executive Parkway
Suite 300
Lehi, UT 84043
Phone: (866)605-6867
Fax: (801)772-2034
Product Category: Computer Software and Hardware, Market
Research, Practice Management, Office Equipment and Supplies
Stiefel, a GSK Company. . . . . . . . . . . . . . . . . . . . . . 607, 608
c/o GSK
20 T.W. Alexander Dr.
Research Triangle Park, NC 27709
Phone: (919)990-6000
Technical Exhibits
Summers Laboratories. . . . . . . . . . . . . . . . . . . . . . . . . . . 320
103 G.P. Clement Drive
Collegeville, PA 19426
Phone: (610)454-1471
Fax: (610)454-1475
UVBIOTEK, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
3 Depot Street
Hudson Falls, NY 12839
Phone: (518)747-3310 x101
Fax: (518)747-2294
Product Category: Medical Lighting Equipment
V
Syneron and Candela. . . . . . . . . . . . . . . . . . . . . . . . . . . . 514
3 Goodyear, Unit A
Irvine, CA 92618
Phone: (949)716-6670
Fax: (949)716-6555
Verisante Technology, Inc. . . . . . . . . . . . . . . . . . . . . . . . 431
306-2309 West 41st Ave.
Vancouver, BC V6M2A3
Phone: (604)605-0507
Fax: (604)605-0508
Product Category: Other Medical Equipment and Supplies
T
Viscot Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
32 West Street
East Hanover, NJ 07936
Phone: (973)887-9273
Fax: (973)887-3961
Product Category: Disposable Medical Supplies
Taro Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
3 Skyline Drive
Hawthorne, NY 10532
Phone: (914)345-9001
Fax: (914)345-0391
Tiber Laboratories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418
5400 Laurel Springs Parkway
Suwanee, GA 30024
Phone: (678)208-0388 ext 241
Fax: (608)208-0988
Tiemann-Bernsco. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406
25 Plant Ave
Hauppauge, NY 11788
Phone: (800)843-6266
Fax: (800)577-6050
Product Category: Disposable Medical Supplies, Laser and Laser
Supplies, Medical Lighting Equipment, Office Equipment and
Supplies, Other Medical Equipment and Supplies, Surgical
Instruments
Triax Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . 824
11 Commerce Dr
Cranford, NJ 07016
U
Upsher-Smith Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . 829
6701 Evenstad Dr
Maple Grove, MN 55369
Phone: (763)315-2000
Fax: (763)315-2244
VisiCom. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
4520 South 36th St
Omaha, NE 68107
Phone: (800)228-3400
Fax: (402)734-6815
Product Category: Office Equipment and Supplies, Practice
Management
W
Warner Chilcott. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
100 Enterprise Drive
Rockaway, NJ 07866
Phone: (800)521-8813
Email: WCRX.com
West Coast Dermatology Billers, LLC . . . . . . . . . . . . . . . . 428
319 East Stuart Ave.
Redlands, CA 92374
Phone: (909)798-0601
Fax: (909)335-8644
Y
Yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
50 W 23rd Street, Ste 401
New York, NY 10010
Phone: (877)276-5104
Fax: (646)753-6312
Young Pharmaceuticals, Inc.. . . . . . . . . . . . . . . . . . . . . . 609
1840 Berlin Turnpike
Wethersfield, CT 06109
Phone: (860)529-7919
Fax: (860)529-6801
Product Category: Cosmetics and Skin Care, Computer Software
and Hardware, Pharmaceutical
www.aad.org
|
97
Technical Exhibits
Theraplex Company,The. . . . . . . . . . . . . . . . . . . . . . . . . . 235
6410 Poplar Ave Suite 110
Memphis, TN 38119
Phone: (888)437-2753
Fax: (888)437-1050
Technical Exhibits
PRODUCT CATEGORY DIRECTORY OF
EXHIBITING COMPANIES
Companies confirmed as of January 7, 2011.
Associations, Foundations,
and Medical Societies
American Academy of Dermatology..........................................906
American Acne and Rosacea Society.........................................433
Dermatology Foundation..........................................................818
Innocutis - A JSJ Pharmaceuticals Co.......................................212
Organization of Teratology Information Specialists..................411
Skin Cancer Foundation, The...................................................734
Clothing
Henry Schein............................................................................915
Medelita Scrubs and Lab Coats.................................................413
Technical Exhibits (by product category)
Computer Software and Hardware
3Gen, LLC/DermLite...............................................................405
Canfield Imaging Systems.........................................................805
Compulink Business Systems, Inc.............................................425
EZ Derm, LLC.........................................................................233
Henry Schein............................................................................915
Mednet Technologies, Inc.........................................................321
Micro4, Inc...............................................................................314
NexTech...................................................................................820
Smile Reminder........................................................................312
Young Pharmaceuticals, Inc......................................................609
Cosmetics and Skin Care
Axia Medical Solutions.............................................................316
Beiersdorf Inc. .........................................................................306
Bio - Oil...................................................................................232
Biopelle, Inc..............................................................................309
Coria Laboratories.....................................................................623
Dalos BioPharma......................................................................414
Delasco.....................................................................................808
DERMAdoctor, Inc..................................................................834
EltaMD Skincare......................................................................817
Fallene Ltd................................................................................203
Foamix Ltd...............................................................................230
Henry Schein............................................................................915
Iredale Mineral Cosmetics.........................................................224
Jan Marini Skin Research, Inc. ................................................802
Johnson and Johnson Consumer Products Company ..............505
La Roche-Posay.........................................................................605
LEO Pharma .......................................................................... 236
MD Moms................................................................................424
Medimetriks Pharmaceuticals, Inc............................................322
Merz Pharmaceuticals...............................................................619
MolluscumRx ......................................................................... 420
Neocutis, Inc............................................................................410
NeoStrata Company.................................................................807
Neutrogena...............................................................................502
Niadyne NIA24/Strivectin......................................................1013
Obagi Medical..........................................................................523
98
|
Pharmaceutical Specialties, Inc. (PSI).......................................823
Photocure..................................................................................331
PhotoMedex..............................................................................524
Procter and Gamble..................................................................515
Revision Skincare......................................................................317
Salvona Technologies................................................................332
SkinCeuticals............................................................................730
Skin Medica..............................................................................335
Summers Laboratories...............................................................320
Theraplex Company,The...........................................................235
Disposable Medical Supplies
3M Drug Delivery Systems.......................................................302
Acuderm, Inc............................................................................509
Bovie Medical...........................................................................329
Cobalt Medical Supply.............................................................415
Delasco.....................................................................................808
Henry Schein............................................................................915
Tiemann-Bernsco......................................................................406
Viscot Medical, LLC.................................................................334
EMR/EHR Systems
Compulink Business Systems, Inc.............................................425
EZ Derm, LLC.........................................................................233
Henry Schein............................................................................915
MELA Sciences . ..................................................................... 409
Micro4, Inc...............................................................................314
NexTech...................................................................................820
Laboratory Services
Caris Life Sciences.....................................................................429
Dermpath Diagnostics..............................................................510
Henry Schein............................................................................915
Histopath Lab PA.....................................................................333
Muhlbauer Dermatopahology Lab............................................416
NeoGenomics Laboratories.......................................................231
ProPath.....................................................................................427
Laser and Laser Supplies
Aerolase......................................................................................223
Alma Lasers................................................................................833
DEKA Medical , Inc..................................................................407
Delasco......................................................................................808
IRIDEX....................................................................................513
National Biological Corporation...............................................613
PhotoMedex..............................................................................524
Ra Medical Systems, Inc...........................................................216
Sandstone Medical Technologies..............................................313
Syneron and Candela................................................................514
Tiemann-Bernsco......................................................................406
Market Research
HRA Research..........................................................................307
Smile Reminder........................................................................312
Technical Exhibits
Medical Lighting Equipment
Delasco.....................................................................................808
Henry Schein............................................................................915
Microsurgery Instruments, Inc..................................................422
MTI..........................................................................................206
Tiemann-Bernsco......................................................................406
UVBIOTEK, LLC....................................................................227
Office Equipment and Supplies
3Gen, LLC/DermLite...............................................................405
Brymill Cryogenic Systems.......................................................826
Conmed....................................................................................821
Henry Schein............................................................................915
Medelita Scrubs and LabCoats . ...............................................143
MTI..........................................................................................206
Smile Reminder........................................................................312
Tiemann-Bernsco......................................................................406
VisiCom....................................................................................328
3Gen, LLC/DermLite...............................................................405
Acuderm, Inc............................................................................509
Bovie Medical...........................................................................329
Delasco.....................................................................................808
Ellman International.................................................................806
Henry Schein............................................................................915
Lucid, Inc................................................................................220
Medelita Scrubs and Lab Coats.................................................413
MTI..........................................................................................206
PhotoMedex ............................................................................524
Tiemann-Bernsco......................................................................406
Verisante Technology, Inc........................................................431
Pharmaceutical
Photographic Equipment
and Imaging Services
3Gen, LLC/DermLite...............................................................405
Lucid, Inc.................................................................................220
MELA Sciences.........................................................................409
MoleSafe USA..........................................................................330
Phototherapy Supplies
and Equipment
Daavlin.....................................................................................519
Delasco.....................................................................................808
Ra Medical Systems, Inc...........................................................216
Practice Management
Abbott.......................................................................................706
Allergan.....................................................................................202
Amgen......................................................................................606
Axia Medical Solutions.............................................................316
Centocor Ortho Biotech, Inc....................................................702
Coria Laboratories.....................................................................623
Dalos BioPharma......................................................................414
Delasco.....................................................................................808
Dusa Pharmaceuticals...............................................................208
Ferndale Healthcare, Inc...........................................................526
Foamix Ltd...............................................................................230
Galderma Laboratories, LP.......................................................506
Genentech.................................................................................430
Graceway Pharmaceuticals........................................................432
CareCredit................................................................................326
Compulink Business Systems Inc. . ..........................................425
Henry Schein............................................................................915
Inga Ellzey Practice Group, Inc. ..............................................426
Kaiser Permanente....................................................................308
Medelita Scrubs and Lab Coats ...............................................143
Micro4, Inc...............................................................................314
NexTech...................................................................................820
Skin and Cancer Associates/Advanced Dermatology Mgmt......318
Smile Reminder........................................................................312
VisiCom....................................................................................328
Yodle.........................................................................................327
West Coast Dermatology Billers, LLC. ....................................428
www.aad.org
|
99
Other Medical Equipment
and Supplies
Henry Schein............................................................................915
Hill Dermaceuticals, Inc...........................................................827
Intendis, Inc..............................................................................801
Medicis.....................................................................................520
Medimetriks Pharmaceuticals, Inc............................................322
Merz Pharmaceuticals...............................................................619
Neocutis, Inc............................................................................410
Obagi Medical..........................................................................523
Onset Therapeutics...................................................................234
Ortho Dermatologics................................................................602
Pharmaceutical Specialties, Inc. (PSI).......................................823
PharmaDerm............................................................................705
Promius Pharma, LLC .............................................................323
Salvona Technologies................................................................332
Stiefel, a GSK Company...................................................607, 608
Taro Pharmaceuticals................................................................226
Tiber Laboratories.....................................................................418
Triax Pharmaceuticals, LLC......................................................824
Upsher-Smith Laboratories, Inc................................................829
Warner Chilcott........................................................................305
Technical Exhibits
Publishing and Educational
Materials
Bovie Medical...........................................................................329
Conmed . .................................................................................821
Delasco.....................................................................................808
Ellman International.................................................................806
Henry Schein............................................................................915
Tiemann-Bernsco......................................................................406
ADVANCE for Healthy Aging.................................................323
Cosmetic Surgery Times/Dermatology Times...........................221
Cutis and Cosmetic Dermatology.............................................310
Delasco.....................................................................................808
Journal of Clinical and Aesthetic Dermatology.........................325
Journal of Drugs in Dermatology/ETAS...................................421
Lippincott, Williams and Wilkins.............................................303
Medesthetics Magazine.............................................................324
Organization of Teratology Information Specialists..................411
Practical Dermatology...............................................................311
Saunders/Mosby-Elsevier..........................................................830
Skin and Aging.........................................................................210
Skin Cancer Foundation, The...................................................734
Skin Disease Education Foundation..........................................222
Surgical Instruments
100
|
For moderate to severe plaque psoriasis
CLOBEX® (clobetasol propionate) Spray, 0.05%, is a super-high potent topical corticosteroid
formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to
20% body surface area (BSA) in patients 18 years of age or older.
Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested.
Clobetasol propionate spray should not be used in the treatment of rosacea or perioral dermatitis
and should not be used on the face, groin or axillae. In controlled clinical trials, the following
adverse reactions have been reported: burning, pruritus, hyperpigmentation, infections and
infestations, nasopharyngitis, upper respiratory tract infection, and skin and subcutaneous
tissue disorders.
Treatment should be limited to 4 weeks. Treatment beyond 2 weeks should be limited to
localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after
the initial 2 weeks of treatment with CLOBEX® Spray, 0.05%. CLOBEX® Spray, 0.05%, should not
exceed 50 g (59 mL or 2 fl oz) per week. CLOBEX® Spray, 0.05%, is not
recommended for use on anyone younger than 18 years of age.
Pregnancy Category C.
Please see adjacent page for brief summary of Prescribing Information.
Committee Meetings
All events are held at the Hilton New York unless indicated otherwise. List current as of February 22, 2011.
Thursday, August 4
Corporate Relations Task Force Meeting
Midtown Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:30 a.m.
Development Committee Meeting
Morgan Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3:00 p.m.
Friday, August 5
Corporate Partners Circle Meeting
Petit Trianon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m.
Cevnal on Education
Midtown Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 p.m.
Major Gifts Work Group
Lincoln Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 p.m.
Council of Government Affairs, Health Policy & Practice
New York Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:15 p.m.
Academic Dermatology Leadership Program Session
Morgan Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1:00 p.m.
Regulatory Policy Committee
East Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1:30 p.m.
SkinPAC Board of Advisors Meeting
Madison Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Private Sector Advocacy Task Force
Midtown Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Corporate Partners Recognition Reception
Petit Trianon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leadership and Mentoring Reception
New York Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2:30 p.m.
4:00 p.m.
5:00 p.m.
5:00 p.m.
Saturday, August 6
Board of Directors Meeting
Mercury Ballroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Coding & Reimbursement Task Force
Midtown Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Health Care Finance Commitee
Midtown Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Workforce Task Force
Madison Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Scientific Assembly Committee Meeting
Morgan Suite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7:00 a.m.
2:00 p.m.
4:00 p.m.
4:00 p.m.
5:00 p.m.
All events are held at the Hilton New York unless indicated otherwise. List current as of February 22, 2011.
WDS Board of Directors Meeting
Concourse A.................................................................................................. Friday, August 5 – 6:30 a.m. to 9:00 a.m.
Breakfast 6:30 a.m.
Meeting 7:00 a.m. to 9:00 a.m.
WDS Center
Concourse B.................................................................................................. Friday, August 5 – 9:00 a.m. to 5:00 p.m.
Saturday, August 6 – 9:00 a.m. to 3:00 p.m.
www.aad.org
|
103
Committee / Ancillary Meetings
Ancillary Meetings
Subject Index
How to Use the Subject Index
The subject index has been updated to help the attendees better plan their educational activities. The index is divided into nine different primary
topics with subtopics listed alphabetically under these primary topics.
The primary topics are:
• Basic Science of Dermatology
• Clinical Dermatology
• Therapeutics – Non-Surgical
• Dermatopathology
• Surgery
• Socioeconomic and Practice Issues
• Diagnostic Methods
• Epidemiology
Subject Index
Basic Science
Basic Methodologies in Skin Research
U011 From the Dermatology-Rheumatology
Management, 49
U016 From Bench to Bedside: Important Clinical Advances, 58
U025 Impact of Nanotechnology and
Dermatology, 71
U031 The Interface of Skin and Psyche, 76
Cutaneous Physiology
Pharmacology
Photophysics and Photobiology, including Lasers
U017 Photodynamic Therapy, 58
Structure and Function of Skin
U010 Skin of Color, 49
Basic Science of Dermatology
Cell Biology
U016 From Bench to Bedside: Important Clinical
Advances, 58
Genetics
Management, 49
Immunology
Management, 49
Advances, 58
Molecular Biology/Genetics
Advances, 58
Pathophysiology
Advances, 58
Photobiology
U017 Photodynamic Therapy, 58
Physiology
Advances, 58
Clinical Dermatology
Acne & Related Disorders
F004 Face to Face: Management of Facial
Dermatoses, 40
S005 Medication Monitoring and
Complications, 48
S012 What’s Breaking Out: Acne and Rosacea, 78
Dermatology, 71
Eczema and Inflammatory Dermatosis, 51
104
|
Aging/Geriatrics
U004 Medical Management of Actinic Keratoses, 38
U019 Cellulitis: A Common (Mis)Diagnosis?, 59
U020 Exploring Evidence Based Cosmeceuticals, 64
Bacterial
Dermatology, 71
U033 Infectious Disease Update What I
Wouldn’t Have Known Without EvidenceBased Medicine, 77
Bullous Dermatoses
F019 Oral Disease, 69
S001 EADV/AAD Joint Symposium, 41
W006 Practical Approaches to Patient Problems, 70
Clinical Dermatology
C003 Derm Exam Prep Course: Refresher, 68
F006 What’s Boiling Over: Atopic Dermatitis
and Other Eczematous Conditions, 43
F008 Cased Based Controversies: Medical, 44
F012 Case Based Challenges for PA/NP’s, 60
U002 Asian American Skin, 38
U008 Quality and Customer Service for a Better
Practice, 48
U018 Dermoscopy for the Non-Dermoscopist, 59
U022 Patch Test Allergens 101: A Detective’s
Toolkit, 65
Dermatology, 71
Dilemmas in Patient Care, 76
Clinical Research
Advances, 58
Dermatology, 71
Collagen Vascular Disorders
W006 Practical Approaches to Patient Problems, 70
Cosmetics
S008 What’s Hot in Women’s Dermatology, 67
U020 Exploring Evidence Based Cosmeceuticals, 64
Dermatology, 71
Diseases of Connective Tissue
Eczemas
F004 Face to Face: Management of Facial
Dermatoses, 40
atch Test Allergens 101: A Detective’s
U022 P
Toolkit, 65
Dermatology, 71
Endocrine Diseases
Fungal
S009 Dermatology Grand Rounds: A Discussion
of Case-Based Dilemmas, 68
Wouldn’t Have Known Without Evidence
Based Medicine, 77
General Dermatology
U003 Hidradenitis Suppurativa: An Update, 38
Practice, 48
U013 What’s New in Non-Melanoma Skin
Cancer, 53
Advances, 58
U023 Use of Light for Diagnosis and Treatment
in Dermatology, 65
Dermatology, 71
Genodermatoses
Dermatology, 71
U032 Spitz’s Genodermatoses, 76
Hair Disorders
F015 Alopecia and Hair Loss, 66
Human Papilloma Virus
Based Medicine, 77
Infections
F005 Infectious Disease and Infestation Update, 43
Dermatology, 71
Based Medicine, 77
Infestations/Bites
F005 Infectious Disease and Infestation Update, 43
Inflammatory Disorders
Subject Index
U011 F
rom the Dermatology-Rheumatology
Management, 49
Dermatology, 71
Psychocutaneous Disorders
Sexually Transmitted
Based Medicine, 77
Sunscreens
F002 Photoprotection, 39
Dermatology, 71
Transplant Medicine
Advances, 58
Urticaria
Viral
Based Medicine, 77
Dermatopathology
Dermatopathologic Findings in the Perforating
Disorders, Atrophies, and Other Disorders
of Dermal Connective Tissue (Includes
Degenerative Disorders)
U024 When Clinical and Histological
Findings Converge: Great Cases From a
Dermatopathologist’s Perspective, 71
Dermatopathologic Findings in Various Benign and
Malignant Cutaneous Neoplasms and Neoplastic
Diseases, Including Cutaneous Lymphomas
F017 Case Based Controversies:
Dermatopathology, 66
U005 Pitfalls in Dermatopathology, 45
Cancer, 53
U021 Controversies in “Dysplastic” Nevi, 64
Dermatopathologic Findings in Various
Connective Tissue Diseases and Other
Rheumatologic Disease
Dermatopathologic Findings in Various Metabolic
and Systemic Diseases, Including the Mucinoses
Dermatopathologic Findings in Various
Dermatopathologic Findings of Hair and Nails,
Including Alopecia
Dermatopathology Differential Diagnosis:
Dermatologic Diseases with Nodular
Inflammation or Infiltrates
Dermatopathology Stains, Including
Histochemistry, Immunohistochemistry,
and Immunofluorescence
Disorders of Pigmentation
Advanced
Basic
Clinical Pathologic Correlations
S006 What’s Hot in Dermatopathology, 57
Dermatopathology
Immunopathology
U024 When Clinical and Histological Findings
Converge: Great Cases From a Dermatopathologist’s Perspective, 71
Epidemiology
Epidemiology
F013 Melanoma, 60
Dermatology, 71
Interpersonal and
Communication Skills
Non-Patient Communication
F010 Legal Dilemmas in Dermatology, 50
S004 Leading High Performance Teams, 47
S007 Effective Communications: Delivering Key
Messages, 58
U001 Your True Colors: Know Yourself and
Understand Others, 38
U006 Bringing Out the Best in Others, 46
U012 Patients Satisfaction: Measurement and
Improvement, 53
Patient Communication
Dermatology Access, 59
S003 Negotiating Your Way to Great Leadership, 42
S007 Effective Communications: Delivering Key Messages, 58
Practice, 48
Improvement, 53
Dermatology, 71
Medical Dermatology
Adult Adnexal Diseases
Adult Disorders of Cornification and Keratinization
www.aad.org
|
105
Subject Index
U011 F
rom the Dermatology-Rheumatology
Management, 49
U019 Cellulitis: A Common (Mis) Diagnosis?, 59
Dermatology, 71
Internal Medicine
F018 Hypercoagulability, Purpura and the Skin, 69
Literature Update/What’s New
Cancer, 53
Malignancy/Tumors
F013 Melanoma, 60
F020 Tumor Board, 70
Cancer, 53
U014 Mastering Moles in Pediatric Patients, 53
Advances, 58
W004 Dermoscopy, 51
Cancer, 53
U027 Practical Dermoscopy, 72
Nail Disorders
Occupational Dermatology
Dermatology, 71
Oral/Mucous Membrane Disorders
Other
U002 Asian American Skin, 38
Practice, 48
U007 Neonatal Dermatology, 46
Dermatology, 71
Photosensitivity Diseases
Dermatology, 71
Pigmentary Abnormalities/Vitiligo
Pregnancy
Pruritus
F022 Psoriasis Guidelines Implementing them in
Your Practice, 73
Dermatology, 71
Psoriasis
Subject Index
Subject Index
Adult Patient Care: Assessment Skills, Plan
Formulation, and Patient Recommendations
F016 Consultative Dermatology, 66
Adult Patient Care: History Taking and Physical
Diagnosis
Dermatology, 71
Adult Patient Care: In-office and Ancillary
Diagnostics
Dermatology, 71
Adult Patient Care: Patient Safety Issues
Dermatology, 71
Adult Patient Care: Population Health and
Preventive Care
Dermatology, 71
Atrophies, Perforating Disorders, and Disorders
of Dermal Connective Tissue
W004 Dermoscopy, 51
Benign and Malignant Cutaneous Neoplasms,
Including Cutaneous Lymphomas
Advances, 58
Disorders of Hair and Nails
Eczematous Dermatoses
Dermatology, 71
Infections, Infestations and Bites
F016 Consultative Dermatology, 66
Dermatology, 71
U033 Infectious Disease Update: What I
Based Medicine, 77
Medical Therapy
F003 Case Based Challenges in Consultative
Dermatology, 40
Practice, 48
Advances, 58
Dermatology, 71
Metabolic and Systemic Diseases
Pruritus
Dermatology, 71
Ultraviolet Light Therapy and other Physical
Treatment Modalities
Advances, 58
Vasculitis, Vasculopathy and Purpura
Miscellaneous Topics
Controversies
Environment Issues
U009 Smoking and the Skin, 48
106
|
Miscellaneous
Practice, 48
Benign Neoplasms, Pediatric Cutaneous
Malignancy, and Tumor Syndromes of Childhood
W005 MOC Self-Assessment Pediatric
Dermatology, 62
Cutaneous Disorders of the Newborn
S011 What’s Hot in Pediatric Dermatology, 78
Ectodermal Dysplasia
Eczematous Eruptions
Hereditary Disorders of Cornification and
Keratinization
Hereditary Disorders of the Dermis, Including
Atrophies
Medical Therapy Issues in the Pediatric Patient
Normal Skin Variants and Developmental
Anomalies
Pediatric Collagen Vascular Disorders and Other
Rheumatologic Disease
U028 Morphea: Not Just for Adults Anymore, 72
Pediatric Disorders of Pigmentation
Pediatric Infections, Infestations, and Bites
Dermatology, 62
Pediatric Metabolic and Systemic Diseases
(Includes Endocrine Disorders and the Skin)
Pediatric Patient Care: Assessment Skills,
Plan Formulation, and Patient/Family
Recommendations
Pediatric Patient Care: History Taking and
Physical Diagnosis
U026 Pediatric Dermatology Jeopardy, 71
Pediatric Patient Care: In-office and Ancillary
Diagnostics
Pediatric Patient Care: Non-surgical Officebased Procedures
Dermatology, 71
Pediatric Patient Care: Patient Safety Issues
Dermatology, 71
Vascular Disorders of Infancy and Childhood,
Including Hemangiomas and Malformations
Dermatology, 62
Vesicobullous Disorders of Childhood
Dermatology, 62
Practice-Based Learning and
Improvement
Access, Assess and Incorporate Evidence-Based
Resources to Improve Practice
Participate in Activities to Assess and Improve
Quality Practice
Practice, 48
Dermatology, 71
W002 MOC Self-Assessment: Office-Based Safety, 45
Teach and Facilitate Learning of Others
Dermatology, 71
Use Technology to Improve Practice
Dermatology, 71
Procedural Dermatology
Anesthesia and Monitoring
Dermatology, 71
Basic Surgical Skills, Biopsy, Techniques and
Excisional Surgery
F023 Pathology and Procedures of the Aging Hand, 77
Dermatology, 71
Botulinum Toxin and Chemodenervation
C001 Live Patient Demonstration: Botulinum
Toxin and Fillers, 47
C002 Live Patient Demonstration: Neurotoxins
and Soft Tissue Augmentation, 57
F021 New Technologies in Minimally Invasive
Skin Rejuvenation, 73
F023 Pathology and Procedures of the Aging
Hand, 77
Dermatology, 71
Cutaneous Oncology
S010 Cutting Edge Surgery and Oncology, 72
Dermatology, 71
U027 Practical Dermoscopy, 72
W001 MOC Self-Assessment: Skin Cancer, 41
Flap Reconstruction
F009 Review and Update of Regional
Reconstruction, 50
Graft Reconstruction
Reconstruction, 50
Instrumentation
Reconstruction, 50
Lasers
U015 Laser Update, 53
Subject Index
Professionalism and
Maintenance of Certification
Leadership
U006 Bringing out the Best in Others, 46
Practice, 48
Dermatology, 71
Professional Development
Practice, 48
Sensitivity to a Diverse Patient Population
Practice, 48
Teamwork
Practice, 48
Volunteerism and Social Consciousness
Dermatology, 71
Socioeconomic & Practice
Issues
Computers
S002 E.H.R. Physician Demonstration, 42
Ethics
F010 Legal D lemmas in Dermatology, 50
Government
S002 E.H.R. Physician Demonstration, 42
Miscellaneous
Practice, 48
Improvement, 53
Office Management/Marketing
S003 Negotiating Your Way to Great Leadership, 42
Practice, 48
Management, 49
Improvement, 53
Quality Assurance
Practice, 48
Risk Management/Malpractice
Surgery
Advanced
F007 Case Based Controversies: Procedural, 44
Anesthesia
F014 Finessing Surgical Technique, 61
Basic/Intermediate
Complications – Prevention of
Lasers
U015 Laser Update, 53
in Dermatology, 65
Micrographic Surgery
F007 Case Based Controversies: Procedural, 44
Reconstruction, 50
Surgery
Reconstruction, 50
Surgical Repair Methods
F007 Case-Based Controversies: Procedural, 44
Reconstruction, 58
Dermatology, 71
Wound Healing
Reconstruction, 58
Dermatology, 71
Systems-Based Practice
Practice Management and the Business of
Dermatology, Including Office Regulation and
Accreditation
Practice, 49
Teaming with Other Providers of Care to Benefit
Your Patients
Practice, 48
Improvement, 53
Utilize Practice Services to Improve Your
Practice, Including Advocacy
Practice, 48
Therapeutics
Antifungals
Dermatology, 71
Based Medicine, 77
Corticosteroids
Dermatology, 71
Dermatopharmacology
Complications, 48
Drug Reactions
Complications, 48
Advances, 58
Dermatology, 71
Gene Therapy & DNA Vaccination
Dermatology, 71
Immunosuppression/Cytotoxic Therapy
Advances, 58
Dermatology, 71
Miscellaneous
Practice, 48
Dermatology, 71
Outcomes Analysis
Phototherapy
in Dermatology, 65
Dermatology, 71
in Dermatology, 65
Retinoids
Complications, 48
Therapeutics – Non-surgical
F013 Melanoma, 60
Advances, 58
Based Medicine, 77
Topical Nonsteroidal Therapy
Dermatology, 71
www.aad.org
|
107
Subject Index
Mohs Micrographic Surgery
Reconstruction, 50
Nail Surgery
F001 Nails, 39
Dermatology, 71
Photodynamic Therapy
Dermatology, 71
Skin Cancer in the Organ Transplant Recipient
Dermatology, 71
Skin Structure and Surgical Anatomy
Reconstruction, 48
F023 Pathology and Procedures of the Aging
Hand, 77
Tissue Augmentation (Fillers and Fat Transplant)
Wound Healing and Wound Care
Reconstruction, 50
Dermatology, 71
Invited Faculty Index
Abbreviations
Affil............................... Affiliate
Anat. ............................ Anatomy
Asst............................. Assistant
Assoc.......................... Associate
Biochem................. Biochemistry
Biol................................ Biology
Br................................... Branch
Canc. ............................. Cancer
Chem............ Chemical/Chemistry
Chf.................................... Chief
Chmn........................... Chairman
Clin...................... Clinic/Clinical
Col................................. College
Cons.......................... Consultant
Cosm........................... Cosmetic
Ctr................................... Center
Dept. ........................ Department
Derm....................... Dermatology
Dermpath......... Dermatopathology
Dir................................. Director
Dis. ............................ Disease(s)
Div. ............................... Division
Emer. ........................... Emeritus
Environ................. Environmental
Exper...................... Experimental
Fac................................. Facility
Fel................................... Fellow
Fndtn........................ Foundation
Gen. .............................. General
Hd..................................... Head
Hlth................................. Health
Hosp. ........................... Hospital
Immunol.................. Immunology
Infect. ........................ Infectious
Info. ......................... Information
Inst............................... Institute
Instr. .......................... Instructor
Int................................. Internal
Invest....................... Investigator
Lect.............................. Lecturer
A
Abrishami, Payam, M.D., 64
Alam, Murad, M.D., Chf, Sect Cut & Aesth Surg, Dept Derm, NW U,
Chicago, IL, 50, 72
Andea, Aleodor A., M.D., 45
Anderson, Bryan Erik, M.D., Asst Prof, Dept Derm, Penn St U, Hershey,
PA, 68
Antaya, Richard J., M.D., Assoc Prof, Dept Derm Yale U Sch Med, New
Haven, CT, 78
B
Baldwin, Hilary E., M.D., Assoc Prof Clin Derm, SUNY, Brooklyn, NY, 78
Barrio, Victoria R., M.D., M.D. Asst Prof Ped and Med (Derm), U.C.S.D.
San Diego, CA, 71
Barton, Simon, M.D., 41
Baum, Christian L., M.D., 41
Berson, Diane S., M.D., Asst Prof Derm, Weill Med Col of Cornell U,
NY, NY, 47
Bhatia, Neal D., M.D., Assoc Clin Prof, Dept Derm, U WI Med Sch,
Madison, WI, 38
Bichakjian, Christopher K., M.D., MD, Asst Prof, U of Michigan, Ann
Arbor, MI, 72
Bikowski, Joseph B., M.D., Clin Asst Prof Derm, OH State U, Columbus,
OH and Director, Bikowski Skin Care Center, Sewickley, PA, 40
Bolognia, Jean L., M.D., Prof, Dept Derm, Yale U, New Haven, CT, 41
Bordeaux, Jeremy S., M.D., M.P.H., Asst Prof, Dept of Derm, Case
Western Reserve University, Univ Hosp Case Med Ctr, Cleveland, OH, 72
Borradori, Luca, M.D., 42
Brewer, Jerry D., M.D., 41, 70, 72
Burdick, Anne E., M.D., M.P.H., Professor, Department of Dermatology,
Associate Dean for TeleHealth, University of Miami, Miami, FL, 43
Burgess, Cheryl M., M.D., Asst Clin Prof,Dept Derm, Georgetown
U Hosp, Washington, DC, 73
Busam, Klaus J., MD, Professor, Cornell University; Attending, Dermpath,
Memorial Sloan-Kettering Canc Ctr, New York, NY, 66
C
Callen, Jeffrey Phillip, M.D., Prof Med (Derm), Div Derm, Scho Med,
U Louisville, Louisville, KY, 68, 70
Camilleri, Michael J., M.D., 41
Campen, Rebecca B., M.D., J.D., Mass Gen Hosp, Dept Derm,
Boston, MA, 50
Cappel, Mark A., M.D., 41
108
|
Med................. Medical/Medicine
Microbiol. .............. Microbiology
Nat’l............................. National
No....................... North/Northern
Occup’l................... Occupational
Opthalmal.............. Opthalmology
Otolaryngol........... Otolaryngology
Parasit. ................... Parasitology
Path. .......................... Pathology
Ped. ........................... Pediatrics
Pharmacol............ Pharmacology
Phys........................ Physician(s)
Physiol...................... Physiology
Plast. .............................. Plastic
Podiat. .......................... Podiatry
Prev. .......................... Preventive
Prof............................. Professor
Prog............................. Program
Psych......................... Psychiatry
Radiol. ....................... Radiology
Res............................... Resident
Rsch............................ Research
Sch. ................................ School
Sci................................ Science
Sect. .............................. Section
Sen. ................................ Senior
So...................... South/Southern
St...................................... State
Surg.................. Surgery/Surgeon
Svc................................. Service
Syphilol.................... Syphilology
Trop. ............................. Tropical
U................................ University
VA................ Vets Administration
Vasc............................. Vascular
Venereol. ................ Venereology
Vet............................. Veterinary
Carlson, John Andrew, M.D., Prof, Div Dermpath, Albany Med Col,
Albany, NY, 66
Carucci, John A., M.D., Ph.D., Chf, Mohs Surg, Cornell U,
New York, NY, 50, 72
Carvajal, Richard, Oncology, 60
Casparian, Jacques Michael, M.D., 45
Chang, Mary Wu, M.D., Assoc Clin Prof, Dept Derm/Ped, U CT,
Dir Pediatric Dermatology of New England, West Hartford, CT, 43
Chiu, Melvin W., M.D., 38
Ciurea, Ana M., M.D., 51
Clarke, Jennie T., M.D., 68
Cohen, Bernard, M.D., Vol Prof, Dept Derm, U Miami, Coral Gables,
FL, 62
Cohen, David Eric, M.D., Vice Chair Dept of Derm, NYU School of
Medicine, New York, NY, 42, 55
Coldiron, Brett M., M.D., Clin Asst Prof Derm, U Cincinnati, Cincinnati,
OH, 61
Colegio, Oscar, M.D., Ph.D., 41, 58
Collishaw, Karen, 47
Cornelius, Lynn Anne, M.D., Chf Div Derm, WA U Sch of Med,
St Louis, MO, 60
Cotliar, Jonathan, M.D., Asst Clin Prof,Division of Dermatology,
David Geffen School of Medicine at UCLA, Los Angeles, CA, 40, 66
D
Daniel, C. Ralph, M.D., Clin Prof Derm, U MS, Jackson, Ms, Clin Assoc
Prof Derm, U AL, Birminham, AL, 39
Davey, William Patrick, M.D., Clin Prof, U KY, Lexington KY, 42
Davis, Dawn M. R., M.D., 44, 72
Davis, Mark D. P., M.D., Prof, Dept Derm, Mayo Clin, Rochester, MN, 44
Del Rosso, James Q., D.O., Derm Res Director, Valley Hosp Med Center,
Las Vegas, NV, 48, 78
DeLeo, Vincent Anthony, M.D., Chmn, Derm, St. Luke’s-Roosevelt &
Beth Israel Med Ctrs, New York, NY, 43
Donofrio, Lisa M., M.D., Asoc Clin Prof, Dept Derm, Yale U Sch Med,
New Haven, CT, Asst Clin Prof, Dept Derm, Tulane U, New Orleans, LA, 47
Draelos, Zoe Diana, M.D., Invest, Dermatology Consulting Services,
High Point, NC, 39, 64
E
Eastern, Joseph S., M.D., Clin Asst Prof, UMDNJ and Seton Hall U,
Newark, NJ, 42
Eichenfield, Lawrence F., M.D., Chf Ped and Adol Derm, Prof Ped Med
Derm, U CA, Rady Child Hosp, San Diego, CA, 43
Elewski, Boni E., M.D., Prof Derm, U AL, Birmingham, AL, 67
Ellis, Charles N., M.D., Prof and Assoc Chmn, Dept Derm, U MI Sch
Med, Ann Arbor, MI, 48
Elmets, Craig A., M.D., Prof, Chmn, Dept Derm, U AL, Birmingham,
AL, 67
Elston, Dirk Michael, M.D., Director, Dept of Dermatology, Geisinger
Med Ctr, Danville, PA, 66
F
Farris, Patricia, M.D., Metairie, LA, 58
Fazel, Nasim, M.D., Asst Prof, UC Davis Sacramento, CA Dept Derm,
U CA, Sacramento, CA, 69
Ferringer, Tammie C., M.D., Assoc, Derm, Dermpath, Geisinger Med Ctr,
Danville, PA, 57
Fisher, Emily J., M.D., 61, 77
Fitzgerald, Rebecca L., M.D., 57
Fox, Lindy Peta, M.D., Asst Prof Derm, UCSF, San Francisco, CA, 40, 66, 68
Fried, Richard G., M.D., Ph.D., Clin Dir, Yardley Derm, Yardley, PA, 76
G
H
Halpern, Allan C., M.D., Chf, Derm Svc, MSKCC, New York, NY, 39, 60
Hamzavi, Iltefat H., M.D., MD,Sr Staff Phys, Henry Ford Hospital,
Detroit, MI, 65
Harper, Julie Claire, M.D., Clin Assoc Prof, Dept Derm, U AL Med Ctr,
Birmingham, AL, 48
Hectorne, Kathleen Julie, M.D., 72
Hernandez, Claudia, M.D., Asst Prof Derm, U of Illinois at Chicago,
Chicago, IL, 59
Hughey, Lauren C., M.D., Asst Prof, Dept Derm, U of AL, Birmingham,
AL, 40, 66
Hurst, Eva A., M.D., 60
Hwang, Sam T., M.D., Ph.D., MD/Ph.D., Sr. Invest., Derm Br, NCI,
Bethesda, MD, 55
J
Jackson, Brooke A., M.D., Asst Clin Prof, Dept Derm, Sch Med,
Northwestern, Chicago, IL, 73
James, William D., M.D., Prof, Dept Derm, U PA, Philadelphia, PA, 59
Jellinek, Nathaniel J., M.D., Asst Prof, Dept Derm, Brown Med Sch,
Providence, RI, 39
Jiang, Shang I. Brian, M.D., 50, 72
Johnson, Timothy M., M.D., U MI, Ann Arbor, MI, 54
Johnson-Jahangir, Hillary, M.D., Ph.D., 45
Johr, Robert H., M.D., Clin Prof Derm Ped, Dir Pgt Lsn, U Miami,
Miami, FL, 72
K
Kalaaji, Amer Nizar, M.D., Mayo Clin, Rochester, MN, 44
Kaufman, Joely Anne, M.D., Asst Prof, Clin Derm, University of Miami
Miller School of Medicine; Miami, FL, 78
Kaufmann, Mark D., M.D., Assoc Clin Prof, Dept Derm, Mt Sinai School
of Med, New York, New York, 42
Keri, Jonette Elizabeth, M.D., Ph.D., 78
Kirby, Joslyn S., M.D., 51
Kroshinsky, Daniela, M.D., 59, 66
l
Lebwohl, Mark, M.D., Prof and Chmn, Dept Derm, Mt Sinai Sch Med,
New York, NY, 51, 67, 73
Lee, Robert A., M.D., Ph.D., Clin Instructor, University of Pennsylvania,
Philadelphia, PA, 38
Levy, Moise L., M.D., Prof Derm & Ped, Baylor Col Med, TX Children’s
Hosp, Houston, TX, 62
Lewis, Amy B., M.D., Clin Asst Prof, Dir Derm Surg, Derm, SUNY HSC,
Brooklyn, NY, 47
Lim, Henry W., M.D., Chmn and C.S. Livingood Chr, Derm, Henry Ford
Hosp, MI, 39, 41, 54
Lizzul, Paul, M.D., Ph.D., 74
Lober, Clifford Warren, M.D., J.D., Clin Assoc Prof, Div Derm, U So FL,
Tampa, FL, 50
Lucas, Jennifer, M.D., Assoc Staff, Cleveland Clin, Cleveland, OH, 47
M
MacCormack, Mollie A., M.D., 58
Margolis, David J., M.D., Assoc Prof, Sch Med, U PA, Philadelphia,
PA, 55
Marks, Victor J., M.D., 68
Marks, Victor James, M.D., Assoc, Geisinger Med Ctr, Danville,
PA, 47, 53
Marks, James G., M.D., 46
Marmur, Ellen S., M.D., Asst Clin Prof, Dept Derm, Sch Med, Mt. Sinai,
New York, NY, 47
Martin, Elizabeth Shannon, M.D., Clin Volunteer Faculty,
Univ of AL, 38
Martinez, Jose Dario, M.D., 43
Martini, Mary C., M.D., 51
Matarasso, Seth L., M.D., Clin Prof Derm, UCSF, San Francisco, CA, 47, 57
Meehan, Shane A., M.D., 57
Mercurio, Mary Gail, M.D., Assoc Prof Derm, U Rochester, Rochester,
NY, 67
Miller, Christopher James, M.D., Dept Derm, U of Pennsylvania,
Philadelphia, PA, 61, 68, 72, 76
Miller, Danielle M., M.D., Ph.D., 76
Miller, Jeffrey J., M.D., Assoc Prof, Dept Derm, Penn State Col Med,
Hershey, PA, 68
Mirowski, Ginat W., M.D., DM.D., Assoc Prof Derm, Northwestern,
Chicago, IL, 69
Morel, Kimberly Dawn, M.D., 60
Mowad, Christen M., M.D., Assoc Prof, Geisinger Medical Center, 51
Moy, Ronald L., M.D., Clin Prof, Div Derm, Sch Med, UCLA, Dir Derm
Surg, VA West, Los Angeles, CA, 54
Mugalian, Ruth, 58
N
Nasir, Adnan, M.D., Ph.D., Clin Asst Prof, Dept Derm, UNC,
Chapel Hill, NC, 71
Neel, Victor Allen, M.D., Ph.D., Dir, Derm Surg, MA General Hospital,
Boston, MA, 44
www.aad.org
|
109
Garden, Jerome M., M.D., Assoc Prof Clin Derm and Ped, NW U,
Chicago, IL, 53
Garg, Amit, M.D., Asst Prof, Dept Derm, Boston U Sch of Med,
Boston, MA, 68
Gasbarre, Christopher C., D.O., 43
Geronemus, Roy G., M.D., Clin Prof Derm, NYU Med Ctr,
New York, NY, 56
Gladstone, Hayes B., M.D., Assoc Prof, Derm/Otolaryngol, Dir,
Div Derm Surg, Stanford U, Stanford, CA, 50, 61
Glaser, Dee Anna, M.D., Prof, Dept Derm, St. Louis U, St. Louis,
MO, 77
Gloster, Hugh M., M.D., Assoc Prof, Dept Derm, U Cincinnati Col Med,
Cincinnati, OH, 61, 77
Gold, Michael H., M.D., Gold Skin Care Ctr, TN Clin Rsch Ctr, 42
Goldberg, David J., M.D., J.D., Clin Prof, Derm, Mount Sinai Sch of Med,
New York, NY, 42
Goldenberg, Gary, M.D., 53, 57
Graf, Jeannette O., M.D., 57
Grando, Sergei A., M.D., Ph.D., UC Irvine, CA, 48
Grant-Kels, Jane Margaret, M.D., Prof, Chmn, Dept Derm, Dir
Dermpath, Sch Med, U CT, Farmington, CT, 46, 68
Groysman, Vlada, M.D., 67
Jorizzo, Joseph L., M.D., Prof and Fmr Chmn, Dept Derm, Wake Forest
U, Winston-Salem, NC, 46, 70
Junkins-Hopkins, Jacqueline M., M.D., Assc Prof Dept Derm, UPENN,
Neff, Ann G., M.D., 77
Nemeth, Shari, M.D., 41
Newman, Catherine Clayton, M.D., 44
Northington, Marian Elizabeth, M.D., Asst Prof, Derm, Birmingham, AL, 67
Nunley, Kara S., M.D., 60
O
Olbricht, Suzanne, M.D., Chf Derm, Lahey Clin, Assoc Prof Derm,
Harvard MS, Boston, MA, 61
Osterwalder, Uli, 39
Ozog, David M., M.D., 61
P
Pandya, Amit G., M.D., Prof, Dept Derm, U TX SW Med Ctr, Dallas, TX,
59
Parsons, Margaret E., M.D., Asst Clin Prof, Dept Derm, UC-Davis,
Sacramento, CA, 47
Patel, Manisha J., M.D., 60
Patel, Rishi R., M.D., 57
Piette, Warren W., M.D., Chr, Div Derm, Cook Cty Hosp; and Prof,
Dept Derm, RUSH Medical Center, Chicago, IL, 69
Powell, Frank C., M.D., Con Derm, Reg Ctr Derm, Mater Hosp, Dublin,
Ireland, 41
Puttgen, Katherine B., M.D., 62
Q
Qureshi, Abrar A., M.D., M.P.H., Co-Dir, Dept Derm, Brigham &
Women’s Hosp, Harvard Med Sch, Boston, MA, 49
R
Rapini, Ronald P., M.D., Prof and Chmn, Dept Derm, U TX,
Houston, TX, 43
Ratner, Desiree, M.D., Assoc Clin Prof, Dept Derm, Columbia U Med Ctr,
New York, NY, 72
Rich, Phoebe, M.D., Clin Prof, Dept of Derm OHSU and Private Practice
Portland, OR, 39
Rigel, Darrell S., M.D., Clin Prof Derm, New York Univ Med Ctr,
Roberts, Wendy E., M.D., Asst Clin Prof Med, Loma Linda U Med Ctr,
Loma Linda, CA, 49, 73
Rogers, Howard Woodling, M.D., 74
Rohrer, Thomas E., M.D., Skincare Phys of Chestnut Hill, Boston U,
Boston, MA, 47
Rokhsar, Cameron K., M.D., 57
Romanelli, Paolo, M.D., AssocProf, Dept Derm/dermpath, Miller Sch Med,
U Miami, Miami, FL, 71
Rosen, Theodore, M.D., Prof, Dept Derm, Baylor Col Med,
Houston, TX, 43
Rosenbach, Misha, M.D., 51
S
Sadick, Neil S., M.D., FAACS, FACP, FACPh, Clin Prof, Dept Derm,
Weill Med College Cornell, New York, NY, 57
Sanchez, Fitzgeraldo A., M.D., 74
Sanchez, Miguel R., M.D., Assoc Prof, Dept Derm, NYU Sch Med,
New York, NY, 77
Sanders, Jonathan Scott, M.D., 50
Schaffer, Julie V., M.D., Asst Prof, Dept Derm and Ped, NYU, New York,
NY, 43, 53, 70
Schalock, Peter C., M.D., 65
Scher, Richard K., M.D., Prof Derm, U NC, Chapel Hill, North Carolina; Prof Emer Derm, Columbia U, New York, NY, 39, 67
Schlosser, Bethanee Jean, M.D., Ph.D., 68, 69
Schmults, Chrysalyne Delling, M.D., Dir, Mohs Micrographic Surgery,
Brigham and Women’s Hosp, Boston, MA, 70
Schwarzenberger, Kathryn, M.D., Assoc Prof, Univ Vermont,
Burlington, VT, 46
110
|
Sengelmann, Roberta D., M.D., Private Practice;Mohs & Cosmetic Derm
Surgery Stanta Barbara, CA, St. Louis, MO; Clin Assoc Prof U C Irvine,
CA, 47
Shalita, Alan R., M.D., Prof & Chmn, SUNY Downstate Med Ctr,
Brooklyn, NY, 78
Shinkai, Kanade, M.D., Ph.D., 40, 66
Shwayder, Tor A., M.D., FAAP, Dir, Ped Derm, Henry Ford Hosp,
Detroit, MI, 46
Sidbury, Robert, M.D., Asst Prof, Div Derm, Dept Ped, Sch Med, U WA,
Seattle, WA, 43, 78
Silverberg, Jonathan I, M.D., 78
Silverberg, Nanette Blythe, M.D., Dir Ped Derm, St Luke’s Roosevelt
Hosp Ctr, Clin Asst Prof, Columbia, New York, NY, 78
Smith, Janellen, M.D., 69
Sperling, Leonard C., M.D., Chmn, Dept Derm, Uniformed Svc U,
Bethesda, MD, 66
Spitz, Joel L., M.D., 76
Srivastava, Divya, M.D., 45
Stein, Jennifer A., M.D., Ph.D., 59
Stern, Dana W.K., M.D., 39
Stone, Stephen P., M.D., Prof Clin Med, Div Derm, SIU Sch Med,
Springfield, IL, 42
Stratman, Erik J., M.D., Dir, Div of Education, Marshfield Clin,
Marshfield, WI, 47, 55, 70
Strober, Bruce Elliot, M.D., Ph.D., Asst Prof, Dept Derm, Sch Med,
NY U, New York, NY, 73
Sundaram, Hema A., M.D., 73
Szeimies, Rolf-Markus, M.D., Assoc Prof, Dept Derm, U Hosp
Regensburg, Regensburg, Germany, 41
T
Taylor, James Selwyn, M.D., Hd Occ Derm, Cleveland Clin,
Cleveland, OH, 45
Thomas, Nancy E., M.D., Assoc Prof, Dept Derm, UNC, Chapel Hill,
NC, 60
Tomecki, Kenneth J., M.D., Vice chairman, Dept Derm, Cleveland Clin,
Cleveland, OH, 41, 43
Torgerson, Rochelle R., M.D., Ph.D., Asst Prof Derm, Mayo Clin Col of
Med, Rochester MN, 69
V
Van Voorhees, Abby S., M.D., Asst Prof, Dept Derm, U PA,
W
Waldorf, Heidi A., M.D., Assoc Clin Prof, Dept Derm, Sch Med, Mt Sinai,
Wang, Steven Q., M.D., Memorial Sloan Kettering Cancer Ctr, NY, 39
Weinkle, Susan H., M.D., Asst Clin Prof, Dept Derm, U S FL, Bradenton,
FL, 57
Weinstock, Martin A., M.D., Ph.D., Prof Derm and Community Hlth,
Brown U, Providence, RI, 60
Wetter, David A., M.D., 44
Willemze, Rein, M.D., Dept Derm, LUMC, Leiden, Netherlands, 41
Wirtzer, Allan S., M.D., Priv Pract, Sherman Oaks, CA, 74
Wisco, Oliver J., D.O., 45
Wolverton, Stephen E., M.D., Prof Clin Derm, Dept Derm, IN U Med
Ctr, Indianapolis, IN, 48
Woolery-Lloyd, Heather Clare, M.D., 78
Wright, Teresa S., M.D., 62
Z
Zaenglein, Andrea L., M.D., Assoc Prof, Derm and Ped, Penn State,
MS Hershey Med Ctr, Hershey, PA, 68, 78
Zeichner, Joshua, M.D., 51
Zic, John A., M.D., Asst Prof, Div Derm, Vanderbilt U Sch Med, Nashville,
TN, 48
Zirwas, Matthew, M.D., Asst Prof, Derm, Columbus, OH, 40
Zwald, Fiona O’Reilly, M.D., Metropolitan Dermatologic Surg, P.C.,
St Joseph’s Hospital, Atlanta, GA, 68
Advertisers Index
American Academy of Dermatology
Abbott Laboratories......................................................................16A-F
Centocor..........................................................................80A-D, 81-82
Galderma Laboratories.................15-16, 36, 79-80, 101-102, IBC-BC
Jan Marini Skin Research...................................................................91
Medicis...............................................................................................7-9
Merz Pharmaceuticals....................................................................93-94
Upsher-Smith Laboratories............................................................. 5, 86
Young Pharmceuricals....................................................................... 111
AAD.org ............................................................................................61
AAD Buyer’s Guide............................................................................64
AAD Sponsorship Recognition...................................3, 10, 11, 20, 33
Academy Resource Center............................................................34, 35
Annual Meeting 2011 Audio Recordings .........................................67
Dermatology in Action.......................................................................42
Derm Exam Prep Course...................................................................68
Dermatology Self-Assessment Program (DSAP) Tools......................62
Dermoscopy........................................................................................51
Leadership Institute.............................................................................46
Measurement Tools............................................................................65
Named Lectureships...........................................................................56
Practice Management Essentials Webinars .......................................74
Psoriasis Guidelines: Implementing them in your Practice................74
See SPOT CD ...................................................................................49
Sustaining Fund..................................................................................75
Transition into Practice: A Toolkit for Dermatologists Entering into the Workforce . ....................59
Advertising Representatives
Ascend Integrated Media, LLC
7015 College Blvd.
Suite 600
Overland Park, IL 66211
Cathleen Gorby
Phone: (913) 780-6923, Fax: (913) 780-4344
E-mail: [email protected]
Amy Galey
Phone: (913) 344-1359, Fax: (913) 344-1492
Advertisers Index
Maureen Mauer
Phone: (913) 780-6633, Fax: (913) 780-0088
Future Academy Meetings
Annual Meetings
2012
70th Annual Meeting
March 16-20
San Diego, Calif.
2013
71st Annual Meeting
March 1-5
Miami Beach, Fla.
2014
72nd Annual Meeting
March 21-25
Denver, CO.
2015
73rd Annual Meeting
March 20-24
San Francisco, Calif.
2016
74th Annual Meeting
March 4-8
Washington, D.C.
2017
75th Annual Meeting
March 3-7
Orlando, Fla.
2018
76th Annual Meeting
Feb. 16-20
San Diego, Calif.
2019
77th Annual Meeting
March 1-5
Washington, D.C.
summer ACADEMY Meetings
112
|
2012
August 15-19
Hynes Convention Center
Boston, Mass.
2013
2014
July 30-August 3
Hilton New York
New York, N.Y.
August 6-10
Hyatt Regency Chicago
Chicago, Ill.
Hilton New York
New York, N.Y.
Hilton New York
New York, N.Y.
2015
August 19-23
2016
TBD
2017
July 26-30
EPIDUO™
Rx only
(adapalene and benzoyl peroxide) Gel 0.1% / 2.5%
For Topical Use Only
Not For Ophthalmic, Oral, or Intravaginal Use.
BRIEF SUMMARY
EPIDUO Gel is a combination of adapalene, a retinoid, and benzoyl peroxide,
and is indicated for the topical treatment of acne vulgaris in patients 12 years
of age and older.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and
sunlamps. Wear sunscreen when sun exposure cannot be avoided.
Erythema, scaling, dryness, and stinging/burning may occur with use of
EPIDUO Gel.
ADVERSE REACTIONS
Observed local adverse reactions in patients treated with EPIDUO Gel were
erythema, scaling, dryness, stinging, and burning. Other most commonly
reported adverse events (≥1%) in patients treated with EPIDUO Gel were dry
skin, contact dermatitis, application site burning, application site irritation,
skin irritation.
DRUG INTERACTIONS
Exercise caution in using preparations containing sulfur, resorcinol, or
salicylic acid, medicated or abrasive soaps and cleansers and products with
high concentrations of alcohol or astringents in combination with EPIDUO Gel.
Concomitant use of topical products with a strong drying effect can increase
irritation. Use with caution.
Pregnancy
Pregnancy Category C. There are no well-controlled trials in pregnant
women treated with EPIDUO Gel. Animal reproduction studies have not
been conducted with the combination gel or benzoyl peroxide. Furthermore,
such studies are not always predictive of human response; therefore,
EPIDUO Gel should be used during pregnancy only if the potential benefit
justifies the risk to the fetus.
No teratogenic effects were observed in rats treated with oral doses of 0.15
to 5.0 mg adapalene/kg/day, up to 25 times (mg/m2/day) the maximum
recommended human dose (MRHD) of 2 grams of EPIDUO Gel. However,
teratogenic changes were observed in rats and rabbits when treated with oral
doses of ≥ 25 mg adapalene/kg/day representing 123 and 246 times MRHD,
respectively. Findings included cleft palate, microphthalmia, encephalocele
and skeletal abnormalities in rats; and umbilical hernia, exophthalmos and
kidney and skeletal abnormalities in rabbits.
Dermal teratology studies conducted in rats and rabbits at doses of 0.6-6.0 mg
adapalene/kg/day [25-59 times (mg/m2) the MRHD] exhibited no fetotoxicity
and only minimal increases in supernumerary ribs in both species and delayed
ossification in rabbits.
Nursing Mothers
It is not known whether adapalene or benzoyl peroxide is excreted in human
milk following use of EPIDUO Gel. Because many drugs are excreted in human
milk, caution should be exercised when EPIDUO Gel is administered to a
nursing woman.
Pediatric Use
Safety and effectiveness of EPIDUO Gel in pediatric patients under the age of
12 have not been established.
Geriatric Use
Clinical studies of EPIDUO Gel did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger
subjects.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No carcinogenicity, photocarcinogenicity, genotoxicity, or fertility studies were
conducted with EPIDUO Gel.
Carcinogenicity studies with adapalene have been conducted in mice at topical
doses of 0.4, 1.3, and 4.0 mg/kg/day (1.2, 3.9, and 12 mg/m2/day), and in rats
Galderma is a registered trademark.
14501 N. Freeway
EPI-613 Printed in USA 12/10
hcp.epiduo.com
at oral doses of 0.15, 0.5, and 1.5 mg/kg/day (0.9, 3.0, and 9.0 mg/m2/day).
In terms of body surface area, the highest dose levels are 9.8 (mice) and
7.4 times (rats) the MRHD of 2 grams of EPIDUO Gel. In the rat study, an
increased incidence of benign and malignant pheochromcytomas in the
adrenal medulla of male rats was observed.
No significant increase in tumor formation was observed in rodents
topically treated with 15-25% benzoyl peroxide carbopol gel (6-10 times the
concentration of benzoyl peroxide in EPIDUO Gel) for two years. Rats received
maximum daily applications of 138 (males) and 205 (females) mg benzoyl
peroxide/kg. In terms of body surface area, these levels are 27-40 times
the MRHD. Similar results were obtained in mice topically treated with 25%
benzoyl peroxide carbopol gel for 56 weeks followed by intermittent treatment
with 15% benzoyl peroxide carbopol gel for rest of the 2 years study period,
and in mice topically treated with 5% benzoyl peroxide carbopol gel for
two years.
The role of benzoyl peroxide as a tumor promoter has been well established
in several animal species. However, the significance of this finding in humans
is unknown.
In a photocarcinogenicity study conducted with 5% benzoyl peroxide
carbopol gel, no increase in UV-induced tumor formation was observed in
hairless mice topically treated for 40 weeks.
No photocarcinogenicity studies were conducted with adapalene. However,
animal studies have shown an increased tumorigenic risk with the use of
pharmacologically similar drugs (e.g., retinoids) when exposed to UV
irradiation in the laboratory or sunlight. Although the significance of these
findings to humans is not clear, patients should be advised to avoid or minimize
exposure to either sunlight or artificial irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test,
Chinese hamster ovary cell assay, mouse lymphoma TK assay) or in vivo
(mouse micronucleus test).
Bacterial mutagenicity assays (Ames test) with benzoyl peroxide has provided
mixed results, mutagenic potential was observed in a few but not in a
majority of investigations. Benzoyl peroxide has been shown to produce
single-strand DNA breaks in human bronchial epithelial and mouse epidermal
cells, it has caused DNA-protein cross-links in the human cells, and has
also induced a dose-dependent increase in sister chromatid exchanges in
Chinese hamster ovary cells. In rat oral studies, 20 mg adapalene/kg/day
(120 mg/m2/day; 98 times the MRHD based on mg/m2/day comparison) did
not affect the reproductive performance and fertility of F0 males and females,
or growth, development and reproductive function of F1 offspring.
No fertility studies were conducted with benzoyl peroxide.
PATIENT COUNSELING INFORMATION
– Advise patients to cleanse the area to be treated with a mild or soapless
cleanser; pat dry. Apply EPIDUO Gel as a thin layer, avoiding the eyes, lips
and mucous membranes.
– Advise patients not to use more than the recommended amount and not to
apply more than once daily as this will not produce faster results, but may
increase irritation.
– EPIDUO Gel may cause irritation such as erythema, scaling, dryness,
stinging or burning.
– Advise patients to minimize exposure to sunlight, including sunlamps.
Recommend the use of sunscreen products and protective apparel, (e.g.,
hat) when exposure cannot be avoided.
– EPIDUO Gel may bleach hair and colored fabric.
Marketed by
by:
LABORATORIES, LL.P.
GALDERMA LABORATORIES
P
Worth, Texas 76177 USA
Fort Worth
by:
Manufactured by
Galderma Production Canada Inc
Inc.
QC, H9X 3S4 Canada
Baie dd’Urfé,
Urfé QC
Canada.
Made in Canada
trademark.
GALDERMA is a registered trademark
Revised: December 2008
Revised
008
P51356-00
P51356
FIND THE RIGHT CHEMISTRY
EPIDUO® (adapalene and benzoyl peroxide) GEL 0.1%/2.5%—
The only, once-daily adapalene/benzoyl peroxide combination
for the first-line treatment of inflammatory and comedonal acne
*Individual results may vary. In clinical trials of over 1000 subjects, approximately 30% were clear or almost clear (IGA) by week 12 with a 70% median
inflammatory lesion count reduction from baseline.
Reference: 1. Gollnick HPM, Draelos Z, Glenn MJ, et al; Adapalene–BPO Study Group. Adapalene–benzoyl peroxide, a
unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind,
controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189.
Important Safety Information Epiduo® Gel is a retinoid and antimicrobial combination product indicated for the topical treatment of acne
vulgaris in patients 12 years and older. The most common adverse events associated with use of Epiduo® Gel are erythema, scaling, dryness,
stinging and burning. In addition, in clinical trials, adverse events reported in greater than 1% of patients treated with the Gel included contact
dermatitis and skin irritation. Excessive exposure to sunlight and sunlamps should be avoided during treatment, and use of sunscreen products
and protective clothing is recommended. Concomitant use of irritating topical products (like products containing resorcinol, salicylic acid or sulfur)
should be avoided. Epiduo® Gel has not been tested in pregnant or nursing women, or with the elderly. Pregnancy Category C.
Please see brief summary of Prescribing Information on next page.

Scientific Program - American Academy of Dermatology

Transcription

Similar documents

LA FONDATION LA ROCHE

BEAUTY THROUGH SCIENCE

course flyer - British Association of Dermatologists

SETH LERNER, M.D. JASON C. McBEAN, M.D.

The Mederma Myth: Fading From Sight—New Advances to Minimize

Hickory Dermatology Joins The Skin Surgery Center

Art in Turkish Dermatology

Skin Cancer

Hulusi Behçet - Muslim Heritage

Women`s Health June 2012